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Abstract 
Bacterial cystitis occurs with reasonable frequency in dogs. Persistent infection and repeated 
reinfection (recurrent bacterial urinary tract infection, hereafter termed recurrent UTI) is reported 
less frequently. Recurrent urinary tract infection is predominantly diagnosed in dogs with a 
predisposing or comorbid condition, and episodes are often subclinical. Escherichia coli is the most 
frequently cultured species in both uncomplicated bacterial cystitis and recurrent UTI. 
Antimicrobial therapy limitations and global emergence of bacterial strains that are both virulent 
and multidrug-resistant (MDR) has led to an urgent requirement for novel control strategies in both 
companion animals and humans. Escherichia coli strain 83972 has been successfully used to 
colonise the bladder of humans with recurrent UTI in order to reduce the incidence of subsequent 
febrile UTI via the process of active bacterial interference. This strategy has not been utilised in 
dogs to date but may prove an effective alternative to antimicrobial therapy if it can be shown to 
colonise the bladder of dogs safely and effectively compete with uropathogens. 
 
A retrospective study to examine the signalment, infecting strains, presence of clinical signs, 
and incidence of pyuria in Australian dogs with recurrent urinary tract infection was performed. The 
findings were similar to those of two large North-American studies with regard to signalment, 
predisposing or comorbid diseases, bacterial species isolated, and resistance to commonly used oral 
antimicrobials, although the median age of our dogs was higher at 10 years (7 years in both prior 
studies). Examination of the E. coli isolates from a subset of nine dogs provided new information 
on phylogenetic group, virulence gene profiles, haemolytic phenotype, expression of type 1 
fimbriae, and sequence type (ST). Phylogenetic groups F and B2 were frequently identified, 
representing 13/32 (41%) and 8/32 (25%) of isolates respectively, but no phylogroup B2 isolates 
were MDR, in comparison with phylogroup F isolates, which accounted for 12/16 (75%) MDR 
isolates. Clonal groups of global importance such as ST131-B2, ST354-F, ST38-D and ST457-F 
were represented, with possible implications for both companion animal and human health. Of 
particular concern was the repeated isolation of ST354-F strains from the urine of a paralysed dog 
over a 3-year period. 
 
When competition experiments between E. coli 83972 and a selection of canine 
uropathogenic E. coli (UPEC), including emerging, highly virulent MDR strains with zoonotic 
potential, were performed in pooled canine urine, E. coli 83972 was largely non-competitive against 
the canine isolates after 17 hr of incubation. This finding contrasted with the competitive superiority 
previously exhibited by E. coli 83972 in pooled human urine in competition experiments with 
human UPEC strains. In 5/10 trials, the E. coli 83972 was not outcompeted in canine urine, 
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however, and given that the starting ratio in dogs following prophylactic bladder colonisation would 
favour E. coli 83972, it is feasible that it could outcompete MDR canine UPEC strains in vivo. 
 
A single dose inoculation trial of E. coli strain 83972 (2 X 108 viable cells) was performed 
in six healthy dogs. Although the duration of colonisation was short for the dogs as a group (0-10 
days, median 4 days), two dogs remained colonised for at least 10 days. No dog suffered pyrexia or 
appeared systemically unwell but a small number displayed gross haematuria and/or stranguria. By 
day 3 of each trial (four dogs were re-inoculated on day 20) all clinical signs had resolved. As 
successful colonisation in humans is typically achieved using multi-dose protocols administered 
over several days, we subsequently aimed to design a protocol for canine inoculation that was likely 
to be more effective than a single inoculation but would be practical and acceptable to veterinarians 
and owners. Eight healthy dogs were inoculated with E. coli 83972 (1 X 109 viable cells) at 0, 8 and 
24 hr via an indwelling urinary catheter. Although the majority of dogs quickly expelled the 
inoculated bacteria (median duration of colonisation 2 days), one dog was colonised for 28 days in 
the absence of any discernable anatomic abnormalities or other predisposing factors.  Side effects 
encountered included pollakiuria or stranguria in 4/8 inoculated dogs and 1/3 sham-inoculated dogs 
but by day 8 of the trial all clinical signs had resolved.  
 
In conclusion, the development of a non-antimicrobial strategy for the prevention of 
recurrent UTI in dogs is of importance to both canine and human health, and E. coli 83972 is a 
feasible candidate for use in the dog. In addition, further exploration of the ability of E. coli 83972 
to compete with emerging clonal UPEC strains such as ST131 and ST1193 in both pooled human 
and canine urine may provide insight into why these emergent, multidrug-resistant high virulence-
associated clonal lineages have become so successful in colonising and causing extraintestinal 
infection in individuals of either species. 
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1 Review of Literature
 1 
1.1 General introduction 
Bacterial urinary tract infection (UTI) is common and occurs in approximately 14% of dogs 
that visit a veterinarian in their lifetime (Ling, 1984). In addition, persistent and recurrent urinary 
tract infections are regularly diagnosed in small animal referral practice (Norris et al., 2000; Seguin 
et al., 2003). Norris et al. (2000) suggested that recurrent or persistent UTI are present in up to 4.5% 
of dogs with UTI or 0.3% of the canine hospital population, and recurrent or persistent UTI was 
identified in 27.1% of dogs included in a recent study reporting on urinary bacterial isolates from 
dogs presenting to a veterinary teaching hospital (Wong et al., 2015). Whilst the conventional view 
has been that the majority of bacterial cystitis episodes resolve with a 7-14 day course of oral 
antimicrobials, it is now apparent that assumption of microbiologic cure may be ill advised. Two 
recent studies comparing short-duration treatment with trimethoprim-sulfamethoxazole (Clare et al., 
2014) or enrofloxacin (Westropp et al., 2012) with longer duration treatment with beta-lactam 
antimicrobials revealed that urine of dogs frequently returns to a culture-positive state post-
treatment. Persistent or recurrent urinary tract infections can involve refractory bacterial isolates 
and may also prove difficult to resolve using conventional antimicrobial therapy (Seguin et al., 
2003). A greater understanding of the mechanisms for bacterial persistence and the underlying 
individual factors that make eradication difficult may result in novel, alternative, and ultimately 
more successful treatment approaches to bacterial UTI in dogs.  
 
This review outlines the risk factors for recurrent and multidrug-resistant (MDR) (i.e. 
resistant to three or more classes of antimicrobial) bacterial UTIs in dogs. Additionally, the major 
species of bacteria associated with canine UTI, their likely origins, and the strategies these bacteria 
may use to circumvent host defences and establish persistent infection are considered, using 
Escherichia coli as the paradigm. Expression of antimicrobial resistance by urinary tract pathogens 
is of growing concern, but other mechanisms used by bacteria to evade elimination from the urinary 
tract are also discussed. The zoonotic risks and public health implications associated with MDR 
UTIs in dogs are also explored, including those resulting from the emergence of MDR E. coli 
ST131 strains in humans and their recent detection in dogs.  Finally, alternative approaches to 
antimicrobial agents for the treatment of chronic recurrent canine UTI are considered. 
 
 2 
1.2  Canine bacterial urinary tract infection 
1.2.1  Epidemiology of canine bacterial urinary tract infection  
Urinary tract infection (UTI) is a term that has been used in the veterinary literature to date 
to describe both bacterial cystitis and subclinical bacteriuria. Terms such as persistent urinary tract 
infection and reinfection also encompass both clinical and subclinical presentations. To be more 
precise, bacterial cystitis or urethrocystitis describes bacteriuria as documented by urine culture, 
accompanied by clinical signs of lower urinary tract inflammation including stranguria, pollakiuria 
and gross haematuria, and urinary cytological evidence of inflammation. Subclinical bacteriuria in 
the veterinary literature currently refers to culture-documented bacteriuria in the absence of the 
aforementioned clinical signs of lower urinary tract inflammation (Weese et al., 2011; Wan et al., 
2014), with the presence or absence of pyuria, which is not considered to preclude asymptomatic 
bacteriuria in humans (Kass, 1956; Wullt et al., 2003).  Ideally, future investigations of positive 
bacterial urine cultures in dogs and cats will cite the presence or absence of clinical signs and thus 
allocate subjects into groups including bacterial cystitis (with further division according to 
signalment, number of occurrences), subclinical bacteriuria, and pyelonephritis. 
 
Many reports have shown that bacterial UTI are more common in older female dogs, 
indicating that this is an important risk factor (Kivisto et al., 1977; Bush et al., 1978; Thomsen et 
al., 1986; Cavana et al., 2008; Sidjabat et al., 2009; Hall et al., 2013; Wong et al., 2015). The mean 
age at diagnosis regardless of sex is approximately 7-8 years (Ling et al., 2001; Cohn et al., 2003). 
Other risk factors reported to be associated with an increased prevalence of canine bacterial UTI are 
indicated in Tables 1.1 and 1.2. Risk factors for persistent UTI or reinfection in dogs have also been 
elucidated (Seguin et al., 2003) (Table 1.2). The age and breeds of dogs with recurrent or persistent 
UTI varies widely (Table 1.3) and may reflect to some extent breed lifespan and changes in 
popularity of breeds over time (Cavana et al., 2008). Presence or absence of clinical signs is not 
consistently reported, thus distinguishing between bacterial cystitis and subclinical bacteriuria 
episodes is often not possible. 
 
Up to 95% of UTIs in dogs with comorbid conditions are subclinical, however (Forrester et 
al, 1999; Lulich and Osborne, 1999; McGuire et al., 2002). In dogs with recurrent or persistent UTI, 
many of which have a predisposing factor or comorbid disease, approximately half are subclinical 
on initial presentation (Seguin et al., 2003).  
 
Urinalysis may yield an unremarkable sediment examination in the presence of bacteria, 
typically in association with subclinical bacteriuria, emphasising the need for a positive culture 
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result in order to confirm the diagnosis of significant bacteriuria (Forrester et al., 1999; Seguin et 
al., 2003).  As has been reported in cats (Bailiff et al., 2008), a low urine specific gravity does not 
appear to predispose dogs to UTI (Forrester et al., 1999; Seguin et al., 2003).  
 
Accurate identification of urinary tract pathogens is of paramount importance and requires 
appropriate sampling technique, e.g. urine collection via cystocentesis, as urine samples collected in 
this manner are much less often contaminated with commensal bacteria of the skin and urogenital 
tract and faecal bacteria (Comer and Ling, 1981). Multidrug-resistance is increasingly observed in 
faecal E. coli (Mulvey et al., 2000; Johnson et al., 2001a; Prasad et al., 2009; Guo et al., 2013) and 
unintentional isolation of these organisms during the diagnostic workup for UTI may result in 
overuse of antimicrobials. 
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Table 1.1 Risk factors previously identified as associated with increased prevalence of 
bacterial UTI in dogs 
 
 
Table 1.2 Possible contributory disorders in dogs with recurrent UTI  
(Seguin et al., 2003) 
Abnormal micturition Alteration of urothelium 
- paraparesis - urolithiasis 
- detrusor dyssynergia - transitional cell carcinoma 
- prostatic cysts or abscesses Altered urine composition 
Anatomic defects - Hypoadrenocorticism 
- urethrostomy - Diabetes mellitus 
- urethral avulsion/rupture Impaired immunity 
- ectopic ureters - Corticosteroid therapy 
- incontinence - Chemotherapy administration 
- pelvic bladder with incontinence - Systemic lupus erythematosus 
- vestibular-vaginal stenosis - Hyperadrenocorticism 
- hooded vulva  
  
Risk factor Reference 
Surgically treated intervertebral disc disease Stiffler et al. (2006) 
 
Intermittent bladder catheterisation Thomas (1979) 
 
Placement of indwelling catheters Ogeer-Gyles et al. (2006a) 
Bubenik et al. (2007) 
Tube cystostomy placement Stiffler et al. (2003) 
Beck et al. (2007) 
Hyperadrenocorticism Forrester et al. (1999) 
 
Diabetes mellitus Forrester et al. (1999) 
McGuire et al. (2002) 
Chronic corticosteroid use Ihrke et al. (1985) 
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Table 1.3 Breed predispositions for recurrent UTI in dogs 
Breed Reference 
German Shepherd Doga Norris et al. (2000) 
Miniature/Toy Poodlea,c  
Labrador Retrievera,d  
Mixed breed dogsa,c  
Dachshunda,e  
Doberman pinschera  
Springer Spaniele  
Golden Retrieverb  
Dalmatianb,d  
Great Daneb  
Bassett Houndb  
Alaskan Malamuteb  
Rottweilerb  
Shetland Sheepdogc  
  
Mixed breed dogsa Seguin et al. (2003) 
Golden Retrievera  
Dachshunda  
Cocker Spaniela  
Labrador Retrievera  
a Breeds accounting for more for ≥ 5% of cases   
b Breed identified as having a young (< 7 years) average age at first diagnosis in both sexes 
c Breed identified as having an old (≥ 7 years) average age at first diagnosis in both sexes 
d Breed for which males are significantly over-represented 
e Breed for which females are significantly over-represented 
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Table 1.4 Prevalence of E. coli isolates in bacterial UTI in dogs 
 
 
 
 
 
 
 
 
a Dogs with hyperadrenocorticism and/or diabetes mellitus. 
b Dogs with recurrent or persistent UTI. 
 
1.2.2  Bacterial pathogens of the canine urinary tract 
As in humans (Johnson et al., 2009a) and cats (Bartges and Barsanti, 2000), the most 
common pathogen isolated from the canine urinary tract is E. coli, accounting for between 33-55% 
of isolates obtained from UTI cases  (Forrester et al., 1999; Norris et al., 2000; Ling et al., 2001; 
Cohn et al., 2003; Seguin et al., 2003; Hall et al., 2013; Windahl et al., 2014; Wong et al., 2015) 
(Table 1.4).  
 
Escherichia coli is also the most prevalent pathogen in persistent or recurrent canine UTIs, 
but bacterial species such as Pseudomonas aeruginosa and Enterococcus spp. have a higher 
prevalence in these cases compared to uncomplicated UTI (Seguin et al., 2003). Both species are 
intrinsically resistant to a number of antimicrobial classes thus are selected in the face of 
antimicrobial pressure, and recent evidence supports invasion of urothelial cells by Enterococcus 
faecalis as another mechanism facilitating persistent infection (Horsley et al., 2013). Additionally, 
Enterococcus spp. is a significant nosocomial risk, effectively colonising surfaces in veterinary 
hospitals (Hamilton et al., 2012; KuKanich et al., 2012) and isolated (MDR clonal strains) from the 
faeces of dogs following hospitalisation in an intensive care unit (Ghosh et al., 2011). In two large 
retrospective studies of dogs with persistent or recurrent UTI, the six most frequently isolated 
bacterial species were E. coli, Klebsiella spp., Staphylococcus spp., Enterococcus spp., Proteus spp. 
and Pseudomonas spp. (Norris et al., 2000; Seguin et al., 2003). Multiple bacterial species may be 
isolated from the urine in recurrent or persistent UTI, i.e. polymicrobial cultures, which can 
sometimes complicate treatment options (Norris et al., 2000; Seguin et al., 2003).  
 
 
E. coli isolates 
n (%) 
 
Total isolates 
Forrester et al. (1999)a 29 (55) 53 
Norris et al. (2000)b 891 (41.2) 2165 
Ling et al. (2001) 3681 (44.1) 8,354 
Cohn et al. (2003) 547 (37) 1478 
Seguin et al. (2003)b 208 (47.2) 441 
Hall et al. (2013) 644 (52.9) 1218 
Windahl et al. (2014)  429 (68.9) 623 
Wong et al. (2015) 858 (52.4) 1636 
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When managing recurrent UTI, it is important to rectify any treatable comorbid conditions 
and to determine whether the same bacterial strain is involved in subsequent infections, e.g. 
persistent infection or relapse versus reinfection, as well as identify any changes in antimicrobial 
susceptibility, as these factors dictate treatment strategy (Seguin et al., 2003). In 100 dogs with 
recurrent UTI, 42% of isolates from the second recorded culture were of the same bacterial species 
with an identical susceptibility pattern, indicating possible persistence of or relapse of infection with 
the same strain (Seguin et al., 2003). Over interpretation must be avoided, however, as antibiograms 
alone are not a reliable test for clonality (Drazenovich et al., 2004; Freitag et al., 2006). The 
majority (71%) of isolates from the same group of dogs were susceptible to at least one commonly 
prescribed oral antimicrobial, with only a small proportion (4%) resistant to all tested antimicrobials 
(Seguin et al., 2003).  
 
1.2.3  Origin of canine uropathogens 
Most UTIs are thought to represent ascending infections rather than secondary 
haematogenous/lymphatic spread (Reid and Sobel, 1987). The two prevailing theories for the 
progression to uropathogenesis in humans are the ‘prevalence’ hypothesis and the ‘special 
pathogenicity’ hypothesis (Plos, 1995). The prevalence hypothesis argues that bacterial strains 
present in the highest numbers in the colonic microbiota are most likely to successfully invade and 
establish a UTI, whilst the special pathogenicity hypothesis suggests that bacteria with the 
appropriate extraintestinal virulence factors (VFs) are most likely to become uropathogens, despite 
their lower prevalence in the colonic microbiota. An E. coli isolate may be classified as an 
extraintestinal pathogenic E. coli (ExPEC) if it satisfies certain criteria with regard to virulence 
gene carriage; it must exhibit > 2 of pap (P fimbriae), sfa/foc (S/F1C fimbriae), afa/dra (Dr binding 
adhesins), iutA (aerobactin receptor), and kpsMT II (group 2 capsule synthesis) virulence genes 
(Johnson et al., 2003b). Most ExPEC in humans, including those associated with UTI, belong to 
phylogenetic group B2 (isolates in this group are generally found to contain more virulence genes) 
and to a lesser extent group D, and a similar distribution has been reported in dogs (Picard et al., 
1999; Clermont et al., 2000; Johnson et al., 2003a; Platell et al., 2011c). These groups of organisms 
are phylogenetically distinct from commensal and intestinal E. coli, which predominantly belong to 
groups A and B1 (Picard et al., 1999; Tenaillon et al., 2010). It must be noted that a new quadruplex 
PCR phylotyping method has been developed and E. coli isolates can now be assigned to one of 
eight phylogenetic groups (A, B1, B2, C, D, E, F, or cryptic clade I) (Clermont et al., 2013). Whilst 
isolates belonging to phylogenetic groups B1 and B2 have not been reassigned, those belonging to 
group D can be reassigned to groups D, E, F and cryptic clade I, and those belonging to group A to 
groups A and C. Specific uropathogenic characteristics and VFs are required for bacterial strains to 
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initiate an infection, regardless of the presence of a competitive colonisation advantage in the gut. 
Virulence factors of importance to uropathogenic E. coli (UPEC) include capsular factors, 
cytotoxins, invasion factors (invasins), siderophores and related transport systems, as well as 
adhesins that mediate binding to the renal tubule (P, S and F1C fimbriae) and bladder urothelium 
(type 1 fimbriae) (Yuri et al., 1998b, a; Johnson et al., 2003a). This is likely to be of particular 
importance in dogs with intact urinary tract defence mechanisms because to establish a UTI, host 
defences must be overcome. It should be noted, however, that phylogenetic group A and B1 E. coli, 
whilst generally possessing fewer VFs than group B2 and D (triplex PCR typing method) E. coli, 
may also initiate UTI in dogs if host defences are compromised (Sidjabat et al., 2009). 
 
1.2.4  Observations of increasing antimicrobial resistance in canine uropathogens 
One concerning trend documented in recent years has been the increased prevalence of non-
susceptibility to antimicrobials observed in canine urinary tract isolates, in particular to 
fluoroquinolones, third generation cephalosporins, and clavulanic acid-potentiated β-lactams 
(Cooke et al., 2002; Mazzuli, 2002; Ball et al., 2008; Sidjabat et al., 2009; Platell et al., 2011a; Hall 
et al., 2013; Wagner et al., 2014; Chang et al., 2015; Rzewuska et al., 2015). The availability of 
many of these drugs in oral forms that reach high concentrations in the urine following absorption, 
along with their efficacy against Gram-negative pathogens in particular, has resulted in their 
widespread use in companion animals.  
 
An Australian study of canine urinary isolates spanning 9 years (1992-2001) demonstrated 
increasing resistance to fluoroquinolones over time, particularly in E. coli (Sidjabat et al., 2009). 
The efficacy of fluoroquinolones remained high, however, with more than 80% of isolates showing 
in-vitro susceptibility. Another study of canine urinary E. coli isolates in a United States veterinary 
teaching hospital (1996-1998) reported a significant increase in the proportion of enrofloxacin-
resistant isolates recorded in the second year of the study following a documented increase in the 
quantity of enrofloxacin dispensed from the hospital pharmacy in the preceding year (Cooke et al., 
2002). Molecular fingerprinting (pulsed-field gel electrophoresis) of resistant isolates revealed a 
diversity of DNA macrorestriction profiles, thus the growing enrofloxacin resistance in this hospital 
was not attributable to a single enrofloxacin-resistant clone and more likely reflected a collective 
increase in resistance among several UPEC clonal lineages (Cooke et al, 2002).  
 
When the number of antimicrobials to which recurrent E. coli urinary isolates were resistant 
was examined in a Canadian veterinary teaching hospital (2002-2007), a significant increase was 
demonstrated over time, whilst this was not the case for non-recurrent E. coli, Enterococcus, S. 
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intermedius and Proteus spp. (Ball et al., 2008). A change in the predominant MDR E. coli 
resistance profile in an Australian veterinary teaching hospital over time (1999-2006) has also been 
documented (Gibson et al., 2008). Profiles prevalent in later years, although similar to the 
prevailing early profile, changed in susceptibility to 3rd generation cephalosporins and cefoxitin 
(Gibson et al., 2008). More recently, a study conducted on positive canine urine cultures in the 
United Kingdom documented increasing multiple antimicrobial resistance for P. aeruginosa and E. 
faecalis over a 10-year period, and reduced effectiveness of enrofloxacin, cephalexin and 
tetracycline (Hall et al., 2013). 
 
Multidrug-resistant E. coli (MDREC) isolates from canine urinary tract infection have been 
associated with numerous resistance genes (Feria et al., 2001; Sanchez et al., 2002; Sidjabat et al., 
2006a; Wagner et al., 2014; Chang et al., 2015). Similar isolates also carrying several resistance 
genes were isolated from cases of nosocomial infection, rectal carriers, and the environment of a 
large veterinary teaching hospital in Australia (Sidjabat et al., 2006b). The resistant isolates in this 
study comprised two distinct groups and it was concluded they arose via clonal expansion rather 
than via the transfer and spread of a single MDR plasmid between genetically unrelated isolates. 
The hospital environment could thus be implicated as a source of MDR E. coli opportunistic 
infections. A particular concern to spread of resistance is that some resistance genes have been 
identified on large MDR plasmids that could be readily transferred to other Enterobacteriaceae 
(Sidjabat et al., 2007).  
 
1.3  Bacterial resistance 
1.3.1  Observations of increasing antimicrobial resistance in strains isolated from faecal and 
environmental reservoirs 
As ExPEC strains causing cystitis in humans and dogs are predominantly derived from the 
faecal microbiota, regardless of whether they represent the dominant strain, changes in this bacterial 
population could logically influence the type and severity of UTIs (Johnson et al., 2005).  This 
could be another factor to consider in the emergence of an increased number of refractory canine 
UTIs, with a shift towards faecal carriage of less susceptible organisms in some dogs (Mulvey et al., 
2000; Johnson et al., 2001a; Prasad et al., 2009). Canine faecal deposits collected from a suburban 
neighbourhood were shown to contain E. coli strains with similar virulence traits and phylogenetic 
characteristics to human ExPEC, revealing that dogs may be common reservoirs of these organisms 
(Johnson et al., 2001a). The predominant faecal strain was a papG-positive (an adhesin allele) E. 
coli and most isolates correlated with clinical isolates derived from cases of cystitis, pyelonephritis 
and bacteraemia in humans.  
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The proportion of antimicrobial-resistant rectal E. coli isolates has been shown to increase as 
the duration of hospitalisation in an intensive care unit increases (Ogeer-Gyles et al., 2006). More 
specifically, fluoroquinolone administration was associated with a much greater likelihood of 
colonisation with a quinolone-resistant E. coli strain (Ogeer-Gyles et al., 2006). The majority of 
dogs with MDR E. coli and Enterobacter extraintestinal infections in another study had been 
hospitalised for ≥ 3 days and had received prior treatment with antimicrobials (Gibson et al, 2008). 
It has also been found that specimens from hospitalised animals or those housed in kennels are 
significantly more likely to yield enterococci containing two or more resistance genes, compared to 
individual non-hospitalised animals (Mulvey et al., 2000). Additionally, the Tn1546 transposon, 
indistinguishable from that found in vancomycin-resistant human enterococcal (VRE) isolates, has 
already been reported in a canine vancomycin-resistant E. faecium isolate, demonstrating that 
exchange of resistance determinants between human and canine enterococcal strains is possible 
(Johnson et al., 2005).  
 
1.3.2  Consequences of bacterial resistance acquisition 
Antimicrobial resistance acquisition may be associated with loss of VFs, as documented in 
quinolone-resistant human uropathogenic E. coli (Horcajada et al., 2005; Moreno et al., 2006; Soto 
et al., 2006). Soto et al. (2006) reported an association between fluoroquinolone resistance and the 
partial or complete loss of pathogenicity island clusters of urovirulence genes including 
haemolysins, cytotoxic necrotising factor 1, P fimbriae, and the autotransporter sat. 
 
Potential loss of virulence in fluoroquinolone-resistant UPEC has also been investigated in 
dogs (Ferrieres et al., 2007). Fluoroquinolone-susceptible and fluoroquinolone-resistant isolates 
were phylogenetically grouped (A, B1, B2, and D) and the presence of an array of virulence-
associated genes was compared. Fluoroquinolone-resistant isolates had a significantly lower 
prevalence of most virulence marker genes examined and a shift away from the virulence-
associated phylogenetic group B2. It is important to note, however, that 26% of fluoroquinolone-
resistant isolates still had sufficient VFs to qualify as ExPEC.  Fluoroquinolone-resistant strains 
with decreased VFs are common in asymptomatic bacteriuria (ASB), frequently identified in 
humans with disorders predisposing to UTI (Vranes et al., 2003). Wagner et al. (2014) more 
recently reported on MDR and susceptible E. coli isolates from canine urinary tract infections and 
found that susceptible isolates frequently belonged to phylogroup B2 and had significantly lower 
levels of carriage for 7/11 virulence factors in comparison to MDR isolates. 
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A paradigm shift in the hypothesis that MDR uropathogens are less virulent than their 
sensitive counterparts occurred recently, however, following the global dissemination of a human E. 
coli clonal lineage (O25b:H4-ST131) that is both MDR and highly virulent. This clonal lineage 
belongs to phylogenetic group B2 and possesses key ExPEC virulence-associated genes in addition 
to resistance to several classes of antimicrobial agents, including fluoroquinolones and sometimes 
third generation cephalosporins (Ewers et al., 2010).  
 
1.4  Bacterial mechanisms promoting UTI 
1.4.1  Mechanisms to evade eradication in the canine urinary tract 
As effective as the acquisition of resistance is in evading eradication in the face of 
antimicrobial therapy, bacteria have developed additional mechanisms for circumventing host 
defences, such as long-term persistence in the bladder wall. Long-term UTI caused by a single 
persistent bacterial strain is an area of increasing interest. Molecular fingerprinting, detection of 
virulence markers, and antibiogram profiling have demonstrated that, despite the presence of 
numerous host defences and seemingly appropriate antimicrobial therapy, some uropathogens can 
persist in infected bladder epithelial cells for extended periods of time, manifesting as recurrent 
infections (Mulvey et al., 2000).  
 
One potential mechanism for persistence is invasion of superficial bladder epithelial cells 
and parenchyma (Johnson et al., 2001b; Horsley et al., 2013), allowing significant numbers of 
bacteria to persist in the bladder for days to weeks. Whilst it was previously thought that bladder 
epithelial cells internalised bacteria as part of the host defence mechanism, it has now been 
proposed that type-1 fimbriae-mediated invasion of these host cells by UPEC may actually benefit 
the pathogen, allowing them to evade the numerous host defences present in the urine and bladder 
tissue whilst accessing a nutrient rich environment for replication or persistence (Johnson et al., 
2001b). In the bladder cells of mice infected ex-vivo, it appeared that whilst UPEC expressing type 
1 fimbriae may induce programmed cell death and exfoliation of bladder epithelial cells, this host 
defence mechanism could be resisted by invasion of deeper tissue, thus creating the potential for 
infection persistence and recurrence despite antimicrobial therapy (Mulvey et al., 1998).  
 
Furthermore in mice (both TLR-4 mutant and wild-type) with experimentally-induced 
UPEC UTI, bacteria were shown to organise intracellularly into “pods” which projected from the 
bladder epithelial cell wall (Anderson et al., 2003). Intertwinement of bacterial fibres and a 
surrounding polysaccharide-rich matrix appeared to provide a scaffold of support for each 
bacterium and the pod had a protective shell of uroplakin, a cell surface protein. It was apparent that 
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type 1 fimbriae may have some involvement in the process as some but not all of the bacteria 
appeared to express these structures, but type 1 fimbriae involvement was not supported by a later 
study (Hancock et al., 2007). Creation of such pods by bacteria may provide another explanation for 
persistence of infection, lack of efficacy of antimicrobials, and ability of bacteria to provide a 
reservoir for ongoing infection of bladder epithelial cells. 
 
Another potential mechanism which may add to the ability of bacteria to evade host 
defences and medical interventions, including the flushing effect of urine flow and antimicrobials, 
is the formation of biofilms by sessile adhesive communities associated with the bladder wall 
(Hancock et al, 2007). A biofilm is a surface accumulation of microorganisms in which large 
amounts of organic polymer of microbial origin bind the cells and other organic materials together 
and to the substratum (Kumon, 2000). The formation of a biofilm allows bacteria to evade 
antimicrobials and host defences. The bacteria not involved in a biofilm (planktonic bacteria) are 
eradicated by antimicrobial chemotherapy but those that persist remain poised to re-emerge at a 
later time (cryptic bacterial infection), the urine appearing sterile in the intervening period. 
 
The aforementioned bacterial strategies may give some insight into treatment failures and/or 
recurrence of canine UTI following repeated administration of antimicrobial therapy. Whilst none 
of these mechanisms for circumventing host defences have been studied specifically in dogs, the 
pathogenesis is likely to be similar. 
 
1.4.2  Mechanisms to aid bacterial establishment in the urinary tract 
It is likely that P fimbriae play an important role in the early establishment of E. coli in the 
urinary tract (Wullt et al., 2000). Colonisation of the urinary tract in human patients with a history 
of recurrent UTI was shown to be more successful initially when P-fimbriated transformants of the 
asymptomatic bacteriuria strain E. coli 83972 were used, in comparison to the unaltered strain. The 
pap+/prs+ transformants established bacteriuria more rapidly, required fewer inoculations to reach 
105 CFU/mL, and resulted in higher daily bacterial counts in the first 72 hr There was a rapid 
dilution of the P-fimbriated strain in vivo, however, with the phenotype lost within 24 hr after each 
inoculation, which may suggest an adaptation of ASB strains to minimise stimulation of host 
defensive responses (Wullt et al., 2000).   
 
In keeping with the theory that fimbriae may trigger host defensive responses, in another 
study using transformed (with pap and pil DNA sequences encoding GalD1-4GalE- and mannose 
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specific [type 1] adhesins) E. coli 83972, these strains were selectively eliminated by the host, with 
persistence of the wild-type strain (lacking expressed adherence factors) (Andersson et al., 1991). 
 
1.4.3  Mechanisms associated with recurrent UTI 
In humans, E. coli strains associated with persistence or relapse are more likely to belong to 
phylogenetic group B2 and have a higher number of virulence genes than those that are not detected 
at follow-up (Ejrnaes et al., 2011). Additionally, no combination of virulence genes was found that 
would serve to predict that an individual strain would be likely to be isolated repeatedly, and in 
vitro biofilm formation was not higher for persistent or relapsing strains. 
 
Little has been published with regard to mechanisms associated with recurrent or persistent 
UTI in dogs. For 100 affected dogs for which both the initial and subsequent culture results were 
available, 42% of isolates appeared (based on species and antimicrobial susceptibility profile) to 
represent relapsed or persistent strains, and 50% to be new strains (Seguin et al., 2003). These 
results need to be regarded with caution, as previously noted, given the reliability of antimicrobial 
susceptibility profiles in identifying identical strains (Drazenovich et al., 2004; Freitag et al., 2006). 
There is no information available regarding phylogenetic groups or virulence factor genes 
associated with isolates from dogs with recurrent urinary tract infection.  
 
1.5  Broader consequences of urinary tract infection in dogs 
1.5.1  Transmission of uropathogens between humans and dogs: a public health concern 
Cross-species transmission may be an important epidemiological factor for UTI in dogs and 
humans (Low et al., 1988). Two MDR E. coli isolates closely related to canine strains were 
obtained from rectal swabs of staff working in a veterinary hospital, demonstrating likely transfer of 
MDR E. coli between dogs and humans via the faecal-oral route (Sidjabat et al., 2006b). Isolation of 
E. coli from the faeces of humans and animals within the same household has also been undertaken 
to determine the level of sharing of bacterial strains between cohabiting hosts (Johnson et al., 2006). 
Within-household strain transmission was shown to occur among cohabiting humans and transfer 
between humans and pets occurred to a similar extent. Hence, rectal carriage of resistant bacteria in 
either species could provide a risk for the other, especially when physical contact is close. This is 
particularly significant with the recent detection of the human UTI pandemic MDR E. coli strain 
O25b:H4-ST131 in dogs (Platell et al., 2010). In Australia, the significantly higher prevalence of 
this clonal lineage among fluoroquinolone-resistant E. coli isolates from humans compared to dogs 
suggests that human-to dog transmission may currently predominate (Platell et al., 2010). 
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In addition to understanding the pathogenesis of canine UTI to facilitate effective treatment 
of individual dogs, we must also be cognisant of global concerns regarding resistant urinary tract 
pathogens in human and canine medicine and the possibility that cross- species transmission may be 
an important epidemiological factor for UTI in each host (Feria et al., 2001).  
 
Canine and feline uropathogenic E. coli have been found to share many virulence factors in 
common with human isolates (Feria et al., 2001; Johnson et al., 2001b). Johnson et al. (2001) 
reported that the majority of 17 canine urine isolates were from E. coli phylogenetic groups B2 or D 
(triplex PCR), expressed papG allele III, and exhibited numerous other putative virulence genes that 
are characteristic of human extraintestinal E. coli (ExPEC), rather than representing dog-specific 
pathogens (Johnson et al, 2001b). A more recent paper examined phylogenetic group distribution in 
both susceptible and MDR E. coli (12 and 18 isolates, respectively) from canine urinary tract 
infections and found similarly that the B2 phylo-group accounted for 67% of susceptible isolates 
and D for 20% (triplex PCR). The distribution was more even for MDR isolates; A, B1, B2 and D 
were represented by 28%, 22%, 11%, and 33%, respectively (Wagner et al, 2014). As previously 
noted, some group D isolates would be reclassified to phylo-groups E, F and cryptic clade I and 
some A to group C using a new quadruplex PCR (Clermont et al, 2013). 
 
In a study to examine the prevalence of urovirulence genes (cnf, hlyD, sfa/foc, and papGIII) 
in faecal E. coli from healthy dogs and their owners, it was found that female owner history of UTI 
was associated with each of the four virulence factors in E. coli strains isolated from their dog’s 
faeces (Stenske et al., 2009). This finding would take on more significance in terms of implicating 
dogs as a source of uropathogens if sampling performed during a UTI episode in the women had 
identified the virulence factors in a contemporaneously collected canine housemate faecal sample. 
The prevalence of genes for urovirulence factors in E. coli isolates dog owners, their pets, and non-
dog owners was low overall (22%), however, and it was rare for both dog and owner to have faecal 
E. coli with these virulence genes. 
 
The suspicion that rectal carriage of resistant bacteria in either species could provide a risk 
for the other, especially when physical contact is close takes on greater significance with the recent 
detection of the human UTI pandemic MDR E. coli O25b:H4-ST131 in dogs (Pomba et al., 2009; 
Ewers et al., 2010; Platell et al., 2010, 2011c). This clonal group is associated with fluoroquinolone 
resistance and may produce the extended-spectrum Elactamase CTX-M-15, which confers 
resistance to a wide range of beta-lactam antimicrobials, including cefotaxime and ceftazidime, and 
thus proves a considerable therapeutic challenge (Canton et al., 2006; Livermore et al., 2007). It has 
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emerged and disseminated in humans in different continents, and has largely been associated with 
urinary tract infections and bacteraemia (Clermont et al., 2008; Nicolas-Chanoine et al., 2008; 
Blanco et al., 2009; Oteo et al., 2009). In Australia, the significantly higher prevalence of this clonal 
lineage among fluoroquinolone-resistant E. coli isolates from humans compared to dogs suggests 
that human-to-dog transmission currently may predominate (Platell et al., 2010). 
 
Other human associated-clonal groups of interest in dogs with positive urine cultures include 
O1-ST648, O15:K2:H1-ST393-D, ST130, O7-ST457F, O1-ST648-F, and O1-ST38-D (Wagner et 
al., 2014; Guo et al., 2015). ST354 (phylogroup F) has also increased in prominence in recent times 
with recognition that it is capable of both colonising the gastrointestinal tract and causing extra-
gastrointestinal clinical disease in dogs, and represents a proportion of canine urinary isolates 
capable of producing certain extended-spectrum E-lactamases (namely CTX-M-14) (Mora et al., 
2011; Tamang et al., 2012; Guo et al, 2015). 
 
1.5.2  Development of non-antimicrobial treatment/prevention options 
The challenge of preventing chronic, recurrent UTI in humans has led to the development of 
a number of non-antimicrobial alternatives (vaccines, cranberry juice/extract, probiotics, and 
adherence/colonisation inhibitors) to low-dose once-a-day treatment with antimicrobials (Guay, 
2009). A strategy known as bacterial interference has been utilised to some extent, with E. coli 
strain 83972 being the best-known strain used for colonisation of the urinary tract in human patients 
susceptible to recurrent UTI (Hull et al., 2000; Darouiche et al., 2001, 2005). 
 
1.5.3  Asymptomatic bacteriuria E. coli strain 83972 
Escherichia coli 83972 (lac+), serotype OR:K5:H- was isolated from a young female patient 
with ASB who had carried it for several years without apparent adverse effects (Andersson et al, 
1991). E. coli 83972 is resistant to penicillin, erythromycin and tetracycline, and carries a unique 
1.2 kb plasmid. It lacks defined O and K surface antigens and carries adhesin gene clusters but does 
not express fimbriae or functional adhesins after in vitro culture or when recovered from the human 
urinary tract (Andersson et al., 1991; Hull et al., 1999). 
 
There has been much interest in the characteristics of E. coli 83972 that allow it to persist in 
the urine for prolonged periods and in an attempt to better describe E. coli 83972, Roos et al. 
(2006b) carried out a series of experiments including growth and competition experiments, and 
global gene expression profiles of E. coli 83972 grown in urine and laboratory media. E. coli 83972 
was found to grow faster in urine than a variety of uropathogenic E. coli and to substantially 
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outcompete each strain when urine was inoculated with equal amounts of each (E. coli 83972 
comprised 71-97% of the population with overnight growth). When E. coli 83972 growth in pooled 
human urine was compared to that in laboratory media, virulence genes associated with iron 
acquisition (uptake and transport) and sugar and carbohydrate transportation and degradation were 
expressed at significantly higher levels, suggesting that E. coli 83972 is well adapted to this iron-
restricted, nutrient-limited growth medium. 
 
Asymptomatic bacteriuria strains, including E. coli 83972, have also been found to have 
superior biofilm-forming capacity to their uropathogenic counterparts (Ferrieres et al, 2007; 
Hancock et al., 2007). The ability to form biofilms does not appear to be related to fast growth rate, 
high carrying capacity, motility, expression of type 1 fimbriae or other surface elements such as 
curli and cellulose fibres or presence or absence of a capsule (Hancock et al., 2007). Asymptomatic 
bacteriuria strains (including E. coli 83972) were also shown to out-perform uropathogenic E. coli 
and Klebsiella strains during mixed-strain biofilm formation in urine experiments, even though 
some Klebsiella strains had superior monoclonal biofilm formation ability, independent of growth 
rate in urine (Ferrieres et al, 2007). This remained true when the experiment (E. coli 83972 vs. 
UPEC strain CFT073, a well-characterised uropathogenic strain isolated from a human patient with 
severe urinary tract infection) was performed in a hydrodynamic flow chamber system, designed to 
mimic the flushing effect of constant urine flow. 
 
1.5.4  Inflammatory response to E. coli 83972 
In addition to work done to allow an understanding of how E. coli 83972 persists in the 
urinary tract for prolonged periods without causing clinical signs of infection, an examination of the 
inflammatory response to colonisation of the urinary tract with E. coli 83972 has been conducted 
(Hedges et al, 1991). In human patients deliberately inoculated with E. coli 83972, there was 
increase in both urine interleukin-6 (IL-6) and polymorphonuclear leucocytes (PMN) in the days 
following inoculation. In two patients not successfully colonised, the IL-6 response was low and 
transient in comparison to the colonised patients, indicating that although catheterisation provoked 
some response, the most important stimulus for IL-6 secretion was E. coli 83972. Interleukin-6 
secretion remained local and serum levels were low or undetectable. The PMN response, in contrast 
to IL-6, was similar in both colonised and non-colonised individuals. There appeared to be a 
significant threshold for IL-6 secretion (≥ 105 bacteria per mL) above which there was significantly 
more IL-6 secreted whereas there was no such threshold for PMN response. There was also no 
correlation between IL-6 and PMN responses in individual patients. Massive PMN recruitment did 
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not appear to hinder the persistence of E. coli 83972 and the possible contribution of IL-6 was not 
elucidated. 
 
Naturally occurring asymptomatic bacteriuria in women is also associated with an elevation 
in urinary IL-6 activity, with no significant difference between this and the urinary tract response to 
acute pyelonephritis (Hedges et al, 1992). Increased IL-6 activity was detected in the majority of 
bacteriuric women, regardless of the severity of clinical signs. In contrast, however, elevated serum 
IL-6 levels were largely seen in women with acute pyelonephritis. Bacterial stimulation of the 
urinary tract appeared to be responsible for urinary tract IL-6 production because increased urine 
IL-6 activity resolved after antibiotic treatment and was not detected in uninfected controls. 
Additionally, there was no correlation between urine and serum IL-6 levels in individual patients. 
 
1.5.5  Clinical work with E. coli 83972 
Andersson et al. (1991), inoculated eight female patients with recurrent urinary tract 
infection (three of whom had significant post-void residual urine volumes) with a mixture of wild-
type E. coli 83972 (lacking expressed adherence factors) and transformed adhesin-replete strains 
(Andersson et al., 1991). Stable bacteriuria was achieved for > 30 days in 7/12 (58%) individuals. 
The transformed strains appeared to be selectively eliminated by the host within 48 hr suggesting 
that the presence of adhesins does not enhance the ability of E. coli 83972 to colonise the urine 
long-term. The patients tolerated the inoculation well with no signs of fever or systemic illness and 
signs of lower urinary tract disease in just one patient, who was treated with antimicrobials on Day 
9 post-inoculation. The successfully colonised patients were reported to experience subjective 
clinical improvement and normal renal function was retained in all cases. 
 
Deliberate colonisation with E. coli 83972 was also attempted in 16 patients with refractory 
recurrent urinary tract infection (12 with neurogenic bladder disorders) in order to evaluate the 
effect of urodynamic factors on success of colonisation (Wullt et al, 1998). Six of 12 patients with 
neurogenic bladder disorders were colonised long term (5 months to 2 years) and three became 
short-term carriers in comparison to minimal success in four patients with normal bladder function 
(one was colonised for 7 days). It appears that urodynamic factors played an important role in 
successful colonisation with E. coli 83972, but there was also variation in success of colonisation 
amongst those with voiding disorders. Escherichia coli 83972 colonisation has also been shown to 
reduce the incidence of UTI in humans with spinal cord injuries, obviating the requirement for 
repeated courses of antimicrobials (Hull et al., 2000).  
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A later randomised, placebo-controlled, double-blinded trial examined the development of 
urinary tract infection in 27 male patients (21 inoculated, 6 control) following bladder inoculation 
with E. coli 83972 (2 inoculations daily for 3 days) (Darouiche et al., 2005). There was a two-fold 
reduction (46% vs. 93%) in the likelihood of development of UTI in the 13/47 (28%) patients who 
were colonised versus uncolonised patients (this group included 6 control patients and eight patients 
unable to be colonised) and only one patient developed a UTI whilst E. coli 83972 could still be 
cultured from his urine. Further to this, a variant of E. coli 83972 without the genetic potential for 
expressing P-specific adherence, E. coli HU2117, has also been shown to reduce the incidence of 
UTI episodes per patient year in a randomised controlled trial in 65 patients, 17/45 (38%) of which 
became colonised and were available for comparison to 10 control patients (Darouiche et al., 2011). 
 
Escherichia coli 83972 has also been used to coat urinary catheters which were then retained 
for three days following urethral insertion (Prasad et al., 2009). The success rate for urine 
colonisation (≥3 days duration) using this method was 62%. Individuals who became colonised with 
E. coli 83972 as a result of catheterisation had a decreased incidence of symptomatic UTI in 
comparison to that prior to colonisation. Colonisation with E. coli 83972 additionally appeared to 
lessen the clinical impact of uropathogens present concurrently with the ASB strain. Colonisation 
with E. coli 83972 was more successful when patients were pre-treated with antimicrobials 
targeting isolates with which they were infected prior to the study even though the antimicrobials 
rarely eradicated those isolates. 
 
Apart from anecdotal reports, no studies on the efficacy of novel strategies have been 
performed in dogs other than identification of bacteriophages capable of lysing canine and feline 
UPEC isolates (Freitag et al., 2008). Given the problems with resistance development in 
uropathogens associated with chronic, recurrent UTI in dogs (Seguin et al., 2003; Wagner et al., 
2014), consideration should be given to the use of low pathogenicity ASB strains to establish long 
term colonisation of the canine bladder in these cases (Thompson et al., 2010).  
 
1.6  Conclusions 
Urinary tract infections in dogs, in particular those that are persistent or recurrent and 
involve refractory and or MDR bacterial isolates, represent a growing area of concern in canine 
internal medicine. Further research into the mechanisms for bacterial persistence in canine urinary 
tract, especially in dogs with no apparent underlying disorders where there is failure of targeted 
antimicrobial therapy, is needed, as is a greater understanding of how we can minimise the 
population size of resistant isolates with uropathogenic capability in the canine colonic microbiota. 
 19 
Finally, non-antimicrobial therapeutic and/or prevention strategies for recurrent or persistent UTI in 
dogs warrant serious consideration and should be the subject of future clinical trials, both in terms 
of reducing resistance development in pathogens and in achieving clinical success in light of our 
growing knowledge of methods of bacterial evasion of urinary tract defences. Consideration should 
also be given to the recent emergence of highly virulent MDR clones such as O25b:H4-ST131 in 
cases of UTI and their dissemination in both humans and dogs, with the possibility of high 
frequency transfer occurring between both host species. 
 
This thesis commences with a retrospective study of dogs with recurrent UTI in southeast 
Queensland, enabling both comparison of this population to previously reported cohorts and a 
description of the incidence of clinical signs and pyuria coincident with positive urine cultures 
(Chapter 2). Chapter 3 comprises molecular characterisation of E. coli isolates from a subset of 
dogs from the preceding study, providing a better understanding of this species of bacteria in the 
context of canine recurrent UTI. Chapter 4 reports on competition experiments between E. coli 
83972, the ASB strain utilised in humans with recurrent UTI, and MDR canine uropathogenic E. 
coli isolates, predicting to some extent the likely success of E. coli 83972 in dogs with recurrent 
UTI. Chapter 5 examines the safety of intentional bladder colonisation of healthy dogs with E. coli 
83972, and Chapter 6 investigates a protocol for colonising dogs that recognises the competing 
forces of maximising the chance of urinary tract colonisation and dog and owner comfort and 
convenience. The thesis culminates in a discussion on recurrent UTI in dogs, the implications of the 
studies for dogs, veterinarians, owners and the general public, and the potential utility of the ASB 
strain E. coli 83972 as a preventative intervention in dogs with recurrent UTI. 
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2 Recurrent bacterial urinary tract infection in 37 dogs 
(2001-2011): To treat or not to treat? 
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2.1  Introduction 
Recurrent bacterial urinary infection (UTI) is not uncommon, with recurrent or persistent 
UTI identified in 27% of dogs included in a recent study reporting on urinary bacterial isolates from 
dogs presenting to a veterinary teaching hospital (Wong et al., 2015). Management is challenging, 
especially when a predisposing cause cannot be identified and/or ameliorated (Norris et al., 2000; 
Seguin et al., 2003). To date, the presence or absence of clinical signs of lower urinary tract disease 
(LUTD) and pyuria in dogs presenting repeatedly with positive urine cultures has not been 
comprehensively described, but this has important implications for prudent treatment with 
antimicrobials (Weese et al., 2011), as does the recognition that dogs with recurrent UTI  frequently 
have multidrug-resistant bacteria (MDR) isolated from their urine (Seguin et al., 2003; Ball et al., 
2008; Wagner et al., 2014; Wong et al., 2015).   
 
There is great interest in both human and veterinary medicine in the recognition and 
appropriate management of asymptomatic bacteriuria (ASB) or subclinical bacteriuria, as it is more 
appropriately termed in veterinary medicine (Hooton et al., 2000; Harding et al., 2002; Ooi et al., 
2004; Nicolle, 2006; Lin and Farjado, 2008; Weese et al., 2011; Leis et al., 2014; Naik and 
Trautner, 2014; Weese et al., 2015). In humans, ASB is defined as the presence of bacteriuria 
(single species ≥ 102 CFU/mL isolated from a catheterised specimen or ≥ 105 CFU/mL from a 
midstream clean-catch) in the absence of clinical signs of lower urinary tract disease (Nicolle, 
2006). Correspondingly, with an episode of subclinical bacteriuria, an animal presents with no 
clinical signs of lower urinary tract disease yet bacterial urine culture of a cystocentesis urine 
sample is positive. Antimicrobial treatment for ASB in humans is not generally recommended, with 
the exception of pregnant women and patients undergoing urologic surgery, and similar 
recommendations exist regarding subclinical bacteriuria in veterinary medicine (Nicolle, 2006; 
Weese et al., 2011). Additionally, antimicrobial therapy in young women with recurrent urinary 
tract infections has been associated with increased recurrence of symptomatic UTI over the 
subsequent year (Cai et al., 2012) 
 
The aim of this study was to describe the clinical and microbiological findings in dogs from 
southeast Queensland with recurrent UTI, with particular emphasis on the presence or absence of 
clinical signs of lower urinary tract disease, species of bacteria associated with subclinical 
bacteriuria, degree of pyuria, and classification of isolates as MDR.  
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2.2  Materials and methods 
2.2.1 Data collection 
In this retrospective study, medical records at the Small Animal Clinic and Veterinary 
Teaching Hospital, The University of Queensland, and two private referral practices in southeast 
Queensland were searched for dogs with three or more positive urine cultures (minimum of 5 days 
between cultures) within a 12-month period (2001-2011).  Method of urine collection was recorded 
and voided samples excluded.  
 
Age at time of first positive urine culture in the referral hospital, breed, sex, and neuter 
status were recorded, with age rounded to the nearest year. The presence of clinical signs for each 
presentation coinciding with a positive urine culture was recorded, where available. Records were 
also searched for information on the presence of diseases that may predispose dogs to culture-
positive urine (Seguin et al., 2003; Chew et al., 2011).  
 
Presence or absence of clinical signs of lower urinary tract disease, where recorded, was 
used to categorise incidences of positive urine culture as a) lower urinary tract infection (stranguria, 
pollakiuria and/or haematuria), b) subclinical bacteriuria (including both dogs with no clinical signs 
and those with clinical signs other than those consistent with lower urinary tract disease), and c) 
suspected pyelonephritis (as diagnosed by the attending clinician). Positive urine culture episodes in 
dogs with spinal cord injury were assigned to a fourth category, as it was difficult to assess these 
dogs for clinical signs of LUTD. Where a urine sample submitted for culture and susceptibility had 
also been examined for the presence of pyuria (white cell count [cells/HPF]), results were recorded. 
Pyuria was graded as absent (< 5 WBC/HPF), mild (5-10 WBC/HPF), moderate (10-50 
WBC/HPF), or severe (> 50 WBC/HPF). For individual laboratories with non-aligned reference 
intervals, samples with < 10 WBC/HPF were graded as having mild pyuria, 5-30 WBC/HPF 
(overlap with previous range due to different laboratory) as moderate pyuria, and > 30 WBC/HPF 
as severe to avoid understatement of inflammation. In this study, subclinical bacteriuria was defined 
as documentation of a positive urine culture in the absence of LUTD signs in a non-paralysed dog, 
regardless of the degree of pyuria. 
 
2.2.2 Bacterial isolates 
Species, number of isolates per culture (mono versus polymicrobial infections), and non-
susceptibility to nine commonly used antimicrobials (AMC, amoxicillin-clavulanic acid; AMP, 
ampicillin; CAZ, ceftazidime; KF, cephalothin; ENR, enrofloxacin; CN, gentamicin; TET, 
tetracycline; TIM, ticarcillin-clavulanic acid and SXT, trimethoprim sulfamethoxazole) was 
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recorded. Isolates reported to be non-susceptible to ≥ 1 agent in ≥ 3 antimicrobial classes as 
appropriate for family/species were classed as MDR (Magiorakos et al., 2012). Any isolate found to 
be within the intermediate range was classified as being non-susceptible.  
 
2.2.3 Classification of infection as persistent infection or relapse versus reinfection 
Species of bacteria isolated in the first and subsequent positive cultures were compared and 
categorised as: a) the same species as the original culture (representing persistence, relapse or 
possible reinfection with a different strain), or b) a different species to the original culture 
(reinfection only). 
 
2.2.4 Statistical analysis 
Descriptive statistics (mean, percentile, range) were calculated for age at entry into the study 
and number of positive cultures and used to otherwise characterise dogs, predisposing/comorbid 
conditions, presence of clinical signs of lower urinary tract disease, isolates cultured and 
antimicrobial resistance.  
  
2.3 Results 
Thirty-seven dogs from three referral clinics met the criteria for inclusion in the study for 
the study period 2001-2011. Of the 224 positive urine cultures recorded, 223 urine samples were 
collected by cystocentesis and one via urethral catheterisation (neutered male dog). The number of 
positive urine cultures (Table 2.1) ranged from three to 38 per dog (median 4.5, percentile [Q1], 3, 
percentile [Q3], 7) with time elapsed between positive cultures ranging from 5 days to 108 weeks. 
Male dogs had a median of five positive urine cultures whilst female dogs had a median of 4.5 
positive cultures, with three female dogs having greater than 10 positive cultures.  
 
Five of the 37 dogs were described as mixed-breed and the remaining 32 dogs (86%) were 
purebred, representing 25 different breeds (Table 2.1). Breeds represented by more than one dog 
included Miniature Dachshunds (5 dogs), mixed-breed dogs (5 dogs), and Miniature Poodles, 
English Cocker Spaniels, Labrador Retrievers, and Boxers (2 dogs each). Twenty-six of the 37 dogs 
(70%) were neutered females, there were 10 (27%) neutered males, and one entire female dog. Age 
of dogs ranged from 2 to 17 years (median 10 years, percentile [Q1], 8, percentile [Q3], 13). Nine 
dogs (24%) were aged 7 years or less and 28 dogs (76%) were  > 7 years of age.  
 
Likely predisposing or comorbid conditions were identified in 28/37 (76%) dogs (Table 
2.1).  Three dogs each had three predisposing conditions. Diabetes mellitus was most common, 
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affecting six (16%) dogs, and hyperadrenocorticism, exogenous corticosteroid administration, 
urolithiasis, and urinary incontinence each accounted for four (11%) cases. Three dogs had 
hindlimb paralysis with associated upper motor neuron bladder neurogenic bladder dysfunction and 
these dogs were considered separately for analysis. 
 
Of 132 incidences of positive urine culture for which clinical signs had been recorded, 27 
(20%) could be classified as lower urinary tract infection, 98 (74%) as subclinical bacteriuria, and 5 
(4%) as pyelonephritis. Gross haematuria was recorded coincident with 5/45 (11%) positive urine 
cultures in paralysed dogs but the remaining 40 (89%) were not associated with clinical signs of 
bacterial cystitis. Due to the small number of cases, episodes of suspected pyelonephritis were not 
further analysed. It was typically not possible to ascertain from the records the reason for urine 
culture performed in dogs without clinical signs of lower urinary tract disease. 
 
Table 2.1 Signalment, number of positive urine cultures, predisposing condition, presence of 
clinical signs on initial presentation, number of subclinical episodes, and number of MDR 
isolates in 37 dogs with recurrent UTI 
Breed Sex Age 
(yrs) 
Number 
of positive 
urine 
cultures 
Predisposing/comorbid 
condition 
Clinical signs 
of LUTD at 
first incidence 
of positive 
urine culture 
SB 
episodes 
MDR 
isolates 
Miniature 
Fox Terrier 
FS 3 3 Immunosuppressive 
therapy for meningitis of 
unknown origin 
Y 2 3 
Boxer  FS 7 3 None recorded Y 1 0 
Golden 
Retriever 
FS 9 3 None recorded N 1 1 
Miniature 
Poodle 
MN 9 3 Diabetes mellitus N 3 0 
Rottweiler FS 9 3 None recorded N 1 0 
Boxer FS 10 3 None recorded N 2 0 
Lhasa Apso X FS 11 3 Hyperadrenocorticism N 2 0 
Old English 
Sheepdog 
MN 12 3 None recorded N 2 0 
Miniature 
Dachshund 
FS 13 3 Urethral transitional cell 
carcinoma 
N 1 0 
Miniature 
Dachshund 
FS 14 3 Hyperadrenocorticism Y 1 0 
Miniature 
Schnauzer 
FS 2 4 None recorded N 2 0 
Labrador 
Retriever X 
FS 5 4 Recessed vulva Y 1 0 
Chihuahua FS 7 4 Urolithiasis N 2 0 
Mastiff FE 7 4 Polypoid cystitis Unknown 2 2 
Great Dane MN 8 4 Prostatic disease, 
Diabetes mellitus 
Y 2 1 
English 
Cocker 
Spaniel 
FS 11 4 Urethral transitional cell 
carcinoma 
Y 2 1 
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Labrador 
Retriever 
FS 14 4 Urinary incontinence N 4 1 
Australian 
Cattle Dog X 
FS 14 4 Hyperadrenocorticism, 
urinary incontinence 
N 4 2 
Min 
Dachshund 
FS 4 5 None recorded Y 1 0 
Cavalier 
King Charles 
Spaniel 
FS 8 5 Urolithiasis N 3 1 
Border Collie FS 8 5 Diabetes mellitus N 4 0 
Labrador 
Retriever 
MN 11 5 Urinary incontinence N 5 1 
Weimeraner MN 11 5 Chemotherapy for 
intramuscular 
haemangiosarcoma 
 3 3 
Min 
Schnauzer 
MN 12 5 Urinary incontinence N 5 1 
Beagle MN 13 5 None recorded N 4 0 
German 
Shepherd 
Dog 
FS 14 5 None recorded N 3 0 
Terrier X FS 10 6 Diabetes mellitus, 
immunosuppressive 
therapy for meningitis of 
unknown origin 
N 5 2 
Dalmatian MN 9 7 Urate urolithiasis N 3 1 
Min 
Dachshund 
MN 17 7 Hyperadrenocorticism N 4 1 
Pembroke 
Welsh Corgi 
FS 9 8 None recorded N 2 7 
Doberman FS 11 8 Diabetes mellitus Unknown 6 0 
West 
Highland 
White 
Terrier 
FS 6 9 Immunosuppressive 
therapy for atopic skin 
disease 
Y 5 2 
Jack Russel 
Terrier 
FS 9 11 Urolithiasis N 6 3 
Min 
Dachshund 
FS 12 12 Diabetes mellitus N 12 2 
Miniature 
Poodle 
FS 11 5 Hindlimb paralysis N  2 
English 
Cocker 
Spaniel 
MN 5 7 Hindlimb paralysis, 
indwelling urinary 
catheter (1st visit only) 
N  5 
Australian 
Terrier X 
FS 15 38 Hindlimb paralysis N  47 
 
Quantification of neutrophils in urine sediment was available for 139/224 (62%) urine 
samples. For episodes classified as lower urinary tract infection, pyuria was absent in 4/19 (21%) 
urine samples, mild or moderate in 5/19 (27%), and severe in 10/19 (53%) (Figure 2.1) For episodes 
of subclinical bacteriuria, pyuria was absent in 10/43 (23%) urine samples, mild in 6/43 (14%), 
moderate in 11/43 (26%), and severe in 16/43 (37%). In urine from paralysed dogs, marked pyuria 
was the most frequent finding, reported in 23/43 (53%) samples, followed by absence of pyuria in 
10/43 samples (23%). Pyuria was moderate in 9/43 (21%) of culture-positive samples and mild in 
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1/43 (2%). Of the five episodes in paralysed dogs for which gross haematuria was noted by the 
owner; three were associated with severe pyuria and one with mild pyuria. 
 
 
Figure 2.1 Categorisation of pyuria in relation to clinical signs of LUTD in dogs with 
recurrent UTI. UTI; lower urinary tract infection; SB, subclinical bacteriuria; PA, dogs with 
hindlimb paralysis 
 
Escherichia coli was the most frequently isolated bacterial species, accounting for 41% of 
all isolates and present in 46% of positive cultures (Table 2.2). Less frequently documented isolates 
included Enterococcus spp. (14% of all isolates), Proteus spp. (10%), Klebsiella spp. (9%) and 
Staphylococcus spp. (8%). Enterococcus spp. accounted for 28/121 (23%) isolates from the 53 
polymicrobial cultures whilst Pseudomonas spp. was rarely present in polymicrobial cultures (Table 
2.2). 
 
Forty-three isolates were recorded in association with the second positive urine culture for 
the 37 dogs. Of these, 19 (44%) isolates represented a different species to the original culture for the 
individual and therefore constituted a reinfection. Nineteen isolates (44%) were of the same species 
as the original infection and for five isolates a determination could not be made due to failure of 
identification of the genus of the original isolates. Comparison of complete antibiogram was 
possible for 15/19 same species isolates and was identical for 10 (53%) such isolates. Overall, 24/43 
(56%) isolates appeared to represent reinfection. 
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* isolates from
 both m
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icrobial cultures 
 Species 
M
onom
icrobial 
culture (n=175) 
Polym
icrobial 
culture 
(n=121) 
Total num
ber 
isolates for 
species (%
) 
(n=296) 
N
um
ber of 
cultures in 
w
hich present 
(%
) 
(n=224) 
U
rinary tract 
infection* 
(%
) 
(n=41) 
Subclinical 
bacteriuria 
(SB
)* (%
) 
(n=119) 
Pyelonephritis 
(%
) 
n=5 
Paralysed 
dogs 
(%
) 
(n=81) 
 
E. coli 
76 
45 
121 (41) 
104 (46) 
6 (15) 
49 (41) 
2 (40) 
45 (56) 
Enterococcus spp. 
13 
28 
41 (14) 
37 (17) 
3 (7) 
11 (9) 
1 (20) 
19 (23) 
Proteus spp. 
15 
15 
30 (10) 
29 (13) 
14 (34) 
12 (10) 
1 (20) 
7 (9) 
Klebsiella spp. 
20 
7 
27 (9) 
27 (12) 
11 (27) 
8 (7) 
1 (20) 
1 (1) 
Staphylococcus spp. 
14 
9 
23 (8) 
23 (10) 
3 (7) 
11 (9) 
 
2 (2) 
Pseudom
onas spp. 
16 
2 
18 (6) 
18 (8) 
0 (0) 
9 (8) 
 
4 (5) 
Enterobacter spp. 
10 
3 
13 (4) 
18 (8) 
0 (0) 
6 (5) 
 
1 (1) 
Streptococcus spp. 
7 
6 
13 (4) 
14 (6) 
3 (7) 
7 (6) 
 
0 (0) 
Citrobacter spp. 
1 
2 
3 (1) 
3 (1) 
0 (0) 
2 (2) 
 
0 (0) 
U
nidentified/unknow
n 
2 
4 
6 (2) 
6 (3) 
1 (2) 
4 (3) 
 
1 (1) 
Candida 
1 
 
1 
1 
 
 
 
1 (1) 
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All nine bacterial species were isolated at least twice in monoculture in instances of 
subclinical bacteriuria, with E. coli comprising 51/124 (41%) of all subclinical isolates (isolates 
from mixed cultures included) (Table 2.2). The remaining bacterial species each accounted for ≤ 
10% of subclinical isolates. Pseudomonas spp., Enterobacter spp. and Citrobacter spp. were not 
cultured in instances of lower urinary tract infection, whereas Proteus spp. accounted for 14/41 
(34%), Klebsiella spp. 11/41 (27%) and E. coli 6/41 (15%) lower urinary tract infections. In 
paralysed dogs, E. coli accounted for 45/80 (56%) of all isolates.  
 
Eighty-nine of 296 isolates (30%) were classified as MDR. Two dogs with lower urinary 
tract infection episodes accounted for 2/89 (2%) MDR isolates and there were 33 MDR (37%) 
isolates from 15 dogs with subclinical bacteriuria episodes. The three paralysed dogs accounted for 
54/89 (61%) MDR isolates (two dogs accounted for seven isolates and the third paralysed dog 
accounted for 47 MDR isolates - Table 2.1), with gross haematuria detected in association with 
isolation of two MDR isolates. The paralysed dog that yielded 47 MDR isolates had two episodes of 
suspected urosepsis in association with MDR strains. Forty-eight of 89 (54%) MDR  isolates were 
identified as E. coli, with 14 (16%) Enterococcus spp., 10 (11%) Enterobacter spp., 6 (7%) 
Klebsiella spp., 5 (6%) Pseudomonas spp., 3 (3%) Proteus spp., and one (1%) each of 
Staphyloccocus spp., Streptococcus spp., and Citrobacter spp.  
 
Ten dogs, including the three paralysed dogs, had MDR bacteria isolated from their initial 
urine sample. Three of these dogs had concurrent lower urinary tract signs. Fourteen dogs never 
yielded MDR isolates, and 11 dogs, nine of which had subclinical bacteriuria when first presented, 
had relatively susceptible isolates initially followed by at least one MDR isolate in subsequent urine 
cultures. An additional dog with pyelonephritis suspected on initial presentation had a MDR isolate 
cultured on a later visit. 
 
Of 11 MDR isolates from subclinical bacteriuria episodes, one was associated with an 
absence of pyuria, one with mild pyuria, five with moderate pyuria, and four with severe pyuria. Of 
43 MDR isolates in paralysed dogs, there were 15 (35%) associated with an absence of pyuria, 6 
(14%) with moderate pyuria and 22 (51%) with severe pyuria. 
 
When susceptibility to individual antimicrobials was examined for all isolates, non-
susceptibility (resistant plus intermediate) to tetracycline (64%) and ampicillin (62%) was most 
common, followed by cephalothin (54%), and ticarcillin-clavulanic acid (45%). Forty-two percent 
of all isolates were non-susceptible to each of trimethoprim/sulfamethoxazole and enrofloxacin, and 
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thirty-five percent to clavulanic acid-potentiated amoxicillin. A smaller percentage of isolates were 
non-susceptible to gentamicin (25%) and ceftazidime (19%) (Figure 2.2).  
 
 
 
Figure 2.2 Disc diffusion susceptibility results for isolates from 37 dogs with recurrent UTI 
against nine antimicrobials. AMC, amoxicillin-clavulanic acid; AMP, ampicillin; CAZ, 
ceftazidime; KF, cephalothin; ENR, enrofloxacin; CN, gentamicin; TET, tetracycline; TIM, 
ticarcillin-clavulanic acid and SXT, trimethoprim sulfamethoxazole (intrinsic resistances not 
included). 
 
Given that E. coli was the most commonly isolated species from each of the three groups, 
susceptibility of that species to individual antimicrobials for dogs with differing clinical 
presentations was separately examined (lower urinary tract infection isolates [n=6, 2 MDR isolates], 
subclinical isolates [n=48, 8 MDR isolates] and isolates from paralysed dogs [n=45, 38 MDR 
isolates]) (Figure 2.3).  Non-susceptibility (including resistant and intermediate results) to 
amoxicillin-clavulanic acid, ampicillin and cephalothin was high (>30%) in all three groups of 
isolates. There was a large variation in non-susceptibility to enrofloxacin and trimethoprim 
sulfamethoxazole between subclinical isolates (14% and 16% respectively) and isolates from 
paralysed dogs (75% and 84% respectively). Gentamicin was the only antimicrobial for which all 
three groups of isolates had less than 20% non-susceptible isolates. 
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Figure 2.3 Disc diffusion susceptibility results (showing percentage of non-susceptible [R +I] 
isolates) for E. coli from three groups (lower UTI, subclinical bacteriuria, and paralysed dogs) 
against nine antimicrobials. AMC, amoxicillin-clavulanic acid; AMP, ampicillin; CAZ, 
ceftazidime; KF, cephalothin; ENR, enrofloxacin; CN, gentamicin; TET, tetracycline; TIM, 
ticarcillin-clavulanic acid and SXT, trimethoprim sulfamethoxazole. 
 
2.4  Discussion 
In this study, subclinical bacteriuria was more common than lower urinary tract infection in 
dogs with repeated positive urine cultures, accounting for 98/132 (74%) of incidences for which 
clinical signs had been recorded. Additionally, subclinical bacteriuria was usually associated with 
pyuria (63% of urine samples had moderate or severe pyuria), although 14% of urine specimens had 
< 10 WBC/hpf and 23% had < 5 WBC/hpf. Bacterial isolates from dogs with recurren UTI were 
also frequently determined to be MDR, and whilst the small number of paralysed dogs accounted 
for 61% of MDR isolates, MDR isolates were identified in 21/37 (57%) dogs overall with the 
majority associated with pyuria. 
 
The signalment of dogs in this study appeared similar to those in previous reports of dogs 
with recurrent urinary tract infection,  however in our study they were slightly older with a median 
age of 10 (in comparison to 7 years in previous studies), predominantly female (70%), and with a 
larger median number of positive urine cultures documented (median of 4.5 per dog compared with 
3 in previous studies) (Norris et al., 2000; Seguin et al., 2003).  
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The frequency with which subclinical bacteriuria was recognised in these dogs over all 
presentations is concordant with what has previously been reported regarding initial presentation of 
dogs with recurrent or persistent UTI (Seguin et al., 2003). Dogs with hindlimb paralysis in our 
study were excluded from assessment of clinical signs of lower urinary tract disease (LUTD) as it 
was difficult to be sure that they could display such signs. Indeed, for the three paralysed dogs in 
this study, the only clinical sign consistent with (but not exclusive to) LUTD was gross haematuria, 
documented on five occasions, and one dog had two episodes of suspected urosepsis. Lack of lower 
urinary tract signs in paraplegic dogs can potentially be attributed to reduced pelvic sensation, as 
has been suggested in human spinal-cord injured patients (Hooton et al., 2010). 
 
Escherichia coli is the most prevalent species isolated from humans with subclinical 
bacteriuria but Proteus mirabilis, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas 
aeruginosa, Enterococcus spp., and Staphylococcus aureus also have been implicated (Ipe et al, 
2013). Subclinical bacteriura in healthy female dogs has recently be reported in association with E. 
coli, K. pneumoniae, Staphylococcus pseudintermedius, Enterococcus faecium, Enterococcus 
faecalis, and Streptococcus canis (Wan et al., 2014). Similarly, in our study, episodes of subclinical 
bacteriuria were associated with all of the species of bacteria isolated from dogs with recurrent 
lower urinary tract infection. Proteus spp. and  Klebsiella spp. each accounted for greater than 25% 
of isolates associated with clinical signs and 10% or less of subclinical isolates, suggeting that these 
species may be more likely to trigger clinical signs of lower urinary tract disease. 
 
It is currently recommended in veterinary medicine that subclinical episodes of bacteriuria 
not be treated with antimicrobials, providing that urine sediment is inactive (Weese et al., 2011). 
Evidence of urinary tract inflammation was present in the majority of episodes of subclinical 
bacteriuria in this study, pyuria being absent in only 10/43 (23%) episodes, and mild in a further 
6/43 (14%) with the remaining 63% of episodes associated with moderate or severe pyuria. It 
should be noted that for many episodes of subclinical bacteriuria in this study [55/98 (56%)], 
quantification of urine neutrophils was not performed, which would have made treatment decisions 
more difficult in light of current recommendations and could have altered the above result. Records 
revealed that subclinical episodes were almost invariably treated with antimicrobials in this study, 
regardless of the degree of pyuria, possibly reflecting a lack of knowlege of subclinical bacteriuria 
and absence of a consensus on treatment of subclinical bacteriuria in dogs in the years that these 
cases were seen. The findings of this study, however, in particular the apparent selection for MDR 
organisms and recurrence of positive urine cultures in spite of therapy, support witholding treatment 
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in dogs with subclinical bacteriuria and pyuria, in contrast with current veterinary 
recommendations. 
 
The percentage of isolates susceptible to trimethoprim/sulphamethoxazole, amoxicillin-
clavalanic acid, and enrofloxacin was approximately 60%, and greater than 50% of isolates were 
non-susceptible to amoxicillin, tetracycline and cephalothin. Thirty percent of isolates, 54% of 
which were E. coli, were classified as MDR, which is not surprising given that prior exposure to 
antimicrobials is a recognised risk factor for multidrug-resistance (Gibson et al., 2008; Hernandez et 
al., 2014). Twelve dogs in this study did not have MDR isolates on initial presentation but 
subsequently had MDR isolates cultured. Nine (75%) of these dogs had subclinical bacteriuria on 
initial presentation and it could be hypothesised that witholding antimicrobial treatment for these 
and subsequent subclinical episodes may have reduced the frequency of or prevented urinary tract 
colonisation by MDR bacteria in these dogs.  
 
Although numbers were small, most of the MDR isolates from episodes of subclinical 
bacteriuria were associated with moderate or severe pyuria, which is currently considered an 
indication for antimicrobial treatment. With regard to E. coli, both long-term colonisation and 
multidrug-resistance have been associated with attenuation of virulence factors (Horcajada et al., 
2005; Salvador et al., 2011), which implies that subclinical colonisation with E. coli, even isolates 
classified as MDR, may be reasonably “safe” for the individual. It is also possible that an untreated 
MDR strain would be be replaced with a more susceptible strain over time (Hooton et al., 2000). 
Transfer of MDR bacteria, in particular strains belonging to emerging succesful clonal groups such 
as ST131, which are both virulent and MDR, between dogs and in-contact humans and animals 
cannot be excluded, however, and must be considered a potential risk of a no-treatment strategy 
(Platell et al., 2010).  
 
The three paralysed dogs accounted for 61% of MDR isolates in this study and all had MDR 
isolates on initial urine culture at the referral facility. Accordingly, when susceptibilty of E. coli 
isolates to antimicrobials excepting ceftazidime and gentamicin was examined, the majority (69% 
or greater) of E. coli from paralysed dogs were found to be non-susceptible. The most likely 
explanation is frequent culture of urine in paralysed dogs, routine treatment of positive cultures with 
antimicrobials, and subsequent intense selection pressure for antimicrobial-resistant bacterial 
strains. It should be noted that one paralysed dog, which had 38 positive urine cultures during the 
study period, alone accounted for 51 MDR isolates. This also was the dog that had two episodes of 
suspected urosepsis. The majority of this dog’s isolates were MDR E. coli with similar 
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antimicrobial resistance profiles, and further studies such as molecular characterisation would be 
necessary to investigate whether they represented a single strain.  Possible adaptations of individual 
strains to reduced virulence or tendency for reinfection with less virulent strains over time could 
also be examined. We did not attempt to confirm that subsequent isolates represented true 
reinfection or relapse/persistence in this study, beyond noting that approximately 50% of isolates 
from the second positive culture represented a different bacterial species to the first, confirming 
reinfection, and approximately 25% of isolates were of the same species with an identical 
susceptibility pattern. Many of our repeat isolates were E. coli and speculation based on 
antimicrobial susceptibility patterns has been found to be unreliable thus caution must be exercised 
in assuming persistence or relapse (Drazenovich et al., 2004; Freitag et al., 2006). 
 
Treatment decisions for dogs with recurrent urinary tract infection remain complicated. 
Many episodes are subclinical but associated with pyuria, and studies to assess the safety and 
possible benefits of witholding antimicrobial therapy in such animals, including when MDR 
organisms are isolated, are needed. Pyuria is common in humans with ASB and has not been shown 
to have prognostic significance, thus having minimal impact on treatment decisions in patients 
(Harding et al., 2002; Nicolle, 2006). It is possible that dogs with repeated subclinical positive urine 
cultures also would fare well in the absence of antimicrobial therapy and that such management 
would reduce the selection of MDR bacteria. With regard to dogs with clinical signs, E. coli isolates 
showed high levels of non-susceptibilty to first-line and second-line antimicrobials such as 
amoxicillin, amoxicillin-clavulanate, enrofloxacin and trimethroprim-sulfamethoxazole (range 33-
100%) and change in treatment regimen following return of culture results may thus be necessary, 
should inappropriate empiric treatment have been commenced due to severity of clinical signs. 
 
Dogs with spinal cord disease and hindlimb paralysis may be more difficult to assess with 
regard to the likely safety of witholding antimicrobial therapy but in humans with spinal cord injury 
urine sterility following antimicrobial treatment is short-lived, and concern around selection and 
dispersal of MDR organisms is such that treatment of ASB in such patients is deemed questionable 
(Waites et al., 1993). Studies to assess the safety of witholding antimicrobials in paralysed dogs are 
warranted. Limitations of our study included the relatively small number of dogs, and the fact that 
isolates were not evenly distributed amongst dogs (e.g. a large number of isolates and a high 
percentage of MDR isolates came from a single paralysed dog), which may have skewed the data. 
Additionally, documentation of clinical signs and urinary neutrophilia was not available for all 
presentations and outcome of witholding treatment could not be assessed because with scant 
exceptions, dogs with positive urine cultures were treated with antimicrobials. 
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2.5  Conclusions 
Subclinical bacteriuria in dogs with recurrent urinary tract infection is prevalent but 
frequently associated with pyuria, which raises questions as to the ideal treatment regimen. Current 
guidelines for treatment of dogs with subclinical bacteriuria support the withholding of 
antimicrobial drugs in dogs without pyuria but further research is needed to determine how 
similarly presenting dogs with pyuria, and dogs with hindlimb paralysis and neurogenic bladder 
dysfunction, should best be managed. In addition, further studies, including molecular 
characterisation of isolates, are needed to determine the safety of withholding antimicrobial 
treatment in dogs with multidrug-resistant bacteria, both to the individual and to in-contact humans 
and animals. 
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3 Molecular investigation of Escherichia coli isolated from 
dogs with recurrent bacterial urinary tract infection  
(2001-2011) 
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3.1 Introduction 
Escherichia coli is the bacterial species most commonly isolated in canine recurrent 
bacterial urinary tract infection (UTI), can be implicated in both monomicrobial and polymicrobial 
infections, and may be multidrug-resistant (MDR) (Norris et al., 2000; Seguin et al., 2003; Wagner 
et al., 2014). Additionally, MDR E. coli strains from emerging human-associated clonal groups, 
such as O25b:H4-ST131 (phylogroup B2), O1-ST648 (phylogroup F), O15:K2:H1-ST393 
(phylogroup D), ST130 (phylogroup E), O7-ST457 (phylogroup F), and O1-ST38 (phylogroup D), 
have been isolated from canine urine (Gibson et al., 2008; Platell et al., 2010; Wagner et al., 2014; 
Guo et al., 2015), raising concerns that dogs could serve as a reservoir for these strains with the 
potential for frequent transmission between in-contact humans and animals. In a recent study of 
Australian canine isolates previously classified as phylogenetic group D using the original Clermont 
method, ST354 (phylogroup F) was the most prevalent strain isolated from both extraintestinal 
infections, most of which were UTIs, and faeces (Guo et al., 2015).  Whilst a small number of dogs 
reported in the aforementioned studies had greater than one positive culture, little is known about 
the clonality of strains in dogs with recurrent UTI. 
 
Given that affected dogs typically have repeated positive urine cultures over months to years 
(Norris et al., 2000; Seguin et al., 2003), it is possible that they could act as reservoirs for MDR 
pathogens, resulting in both endogenous infections as well as posing a risk of strain transfer to in-
contact animals and/or humans.  
 
The aim of this study was to characterise E. coli isolates from a group of dogs with recurrent 
UTI to determine strain clonality. The isolates were subjected to phylogenetic grouping, 
antibiogram phenotyping, virulence gene profiling, and multilocus sequence typing (MLST) as well 
as fumC/fimH typing in selected isolates. For individual dogs with repeated isolation of significant 
zooanthroponotic E. coli clonal groups such as ST131-B2 and ST354-F, the patterns and chronicity 
of infection were analysed in more detail. 
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3.2 Materials and methods 
3.2.1 Selection of isolates 
Chapter 2 reported on recurrent UTI (> 3 positive cultures over a 12-month period) in 37 
dogs from three referral clinics between 2001 and 2011 (including 11 dogs presenting to the 
University of Queensland Veterinary Teaching Hospital [UQVTH]). Isolates had been stored for the 
dogs presented to the UQVTH but not for those from the two private referral clinics as the 
corresponding urine samples had been processed by commercial laboratories. Of the 63 E. coli 
isolates obtained from cystocentesis urine samples taken from 10 dogs presenting to the UQVTH, a 
total of 56 could be recovered from The University of Queensland Veterinary Diagnostic 
Laboratory -80oC culture collection. The isolates were recovered from the frozen stock, plated onto 
sheep blood agar (SBA) and MacConkey agar (MCA), and incubated at 37oC. Isolates with poor 
growth in the first incubation period were re-plated and the process repeated. 
 
3.2.2 RAPD profiling and virulence gene comparison 
The 56 isolates (23 of which have previously been reported on elsewhere and are indicated 
by QUC isolate numbers) (Guo et al., 2015) underwent random amplified polymorphic DNA 
(RAPD) analysis using arbitrary decamer 1254 (5’-CCGCAGCGAA-3’) (Osek et al., 2000). 
Isolates were grown in low-sodium Luria Bertani broth at 37oC overnight. A 100 µL aliquot of the 
overnight culture was added to 1 mL DNase/RNase-free distilled water and centrifuged for 1 min at 
14000 x g (Eppendorf MiniSpin Plus, Wesseling, Germany). The supernatant was discarded and the 
pellet resuspended in 6% Chelex 100 (Bio-Rad Laboratories, Hercules, CA) prior to incubation 
(56oC water bath for 15 min), vortexing, and repeat incubation (100oC for 8 min). Samples were 
again vortexed, centrifuged for 3 min at 14000 x g and frozen at -20oC until needed. RAPD 
reactions were performed in 25 µL volumes containing 2 µL template DNA, 2 µM of 1254 primer 
(Sigma-Aldrich, Australia), 1.25 U of MyTaq Red DNA polymerase (Bioline, London, UK), and 5 
µL of MyTaq Red buffer (Bioline, London, UK). Reactions were heated to 95oC in an automated 
thermal cycler (PTC-100; MJ Research, Watertown, MA) for 12 min to activate the MyTaq Red 
DNA polymerase. This was followed by 45 cycles of denaturation (94oC for 1 min), annealing 
(38oC for 5 min), and extension (72oC for 2 min), followed by a final extension (72oC for 10 min). 
Samples were electrophoresed in 2% agarose gels, then stained with SYBR Safe DNA gel stain 
(Life Technologies, Carlsbad, CA) and photographed by use of an ultraviolet transilluminator and 
digital capture system (Bio-Rad Molecular Imager Gel Doc XR System, Bio-Rad Laboratories, 
Hercules, CA). The sizes of amplicons were determined by comparing them with a 100-bp DNA 
ladder (Hyperladder 100bp, Bioline, London, UK). The gels were analysed using BioNumerics 
software Version 7.1 (Applied Maths, Kortrijk, Belgium).  A cut-off was used such that only one 
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isolate was retained per dog when isolates had a RAPD profile with greater than 95% similarity. 
Isolates retained were used to construct a dendrogram based on RAPD 1254 profiles, using the 
unweighted pair group arithmetic mean (UPGMA) method and Pearson’s coefficient. The settings 
used for optimisation and curve smoothing during dendrogram construction were 0.5% and 1.25 
respectively (Guo et al., 2015). 
 
For the purposes of virulence gene (VG) comparison among the isolates remaining 
following RAPD profiling, only one isolate with a distinct VG profile was retained for each dog. 
Isolates were screened for 17 extraintestinal pathogenic E. coli (ExPEC)-related VGs by multiplex 
PCR (Johnson et al., 2000, 2006; Johnson et al., 2008; Guo et al., 2013). Virulence genes included 
fimH (type 1 fimbriae adhesin), papGII (adhesin papG class II), papGIII (adhesin papG class III), 
papEF (adhesin papEF), and focG (F1C fimbriae subunit protein), hlyA (haemolysin A), hlyF 
(haemolysin F), cnf1 (cytotoxic necrotising factor 1), iroN (salmochelin siderophore receptor gene), 
iutA (aerobactin siderophore receptor gene), fyuA (siderophore receptor gene), chuA (haem receptor 
gene), ompT (episomal outer membrane protease gene), iss (episomal increased serum survival 
gene), kpsMT K1 (K1 capsule), kpsMT K5 (K5 capsule) and malX (pathogenicity-associated island 
marker). The virulence gene (VG) profile was the combination of virulence genes possessed by the 
isolate and the VG score the total number of virulence genes. 
 
Multiplex PCR reactions were performed as previously described with modifications 
(Johnson et al., 2000; Johnson et al., 2008). Primers were divided into four pools, with the primer 
pairs listed in order of decreasing amplicon sizes (bp) within each pool; pool 1 malX (922), fyuA 
(880), cnf1 (498), chuA (278), papGII (190); pool 2 fimH (508), papEF (336), K1 (153); pool 3 
hlyA (1177), afa/draB (559), focG (360), papGIII (258), K5 (159); pool 4 iroN (533), ompT (496), 
hlyF (450), iss (323), iutA (302).  The 25 uL reaction mixture (pools 1-3) included 2 µL template 
DNA, 4 mM MgCl2, 1U AmpliTaq Gold DNA polymerase (Life Technologies, Carlsbad, USA), 0.8 
mM each of 4 dNTPs, 0.3 µM of each primer (Sigma-Aldrich, Australia), and 2.5 uL 10 X PCR 
Buffer II (Life Technologies, Carlsbad, CA, USA) supplemented with appropriate volumes of 
double distilled water. Reactions were heated to 95oC in an automated thermal cycler (Biorad 
C1000 Thermal Cycler; Applied Biosystems, Foster City, USA) for 12 min followed by 25 cycles 
of denaturation (94oC for 30 s), annealing (63oC for 30s), and extension (68oC for 3 min) with a 
final extension (72oC for 10 min). For pool 4, the 25 uL reaction mixture included 2 µL template 
DNA, 2 mM MgCl2, 1U Hotmaster Taq DNA polymerase (Prime, Hilden, Germany), 0.25 mM each 
of 4 dNTPs, 0.3 µM of each primer (Sigma- Aldrich, Australia), and 2.5 µL 10 X Hotmaster Taq 
Buffer (5 Prime, Hilden, Germany) supplemented with appropriate volumes of double distilled 
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water. Reactions were heated to 94oC in an automated thermal cycler (Biorad C1000 Thermal 
Cycler; Applied Biosystems, Foster City, CA) for 2 min followed by 25 cycles of denaturation 
(94oC for 30 s), annealing (63oC for 30s), and extension (68oC for 3 min) with a final extension 
(72oC for 10 min). Samples were electrophoresed in 2% agarose gels with positive and negative 
controls run at 90 V for 120 min, then stained with SYBR Safe DNA gel stain (Life Technologies, 
Carlsbad, CA) and imaged as above with amplicon sizes determined by comparing them with a 100-
bp DNA ladder (Hyperladder 100bp, Bioline, London, UK). 
 
3.2.3 Antimicrobial susceptibility 
Antimicrobial susceptibilities of all isolates were determined by disc diffusion susceptibility, 
as previously described (Platell et al., 2011c), to a minimum of nine antimicrobial agents including 
amoxicillin-clavulanic acid (AMC), ampicillin (AMP), ceftazidime (CAZ), cephalothin (KF), 
enrofloxacin (ENR), gentamicin (CN), tetracycline (TET), ticarcillin-clavulanic acid (TIM), and 
trimethoprim sulfamethoxazole (SXT),  several of which are commonly used in the treatment of 
bacterial cystitis in dogs. If an isolate was reported to be non-susceptible to ≥ 1 agent in ≥ 3 
antimicrobial classes as deemed appropriate for the bacterial species or family to which it belonged, 
it was classed as multidrug-resistant (MDR) (Magiorakos et al., 2012). Isolates found to be within 
the intermediate range were classified as non-susceptible. The antimicrobial resistance score was 
the number of antimicrobials (from the above nine) to which the isolate was non-susceptible. 
 
3.2.4 Determination of phylogenetic group 
Phylogenetic group was determined for all 56 isolates using the revised Clermont multiplex 
PCR assay (Clermont et al., 2013). Allocation of isolates to phylogenetic group entailed detection 
of the presence or absence of four DNA markers (chuA, yjaA, TspE4.C2, and arpA). Subsequently, 
arpA-positive strains were screened for a phylogenetic group E-specific arpA allele. The 20 PL 
reaction mixture included 2 µL template DNA, 1 U of MyTaq Red DNA polymerase (Bioline, 
London, UK), 0.4 PM of each primer (Sigma- Aldrich, Australia), and 4 µL of MyTaq Red buffer 
(Bioline, London, UK) supplemented with appropriate volumes of double distilled water. PCR 
cycling conditions entailed denaturation for 5 min at 94oC in an automated thermal cycler (BioRad 
MyCycler Thermal Cycler; Applied Biosystems, Foster City, CA) followed by 30 cycles of 5 
seconds at 94oC, 20 seconds at 59 oC, 30 seconds at 72 oC, and a final 5 min post extension at 72 oC. 
Samples were electrophoresed in 2% agarose gels run at 90 V for 90 min, then stained with SYBR 
Safe DNA gel stain (Life Technologies, Carlsbad, CA) and imaged as above with amplicon sizes 
determined by comparing them with a 100-bp DNA ladder (Hyperladder 100bp, Bioline, London, 
UK). Control strains representing the eight phylogenetic groups and three cryptic clades of E. coli, 
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plus two additional Escherichia species (E. fergusonii and E. albertii), included 22-1Ti19, 33-1 
TC19, B093, B1147, B185, E1118, H120, H252, H383, H442, H605, and TA004. Additionally, 
multilocus sequence typing (MLST); outlined below, was used to confirm assignment of 
phylogenetic group for the majority of isolates. 
 
3.2.5 Haemolysin production and presence of type 1 fimbriae 
Production of haemolysins was investigated for all isolates with sheep blood agar (SBA) as 
previously described (Johnson et al., 1987). Isolates that produced a clear zone of lysis after 
incubation for 24 hr at 37oC were considered positive. Expression of type 1 fimbriae (D-mannose 
binding phenotype) was also examined by observing the ability of isolates to agglutinate yeast 
(Saccharomyces cerevisiae) cells (Schembri et al., 2000). Bacterial isolates were grown in shaking 
culture overnight in Luria-Bertani (LB) broth. Aliquots of washed bacterial suspensions at an 
optical density of 550 nm (OD 550) and a 1% (w/v) suspension of yeast cells were combined on 
glass slides and presence of agglutination was observed. Isolates that were negative for 
agglutination were retested a further three times following 48 hr static incubations in LB broth.  
 
3.2.6 MLST and two-locus clonal typing 
All 56 isolates underwent either full MLST (according to the Achtman scheme for E. coli 
[http://mlst.ucc.ie/mlst/dbs/Ecoli]) and fimH amplification and sequencing (30 isolates 
representative of the major sub-clusters in the RAPD), or fumC and fimH amplification and 
sequencing for CH typing (Weissman et al., 2012) at University of Queensland Animal Genetics 
Laboratory. Contigs (fumC and fimH) were assembled using Chromas Pro (Technelysium, South 
Brisbane, Australia). 
 
3.2.7 Statistical analysis 
Comparisons of proportions were tested using Fisher’s exact test. Virulence scores were 
compared using Mann-Whitney U tests. Analyses were performed using IBM SPSS Statistics for 
Windows, Version 21.0. (Armonk, NY: IBM Corp). The criterion for assuming statistical 
significance was a P value < 0.05. 
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3.3 Results 
3.3.1 RAPD profiles 
Random amplified polymorphic DNA profiling determined the retention of 32 E. coli 
isolates (14 of which have previously been reported on elsewhere) (Guo et al., 2015) with a single 
isolate belonging to each of Dogs 1, 3, 4, 5, and 8. Dogs 2 and 7 each accounted for two isolates, 
Dog 9 for three isolates, and Dog 10 for 19 isolates (Figure 3.1). The RAPD dendrogram resolved 
the isolates into three major clusters (I, II, and III) with a profile similarity level of 10% (Figure 
3.1). Clusters I and II further resolved into sub-clusters (designated a-c and a, b respectively) with a 
profile similarity level of 37-75%.   
 
All but one of the sub-clusters (Ib) contained isolates from multiple dogs. Additionally, 
several dogs were represented by isolates in greater than one sub-cluster. For three pairs of isolates 
from the same dog (Dog 10) the similarity based on RAPD analysis was > 90%, however there 
were also three pairs of isolates from different dogs (Dogs 1 and 10, Dogs 9 and 10, and Dogs 2 and 
3) with a similarity of > 94%. 
 
3.3.2 Antimicrobial resistance 
Antimicrobial resistance scores for the 32 isolates ranged from 0-8 (mean 5, median 6), with 
16/32 (50%) classified as MDR.  
 
Non-susceptibility to individual antimicrobials ranged from 3% (gentamicin) to 84% 
(ampicillin) (Figure 3.2). The majority of isolates were non-susceptible to cephazolin (78%), 
tetracycline (63%), amoxicillin clavulanic acid (63%), and trimethoprim-sulfamethoxazole (56%). 
Resistance to ticarcillin clavulanic acid was slightly lower at 47% and 16% of isolates were non-
susceptible to ceftazidime. Fluoroquinolone resistance within this group of isolates was moderate, 
with 16/32 (50%) isolates non-susceptible, including 14/16 MDR isolates.  
 
3.3.3 Phylogenetic group 
Within the group of 32 E. coli isolates with less than 95% similarity on RAPD profiling, 13 
(41%) could be assigned to phylogenetic group F (including one isolate that was not classifiable by 
PCR but was later assigned using MLST) (Table 3.1). The next most frequently documented 
phylogenetic groups were B2 with 8/32 (25%) and B1 with 6/32 (19%) isolates. Phylogroups A, D, 
and E were less frequently represented, each accounting for < 10% of isolates, and there were no 
phylogroup C isolates.  
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When isolates were separated into MDR and non-MDR groups, the distribution of 
phylogenetic groups was uneven (Table 3.1). Twelve MDR isolates (75%) belonged to phylogroup 
F and other phylogroups were minimally represented. In comparison, the non-MDR isolates were 
represented by phylogroups B2 (50%) and B1 (25%) with only one group F isolate (6%). Ten of 
twelve (83%) F isolates in the MDR group were associated with a single dog, Dog 10. In 
comparison, the eight B2 isolates in the non-MDR group came from seven individual dogs. 
 
3.3.4  Haemolysin production and production of type 1 fimbriae 
Five of the 32 (16%) E. coli isolates produced haemolysins on SBA. All five isolates 
belonged to phylogroup B2 and represented 5/8 (63%) isolates from that group (Figure 3.1). All 
except 2/32 isolates agglutinated yeast cells on glass slides. The two non-agglutinating isolates each 
came from a different phylogroup with one from each of phylogroups D and F. There were thus two 
isolates that caused neither haemolysis nor yeast agglutination. 
 
3.3.5 Virulence gene comparison 
With retention of one isolate per dog with a shared virulence profile, 22 isolates remained 
for VG comparison. Within this group (Dogs 2, 7, and 9 [2 isolates], Dog 10 [10 isolates], all others 
a single isolate), all 17 virulence genes tested were present in a least one isolate (range 1-20 isolates 
positive for each virulence gene). The most common virulence gene was the adhesin fimH, present 
in 20/22 (91%) isolates, followed by the iron acquisition gene chuA in 16/22 (73%) isolates.  
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Figure 3.2 Percentage of E. coli isolates from 10 dogs with recurrent UTI non-susceptible to 
individual antimicrobial agents (AMC, amoxicillin-clavulanic acid; AMP, ampicillin; CAZ, 
ceftazidime; KF, cephalothin; ENR, enrofloxacin; CN, gentamicin; TET, tetracycline; TIM, 
ticarcillin-clavulanic acid, SXT, trimethoprim sulfamethoxazole) 
 
Table 3.1 Phylogenetic group of 32 E. coli isolates from 10 dogs with recurrent UTI including 
assignment according to MDR status 
All 
isolates 
(n=32) 
  MDR (n=16)   Non- 
MDR 
(n=16) 
  
A 1 3% A 0 (0%) A 1 (6%) 
B1 6 19% B1 2 (13%) B1 4 (25%) 
B2 8 25% B2 0 (0%) B2 8 (50%) 
C 0 0% C 0 (0%) C 0 (0%) 
D 3 9% D 1 (6%) D 2 (13%) 
E 1 3% E 1 (6%) E 0 (0%) 
F 13 41% F 12 (75%) F 1 (6%) 
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Table 3.2 Prevalence of 17 virulence genes among 22 E. coli isolates from 10 dogs with 
recurrent UTI, including allocation according to MDR status. Only one isolate representing 
each distinct virulence gene profile was included for individual dogs.  
   Prevalence of indicated trait, no. (%) 
   All isolates 
(n=22) 
MDR* 
isolates 
(n=6) 
Non-
MDR§ 
isolates 
(n=16) 
Category VGs Reference    
Adhesins fimH Johnson and Stell (2000) 20 (91%) 6 (100%) 15 (94%) 
 papGII Johnson and Stell (2000) 1 (5%) 1 (17%) 0 (0%) 
 papGIII Johnson and Stell (2000) 3 (14%) 0 (0%) 4 (25%) 
 papE/F Johnson and Stell (2000) 7 (3%) 1 (17%) 7 (44%) 
 focG Johnson and Stell (2000) 1 (5%) 0 (0%) 1 (7%) 
Haemolysins hlyA Johnson and Stell (2000) 2 (9%) 0 (0%) 2 (13%) 
 hlyF Johnson et al. (2008) 5 (23%) 2 (33%) 3 (20%) 
Iron Acquisition cnf1 Johnson and Stell (2000) 7 (3%) 0 (0%) 7 (44%) 
 iroN Johnson et al. (2008) 10 (45%) 2 (33%) 9 (56%) 
 iutA Johnson and Stell (2000) 6 (27%) 5 (83%) 2 (13%) 
 fyuA Johnson and Stell (2000) 10 (45%) 0 (0%) 10 (63%) 
 chuA Guo et al. (2015) 16 (76%) 4 (67%) 13 (80%) 
Protectins ompT Johnson et al. (2008) 5 (23%) 2 (33%) 4 (25%) 
 Iss Johnson et al. (2008) 5 (23%) 2 (33%) 3 (20%) 
Capsule K1 Johnson and Stell (2000) 2 (9%) 0 (0%) 2 (13%) 
 K5 Johnson and Stell (2000) 8 (36%) 3 (50%) 6 (38%) 
Misc. malX Guo et al. (2015) 9 (41%) 0 (0%) 10 (63%) 
Mean VG score   6  5  6  
Median VG score   5  4  7  
*MDR isolates from Dogs 9 (n=1) and 10 (n=5). §Non-MDR isolates from all dogs with Dogs 2 
and 7 (2 isolates each) and Dog 10 (5 isolates). 
 
The number of virulence genes identified in each isolate ranged from 0-9 (mean 6, median 
5). There were 19 distinct virulence gene profiles (1-2 isolates each). The median VG score for 
MDR isolates was lower than that for non-MDR isolates (Table 3.2) but the difference was not 
significant (P = 0.37). Two virulence genes, fyuA (siderophore receptor gene) (P = 0.0152) and 
malX (pathogenicity-associated island marker) (P = 0.0152), were more prevalent in non-MDR 
isolates in comparison to MDR isolates, in which they were absent. Conversely, iutA (aerobactin 
siderophore receptor gene) was found in 5/6 (83%) of MDR isolates and only 2/16 (7%) non-MDR 
isolates (P = 0.0043).   
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3.3.6  MLST and two-locus clonal typing 
Among the 30 isolates that underwent MLST, there were 22 distinct profiles, including 14 
recognised MLST-based sequence types (STs). Sequencing of fimH revealed 25 haplotypes and CH 
typing, which yielded 25 unique CH types (identical fimH and fumC allelles), was used to predict 
ST for 22 isolates that had not undergone full MLST. ST354-F was the most common ST detected 
(11 isolates confirmed via MLST and a further 8 isolates using CH typing [Table 3.4]). Isolates 
from sub-clusters Ia, IIa, and IIb were identified as ST354-F and were associated with two dogs 
(Figure 3.1). Single isolates were identified as ST131-B2 (Dog 9) in sub-cluster Ic, ST457-F (Dog 
7) and ST38-D (Dog 10) in sub-cluster IIa, and ST372-B2 in sub-cluster III (Dog 5). 
 
The isolates identified as ST354-F were all classified as MDR and fluoroquinolone-resistant. 
The ST457-F isolate was MDR but fluoroquinolone-susceptible, and the ST131-B2 isolate was 
neither MDR nor fluoroquinolone-resistant. 
 
3.3.7  Repeated isolation of important E. coli clonal group isolates in individual dogs 
Two dogs, Dogs 9 and 10, both of which had hindlimb paralysis and upper motor neuron 
neurogenic bladder dysfunction (Table 3.3), had ST354-F strains isolated from their urine on 
multiple occasions. For Dog 9, 2 months elapsed between ST354-F strain isolations. The two 
isolates had identical antimicrobial and virulence gene profiles (Figure 3.1, Table 3.4). The second 
isolate was cultured concurrently with the fluoroquinolone-susceptible ST131-B2 isolate. Three 
subsequent urine cultures in this dog over the ensuing six months did not yield these isolates (data 
not shown).  
 
For Dog 10, there were 19 ST354-F isolates from 47 (40%) urine cultures. The virulence 
gene profiles were identical for all but one isolate (QUC049) (Figure 3.1). The antimicrobial 
resistance profile (AMC, AMP, KF, ENR, TET, TIM, and SXT) also was well preserved, seen in 
11/19 ST354-F isolates from this dog. The remaining isolates had variations for one (5 isolates) or 
two (2 isolates) antimicrobials from this profile. The repeated isolation of ST354-F spanned 35 
months (Table 3.4) with occasional intervening cultures that were either negative or yielded non-E. 
coli monomicrobial isolates including Pseudomonas aeruginosa, Enterobacter cloacae, and 
Candida albicans. There were also two occasions on which a non-ST354-F E. coli was isolated in 
the absence of an ST354-F strain; one was the single ST38-D strain and the other a B1 phylogroup 
strain (Table 3.4). The E. coli ST354-F isolates frequently (11/19 occasions) originated from urine 
samples that yielded polymicrobial cultures, with Enterococcus spp. the most frequent 
accompanying isolate. Follow-up cultures for 18 months following identification of the last ST354-
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F isolate did not yield further isolates from this clonal group but E. coli isolates from phylogenetic 
groups A, B1, B2 and D (Table 3.4) and a number of non-E. coli species were cultured.  
 
 
Table 3.3 Signalment and predisposing condition of dogs with recurrent UTI from which E. 
coli were isolated 
 Breed Sex Age Predisposing 
condition 
Dog 1 Miniature 
Dachshund 
MN 17 Hyperadrenocorticism 
Dog 2 Labrador MN 11 Urinary Incontinence 
Dog 3 Australian Cattle 
Dog X 
FS 14 Hyperadrenocorticism 
Dog 4 German 
Shepherd 
FS 14 None recorded 
Dog 5 Miniature 
Dachshund 
FS 13 Urethral Transitional 
Cell Carcinoma 
Dog 6 Miniature Poodle MN 9 Diabetes Mellitus 
Dog 7 Labrador 
Retriever 
FS 14 Urinary Incontinence 
Dog 8 Miniature 
Dachshund 
FS 14 Hyperadrenocorticism 
Dog 9 Miniature Poodle FS 11 Hindlimb paralysis 
and upper motor 
neuron neurogenic 
bladder dysfunction 
Dog 10 Australian 
Terrier X 
FS 15 Hindlimb paralysis 
and upper motor 
neuron neurogenic 
bladder dysfunction 
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Table 3.4 Summary of phenotypic and genotypic characteristics of E. coli isolates (drawn 
from the original group of 56 isolates) from dogs with ST354-F isolates (Dogs 9 and 10). 
Negative culture results and non-E. coli isolates are not included.  
Isolate Isolation 
date 
(month/ 
year) 
Resistance pattern Phylo ST 
  AMC AMP CAZ KF ENR CN TET TIM SXT   
Dog 9             
QUC054 3/2008 AMC AMP CAZ KF ENR  TET  SXT F ST354-F 
QUR023 5/2008a AMC AMP  KF      B2 ST131-B2 
QUC056 5/2008b AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
             
Dog 10             
 12/2005a AMC AMP  KF ENR  TET TIM SXT  ND 
 12/2005b     ENR  TET    ND 
QUR027 1/2006 AMC AMP  KF ENR  TET TIM SXT F ST354-F 
QUR028 2/2006a  AMP     TET  SXT B1 ST101-B1 
QUC036 2/2006b  AMP  KF ENR  TET  SXT F ST354-F* 
QUC037 6/2006a  AMP  KF ENR  TET TIM SXT F ST354-F* 
QUR031 6/2006b  AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC040 9/2006  AMP  KF ENR  TET TIM SXT F ST354-F 
QUR033 11/2006a          B2 ST1861-B2 
QUC041 11/2006b AMC AMP  KF ENR  TET TIM SXT F ST354-F 
QUC042 12/2006 AMC AMP  KF ENR  TET TIM SXT F ST354-F 
QUR036 1/2007 AMC AMP CAZ KF   TET TIM SXT D ST38-D 
QUC045 2/2007 AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC047 4/2007 AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC048 5/2007a AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC081 5/2007b AMC AMP CAZ KF ENR  TET  SXT B1  
QUC124 5/2007c AMC AMP CAZ KF ENR  TET TIM SXT B1  
QUC082 6/2007 AMC AMP CAZ KF ENR  TET  SXT B1  
QUR043 8/2007a    KF     SXT E  
QUC049 8/2007b AMC AMP  KF ENR  TET TIM SXT F ST354-F 
QUR045 9/2007         SXT E  
QUR046 10/2007a    KF     SXT E  
QUC050 10/2007b  AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC051 12/2007a AMC AMP  KF ENR  TET  SXT F ST354-F 
QUR049 12/2007b  AMP      TIM SXT B1  
QUC083 1/2008a AMC AMP  KF ENR  TET TIM SXT B1  
QUC052 1/2008b AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
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QUC053 2/2008  AMP  KF ENR CN TET TIM SXT F ST354-F* 
QUR053 4/2008 AMC AMP  KF ENR CN TET TIM SXT F ST354-F* 
QUC057 5/2008 AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
QUC059 10/2008 AMC AMP  KF ENR  TET TIM SXT F ST354-F 
QUC061 11/2008a AMC AMP  KF ENR  TET TIM SXT F ST354-F* 
 11/2008b AMC AMP  KF ENR CN TET TIM SXT  ND 
QUR058 5/2009          B2 ST638 
QUR059 7/2009 AMC AMP        B2 ST638* 
QUR060 8/2009 AMC AMP CAZ KF   TET TIM SXT B1  
QUR061 9/2009 AMC AMP   ENR  TET TIM SXT A ST542 
QUR062 10/2009 AMC    ENR     D ST69 
* indicates likely ST based on identical CH type. ND = no data. Dates followed by letters, e.g. 
5/2008a, indicate one of multiple E. coli isolates from the same urine sample.  
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3.4 Discussion 
Escherichia coli is the most common bacterial species isolated from the urine of dogs with 
recurrent UTI (Norris et al., 2000; Seguin et al., 2003) (Chapter 2), but to date there has been 
limited investigation of the molecular characteristics of such isolates. Urine culture in dogs with 
recurrent UTI is frequently positive in the absence concurrent clinical signs of lower urinary tract 
disease (Chapter 2), and current medical and veterinary guidelines for subclinical UTI recommend 
that antimicrobial therapy be withheld, providing that there is no evidence of urinary tract 
inflammation (in the case of veterinary guidelines) (Nicolle, 2006; Weese et al., 2011). Withholding 
antimicrobial treatment in canine recurrent UTI is desirable for prevention of emergence of 
multidrug-resistant (MDR) strains (Gibson et al., 2008) and minimisation of cost and potential side-
effects of antimicrobial agents. Of considerable concern, however, is that dogs with recurrent UTI 
may serve as a reservoir of resistant strains of clinical significance to the individual and in-contact 
humans and animals. 
 
The major finding of this study is that strains belonging to emerging clonal groups of human 
and companion animal importance were isolated from dogs with recurrent UTI. These strains were 
generally multidrug-resistant, had virulence genes both present and expressed, and in the case of 
ST354-F, persisted for prolonged periods of time before presumed eradication. Such strains were 
present in 4/10 dogs but when all dogs were considered there was no evidence of clonal spread of 
MDR strains. Additionally, whilst the majority of dogs had predisposing factors for recurrent UTI 
and thus could be expected to be vulnerable to colonisation with less virulent strains, the isolates 
examined in this study possessed a broad range of virulence genes and expressed traits associated 
with urovirulence. 
 
Strains belonging to ST354-F accounted for the largest group of clonal strains with 19/35 
(54%) isolates from Dog 10 and two isolates from Dog 9 identified as ST354-F by MLST or 
predicted using CH typing, which has an accuracy of approximately 96% (Weissman et al., 2012). 
Antimicrobial susceptibility data and virulence gene profiles were suggestive of a single recurring 
ST354-F strain in Dog 10, but further fingerprinting such as whole genome sequencing would be 
necessary to confirm this. Repeated documentation of ST354-F isolates spanned close to 3 years in 
this dog and ST354-F isolates were present in 40% of cultures performed (including those that were 
negative), the majority in polymicrobial cultures. Following the long period of repeated ST354-F 
isolation, however, S354-F isolates were not cultured from the dog over an 18-month period, in 
spite of greater than 10 subsequent urine submissions, suggesting that this clonal group may have 
finally been eradicated from the urinary tract and/or gastrointestinal tract of the dog.  
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Escherichia coli strains of ST354-F clonal lineage have been isolated from the faeces of 
hospitalised dogs and associated with extraintestinal infections in both humans and dogs, and may 
possess extended-spectrum β-lactamases from the CTX-M group (Kim et al., 2011; Mora et al., 
2011; Harada et al., 2012; Guo et al., 2015). The ST354-F isolates in this study were MDR and 
possessed a relatively conserved and apparently modest profile of four virulence genes; fimH, iutA, 
chuA, K5 (median VG score for MDR E. coli in this study was seven). A virulence gene profile for 
one ST354-F isolate from Dog 10 in this study (QUC040) was previously reported by Guo et al. 
(2015), however, being positive for 10/33 genes tested (fimC, iutA, chuA, crlA, mat, fimC, iucD, 
sitD, ompA, and kpsMTII) and negative for extended spectrum β-lactamases (blaCTX-M variants 1, 2, 
and 9). Given the apparent close relatedness of ST354-F isolates in the current study it is reasonable 
to assume that the remaining isolates possess a similarly comprehensive virulence gene repertoire. 
Transmission of ST354-F from dogs to humans, or vice versa is yet to be reported but if possible, 
persistently colonised dogs could prove a risk to in-contact humans and animals. Whilst transfer of 
strains has not been documented, ST354 strains from dogs, humans and poultry meat have recently 
been shown to be closely related (Vangchhia). Of additional concern the isolation of ST3711 strains 
(clonal complex 354) from the faeces of native birds in a wildlife rehabilitation centre, further 
supporting the contention that such clonal strains successfully persist and are transferred in animal 
care facilities to other birds and potentially to humans (Blyton et al., 2015; Vangchhia).  
 
ST131-B2 strains are of major concern on the global stage as a clonal group that is both 
virulent and drug-resistant, and capable of causing extraintestinal disease in both humans and 
animals (Platell et al., 2011a). A single fluoroquinolone-susceptible ST131-B2 isolate was 
identified, which possessed a comparatively high virulence gene score of eight. An ST457-F isolate 
and an ST38-D isolate were also documented; both are human-associated clonal groups reported to 
cause extraintestinal infections (Lau et al., 2008; Pitout, 2012). 
 
When isolates from all dogs in the study were considered, there was considerable variation 
in RAPD profile, phylogroup, and ST types, as identified using MLST or predicted with CH typing, 
with no evidence of an outbreak of a clonal strain amongst the group of dogs. Lack of evidence for 
clonal spread was expected as the dogs were treated out of hospital (apart from a small number of 
occasions) at the UQVTH over a 10-year period and came from a wide geographic area. It was not 
surprising that Dog 10 had three pairs of isolates with > 90% similarity on the final dendrogram as 
they were all later identified as ST354-F strains. There also were three pairs of dogs with isolates of 
> 94% similarity on RAPD profiles and the same phylogenetic grouping but apart from one pair of 
isolates both being identified as ST354-F (Dogs 9 and 10, seen by the same clinician but Dog 9 had 
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the strain on initial culture and Dog 10 had been diagnosed 2 years prior), MLST and CH typing did 
not support clonality of these pairs. 
 
All but one of the dogs in this study had a predisposing condition to explain their recurrent 
UTI and/or subclinical bacteriuria, as such, it may be expected that they would be vulnerable to 
colonisation with less pathogenic bacterial strains. Nonetheless, the isolates in this study were found 
to contain all virulence genes tested in various combinations. All but one isolate examined in this 
study was positive for the fimH (type 1 fimbriae adhesin) gene and all but two caused agglutination 
of yeast, supporting the presence of functional type 1 fimbriae, a property that has been associated 
with enhanced uropathogenicity (Connell et al., 1996; Mulvey et al., 1998). The ability to cause 
haemolysis, another trait, was less common and present in only five B2 isolates (all non-MDR), two 
of which were positive for the hlyA (haemolysin A) gene. All but one of the isolates possessed at 
least one of the virulence genes examined and the median virulence gene score for the 22 isolates 
examined was 4, which was also the typical virulence gene score for the prevalent ST354-F isolates.  
 
Limitations of the study included the small number of dogs from which the isolates were 
obtained, with 35 of the original 56 E. coli isolates coming from a single dog, Dog 10. An attempt 
was made to minimise analysis of repeated isolates using RAPD screening, but  
Dog 10 still accounted for 19/32 (60%) isolates, 10 of which were ST354-F and possibly 
representative of the same strain. This biased findings such as phylogenetic grouping, antimicrobial 
resistance and virulence gene prevalence. For example, 75% of MDR isolates in this study were 
found to belong to phylogenetic group F, which contrasts the findings of a previous study of MDR 
isolates from canine urinary tract infections, in which isolates in the MDR group were fairly evenly 
distributed amongst the phylogroups (A, B1, B2, and D [of which F is a sub-group using the newer 
quadruplex PCR (Clermont et al., 2013)]) tested (Wagner et al., 2014). If just one phylogroup F 
isolate was retained for each of two dogs in this study, then phylogroup F would account for 2/6 
(33%) MDR isolates. Fifty percent of non-MDR isolates in this study (eight isolates from seven 
dogs) belonged to phylogroup B2 in comparison with 67% in the prior study. The numbers in both 
studies were small, however. Inclusion of 10 ST354-F isolates for Dog 10 may also have falsely 
increased the percentage of isolates non-susceptible to all antimicrobials apart from ceftriaxone and 
gentamicin, which was high for almost all drugs, should they represent a single strain. Nevertheless, 
the inclusion of all isolates from this dog allowed for the important recognition that isolates from a 
human-associated clonal group could be obtained over such a prolonged period of time in a single 
dog as well as being isolated from a second dog with chronic recurrent UTI.  
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Questions regarding ideal treatment regimens for dogs with recurrent UTI, including those 
with human-associated MDR clonal strains and paralysed dogs, remain largely unanswered. The 
results of this study suggest that antimicrobial therapy is not without difficulty, with many isolates 
non-susceptible to oral agents. It could be argued that avoidance of antimicrobials in dogs with 
recurrent UTI that present with subclinical bacteriuria may reduce selection of MDR strains 
(Gibson et al., 2008) and is thus the most responsible approach, but this hypothesis is yet to be 
tested. Dog 10 was invariably treated with antimicrobials when a positive urine culture was 
returned, likely due to both a lack of awareness of recommendations for treatment of subclinical 
bacteriuria and concern that this paralysed dog could not exhibit clinical signs of bacterial cystitis, 
but this proved an ineffective strategy in terms of timely eradication of the ST354-F strains/s from 
either or both gut and urinary tract.  Aside from treatment concerns, the possibility of transfer of 
ST354-F strains from dogs to humans or vice-versa remains. This study provides the basis for 
further studies examining the isolation of E. coli clonal strains such as ST354-F from companion 
animals and humans, with a future goal being the investigation of human and animal housemates for 
identical strains in urine and faeces such that evidence regarding potential transfer, and outcome of 
antimicrobial therapy or avoidance, can be gained. Additionally, comparison of the isolates in this 
study to those from dogs with simple uncomplicated urinary tract infections would be necessary to 
better qualify and understand their pathogenic potential. 
 
3.5 Conclusions 
Dogs with recurrent UTI may be colonised with E. coli that are MDR, possess typical 
ExPEC virulence gene repertoires, including capability to express functional type 1 fimbriae, and 
belong to important human-associated clonal groups, the most prominent of which in this study was 
ST354-F. Importantly, isolates belonging to a single clonal lineage may be detected repeatedly over 
prolonged periods of time and could potentially act as an important reservoir of infection for 
predisposed individual dogs and in-contact humans.  
 
  
 54 
 
 
 
 
 
 
 
 
 
 
 
 
4 Growth competition between asymptomatic bacteriuria 
Escherichia coli strain 83972 and multidrug-resistant canine 
Escherichia coli strains including representatives of emerging, 
highly virulent clonal groups, in canine urine 
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4.1 Introduction 
Escherichia coli 83972 is an asymptomatic bacteriuria (ASB) strain that has been 
successfully used for prevention of recurrent urinary tract infection (UTI) in humans through the 
process of intentional bladder colonisation (Hull et al., 2000; Darouiche et al., 2001, 2005, 2011).  
Colonisation of the bladder of healthy dogs with the strain for up to 28 days with mild, transient 
signs of urinary tract infection has been demonstrated (Thompson et al., 2011, 2012). These 
preliminary canine studies suggest that E. coli 83972 may be a viable preventative measure for dogs 
predisposed to recurrent UTI. In order for prophylactic colonisation of dogs with E. coli 83972 to be 
successful, however, both long-term colonisation of the canine bladder and the ability to 
outcompete invading uropathogenic E. coli (UPEC) would be essential. Previously reported E. coli 
83972 competition experiments performed in human urine with human-origin uropathogens 
demonstrated E. coli 83972 to be competitively superior, likely underpinning its success in 
prevention of recurrent UTI (Roos et al., 2006b), but it is unknown whether such success is 
replicable in competition experiments against canine uropathogens in pooled canine urine. 
 
Of particular current interest is the isolation of multidrug-resistant (MDR) pathogens from 
the urine of dogs with recurrent urinary tract infection (Seguin et al., 2003; Wagner et al., 2014), 
including isolates belonging to emerging clonal groups of importance to both canine and human 
health (Platell et al., 2010, 2011b, 2012; Guo et al., 2015). Isolates belonging to clonal group ST-
354-F were obtained from 2/38 dogs with recurrent UTI, one on many occasions over a 3-year 
period, and clonal groups ST131-B2, ST457-F, and ST38-D also were represented (Chapter 3). 
These E. coli clonal lineages have been associated with extraintestinal disease in dogs and humans 
(Johnson et al., 2010; Kim et al., 2011; Mora et al., 2011) and whilst yet to be confirmed, the 
possibility of transmission of such strains between the two host species is of potential public health 
importance. In dogs colonised with such MDR strains, non-antimicrobial strategies for eradication 
and prevention are likely to be crucial for managing both the animal’s medical condition and 
potential public health impact.   
 
Further to this, possible explanations for any superior competition ability of E. coli 83972 in 
canine urine, such as enhanced iron-acquisition (Roos et al., 2006b; Watts et al., 2012), bear 
exploration. Escherichia coli 83972 siderophore (small, high-affinity iron chelating compounds 
secreted by bacteria) mutants have previously been shown to be outcompeted by the wild-type 
strain in an iron-limited medium, suggesting that iron acquisition may play an important role in the 
competitive performance of E. coli 83972 in human urine (Watts et al., 2012). 
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In this study, the competitive ability of ASB E. coli strain 83972 against canine MDR 
UPEC, including isolates representing four emerging, highly virulent human-associated clonal 
groups in canine urine was investigated. Additionally, it was hypothesised that limiting iron 
availability would enhance the competitive ability of E. coli 83972 in canine urine, and the 
competitive performance of the human ASB in urine in the presence of an iron chelator was 
examined. 
 
4.2 Materials and Methods 
4.2.1 Preparation of pooled canine urine 
Urine was collected via clean voided mid-stream collection from a minimum of three 
healthy male and/or female dogs with no history of UTI or antimicrobial administration in the 
previous 4 weeks. Each sample was centrifuged at 640 x g (Beckman Coulter J6-MI) and the 
supernatant was filter-sterilised using a 0.45 µm syringe filter (Millipore Millex GP). An aliquot of 
100 µL of each filtered sample was cultured on sheep blood agar (SBA) and MacConkey agar 
(MCA) for examination after overnight aerobic incubation at 37oC, and again following a further 24 
hr incubation. Urine was stored at -4oC until required. If a urine sample was noted to have bacterial 
growth during the incubation period, it was discarded. Urine was defrosted at 4oC when required for 
experiments. 
 
4.2.2 Growth conditions for competition experiments  
Two experimental trials (Experiments 1 and 2) were undertaken. In Experiment 1, direct 
competition experiments were performed with E. coli 83972 against each of 10 previously 
published MDR UPEC isolates obtained from canine urine (Tables 4.1, 4.2) (Platell et al., 2010; 
Guo et al., 2013, 2015). Two strains had not undergone MLST but had been compared to MLST-
confirmed strains using random amplified polymorphic DNA (RAPD) analysis and sequence type 
(ST) was assumed on the basis of greater than 95% similarity of profiles on the resultant 
dendrogram (Guo et al., 2015). In Experiment 2, competition experiments were performed both in 
the absence and presence of the iron chelator 2,2′-bipyridyl (DIP) (Watts et al., 2012) to assess 
whether E. coli 83972 competed comparatively better in the iron-limited medium. Only 3/10 strains 
representing major highly virulent and MDR clonal groups of E. coli (QUC013-ST131, QUC007-
ST1193, and QUC018-ST393) were tested. The E. coli 83972 strain used in both experiments had 
been modified using λ-Red mediated homologous recombination to replace the lacZYA genes with a 
kanamycin resistance gene cassette (Thompson et al., 2012). This modification has not been found 
to affect competitive ability of E. coli 83972 (M. Totsika and M. Schembri, unpublished data). 
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Table 4.1 Canine E. coli uropathogenic isolates used in competition experiments with E. coli 
83972 
E. coli  isolate 
ID 
Phylogenetic 
group ± 
pulsotype ± 
ESBL# 
Serogroup MLST group Reference 
83972 B2 OR:K5:H-  Andersson et al. (1991) 
QUC002 B2-905  
CTX-M-15+ 
O25b ST131 Platell et al. (2010) 
QUC008 B2-968 O25b ST131 Platell et al. (2010) 
QUC009 B2-968 O25b ST131 Platell et al. (2010) 
QUC013* B2-1153 O25b ST131 Platell et al. (2010) 
QUC007* B2-1298 O75:K5 ST1193 Platell et al. (2010) 
QUC011 B2-1297 O75 ST1193 Platell et al. (2010) 
QUC018* D O15:K52:H1 ST393 Platell et al. (2010) 
QUC036 F CTX-M-1 and 
CTX-M-9+ 
 ST354 Guo et al. (2015) 
QUC016 F  ST354§ Guo et al. (2015) 
QUC046 F  ST354§ Guo et al. (2015) 
*Strains used in Experiment 2 (iron chelator 2, 2′-bipyridyl (DIP) experiments) 
§Inferred based on > 97% similarity with confirmed ST354 strain on RAPD profile (Guo, 
2015) 
#ESBL, extended spectrum E-lactamase
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T
able 4.2 Identification of virulence genes in the com
peting isolates (X
 indicates presence of the gene) 
*Strains used in iron chelator 2, 2′-bipyridyl (D
IP) experim
ents 
§Johnson et al. (2001), M
abbett et al. (2006)
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For Experiment 1, each pair of competing isolates (E. coli 83972 and respective MDR 
strain) was plated onto SBA, MCA and media with and without kanamycin (50 µg/mL) the day 
prior to the experiment so that fresh colonies were available. Monocultures of E. coli 83972 and the 
MDR strain then were grown separately in 20 mL Brain Heart Infusion Broth to an absorbance of 
0.05 at 600 nm [A600] in a spectrophotometer (U-1800 UV-Vis, Hitachi, Berkshire, UK). The 
monocultures, using 10 µL each, were plated on SBA, MCA and MCA with enrofloxacin and 
gentamicin (MCA EG), for growth and purity checks. The monocultures were incubated during the 
day for growth in a shaking incubator at 37 oC at 130rpm. Samples were extracted every hour for 
measurement of absorbance at 600 nm [A600] until the culture reached a stationary phase. 
 
When the stationary phase was reached, 20 mL of dog urine (warmed to 37oC) was 
inoculated with freshly grown E. coli 83972 and each test organism in an approximate 1:1 ratio to 
an OD600 of 0.05 (approximately 1x108 CFU/mL) as previously described (Roos et al., 2006b). 
Mixed cultures were grown at 37oC for 17 hr and 130 rpm in a bench top orbital shaking incubator 
(N-Biotek NB205). A duplicate competition assay was performed in each batch of pooled urine for 
each pair of competing isolates. Samples were extracted at 0 hr and plated on Plate Count Agar 
(PCA) and MCA, with and without kanamycin (50 µg/mL), to calculate the starting ratio. The 
plating process was repeated following 17 hr incubation (Roos et al., 2006b). Viable counts in 
colony forming units per millilitre (CFU/mL) were subsequently obtained, with each value an 
average of 4-6 individual shake flasks obtained from a minimum of two separate experiments in 
different batches of urine. A ‘degree of relative growth’ ratio was calculated to quantify (and allow 
for comparison of) the increase in proportional representation of each of the two isolates in an 
individual competition experiment over the 17 hr incubation. The proportion of the total population 
represented by E. coli 83972 at 17 hr was divided by that at 0 hr. The same calculation was made 
for the competing organism. The resultant number for the competing organism was divided by that 
for E. coli 83972 to give a ratio for comparison of the relative growth of the competing strain to E. 
coli 83972, e.g. if the proportion of E. coli 83972 was halved following 17 hr incubation (0.5 X 
representation) and the proportion of the competing strain doubled (2 X representation) then the 
degree of relative growth ratio was 1:[2/0.5] = 1:4. This measure was used to overcome difficulty in 
comparing growth in two isolates for which the starting ratio was not exactly 1:1. 
 
For competition experiments between E. coli 83972 and the three canine MDR UPEC 
isolates under iron-limited conditions, competition experiments were performed (two competing 
MDR isolates per experiment) as described above in new batches of pooled urine with and without 
the addition of the iron chelator DIP (50 µM) (Sigma Aldrich, Australia) to the pooled urine prior to 
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incubation. Each batch of was urine was divided into two 80 mL aliquots, DIP (0.63 g) was added 
to one aliquot and the urine divided into four 20 mL volumes for the 17 hr duration mixed culture 
growth stage of the experiment. The urine with no DIP added was similarly divided into four 20 mL 
volumes. Duplicate competition experiments were then performed in each batch of pooled urine for 
two pairs of competing isolates both in the presence and absence of DIP. 
 
4.2.3 Statistical analysis 
Statistical analysis was performed using Microsoft Excel 2013 Version 15.0.4805.1003. 
Viable cell counts at 0 hr and 17 hr were log2 transformed and compared for the two isolates in each 
competition experiment using the paired Student’s t-test. Differences were considered statistically 
significant at P < 0.05. 
 
4.3 Results 
4.3.1 Competition experiments with E. coli 83972 and canine MDR UPEC in pooled canine 
urine (Experiment 1) 
For competition experiments between E. coli 83972 and canine MDR UPEC, the degree of 
relative growth of the MDR UPEC strain was comparable or up to 50% greater than that of E. coli 
83972 for 5/10 isolates; QUC013 (ST131-B2), QUC007 (ST1193-B2), QUC018 (ST393-D), 
QUC036 (ST354-F), and QUC016 (ST354-F) (Table 4.3, Figure 4.1, 4.2). For two isolates, 
QUC018-ST393 (1:0.85) and QUC016-ST354 (1:0.92), the degree of relative growth was greater 
for E. coli 83972. Viable count was not significantly different to that of E. coli 83972 at 17 hr 
incubation for four of the five isolates (QUC007-ST1193, QUC018-ST393, QUC036-ST354, and 
QUC016-ST354) (P < 0.05) i.e. E. coli 83972 was not outcompeted by these isolates. For QUC013-
ST131, viable count was significantly greater than that of E. coli 83972 following 17 hr incubation 
i.e. E. coli 83972 was outcompeted by this isolate. 
 
For four of the remaining isolates [QUC002 (ST131-B2), QUC008 (ST131-B2), QUC009 
(ST131-B2), and QUC011 (ST1193-B2)], the degree of relative growth of the MDR UPEC strain 
was far greater than that of E. coli 83972, ranging from 1:4.5 to 1:5.8, and viable counts of the 
MDR UPEC were significantly higher than that of E. coli 83972 following 17 hr incubation (P < 
0.05) (Table 4.3, Figure 4.1, 4.2). For the final competing isolate, QUC046-ST354, degree of 
relative growth also was far greater than E. coli 83972 (1:5.02), and it was not outcompeted by E. 
coli 83972 following 17 hr incubation (P = 0.16) despite a significantly lower 0 hr colony count (P 
= 0.00) (Table 4.3). 
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Three of the isolates from emerging clonal groups; QUC013-ST131, QUC007-ST1193, and 
QUC018-ST393, were chosen for competition experiments in the presence of DIP as they did not 
outcompete E. coli 83972 under normal in-vitro growth conditions in urine. The hypothesis was that 
under even more severe iron-limiting conditions E. coli 83972 would outcompete these strains from 
MDR clonal lineages. 
 
4.3.2 Competition experiments with E. coli 83972 and canine MDR UPEC in absence and 
presence of 2, 2′-bipyridyl (DIP) (Experiment 2) 
For competition experiments between QUC013-ST131 and E. coli 83972, the degree of 
relative growth of E. coli 83972 was comparable to the MDR strain (1:0.70 in the absence of DIP 
and 1:1.26 in the presence of DIP) (Table 4.4, Figure 4.1).  In contrast to the results for Experiment 
1, there was no significant difference in viable counts at 17 hr incubation between E. coli 83972 and 
QUC013-ST131 in the absence of DIP (P = 0.21), but in the presence of DIP, viable count of 
QUC013-ST131 was significantly greater than that of E. coli 83972 following 17 hr incubation (P 
= 0.01) i.e. QUC013-ST131 appeared to have a competitive advantage over E. coli 83972 when 
iron was further limited. 
 
For competition experiments between QUC007-ST1193 and E. coli 83972, E. coli 83972 
had a lower degree of relative growth, and appeared to compete less effectively in urine under iron-
limiting conditions (1:4.70) in comparison to the MDR strain (1:2.57) (Table 4.4, Figure 4.2). As in 
Experiment 1, QUC007-ST1193 was not outcompeted by E. coli 83972 at 17 hr incubation when 
grown in unadulterated pooled canine urine (P = 0.3) but in the presence of DIP, viable count of 
QUC007-ST1193 was significantly greater than that of E. coli 83972 following 17 hr incubation (P 
= 0.02) i.e. as for QUC013-ST131, QUC007-ST1193 appeared to have a competitive advantage 
when iron was further limited. 
 
Finally, for competition experiments between QUC018-ST393 and E. coli 83972, the degree 
of relative growth of E. coli 83972 was greater in the urine to which DIP had been added (1:0.92) in 
comparison to the unaltered pooled canine urine (1:1.64). Accordingly, in the presence of DIP, E. 
coli 83972 was not outcompeted by QUC018-ST393 (P = 0.47), whilst in the unaltered pooled 
canine urine, QUC018-ST393 was present in higher numbers that E. coli 83972 following 17 hr 
incubation (P = 0.00) i.e. E. coli 83972 appeared gain some competitiveness against QUC018-
ST393 when iron was further limited.  
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 Table 4.3 Competition experiments with E. coli 83972 and 10 multidrug-resistant E. coli 
isolates, including emerging clonal groups [ST131-B2 (QUC002, QUC008, QUC009, 
QUC013), ST1193-B2 (QUC007, QUC011), ST393-D (QUC018), and ST354-F (QUC036)] 
isolated from canine urine (paired two-tailed t-tests on log2 transformed VCC [P < 0.05]) 
 
 E. coli 83972        
0 hr 
MDR isolate         
0 h 
E. coli 83972      
17 hr 
MDR isolate       
17 hr 
QUC002 (ST131-B2)     
VCC (CFU/mL log10)  
(mean ± SE 
 
7.05 ± 0.19 
 
7.15 ± 0.08 
 
7.75 ± 0.07 
 
8.65 ± 0.09 
Range 6.52-7.35 6.92-7.27 7.54-7.85 8.45-8.88 
Proportion of total 
population range  
(mean ± SE) 
 
0.28-0.61 
(0.44 ± 0.07) 
 
0.39-0.72  
(0.56 ± 0.07) 
 
0.07-0.16  
(0.12 ± 0.02) 
 
0.84-0.93  
(0.88 ± 0.02) 
Ratio 1:1.27  1:7.33  
Degree of relative growth   1:5.8  
  P = 0.49  P = 0.00 
QUC008 (ST131-B2)     
VCC (CFU/mL log10)   
(mean ± SE) 
 
6.71 ± 0.10 
 
6.59 ± 0.10 
 
7.61 ± 0.16 
 
8.48 ± 0.02 
Range 6.48-7.06 6.32-6.83 7.08-8.10 8.42-8.56 
Proportion of total 
population range  
(mean ± SE) 
 
0.34-0.85  
(0.55 ± 0.11) 
 
0.15-0.66  
(0.45 ± 0.11) 
 
0.13-0.31  
(0.21 ± 0.04) 
 
0.69-0.87  
(0.79 ± 0.04) 
Ratio 1:0.82  1:3.76  
Degree of relative growth   1:4.6  
  P = 0.64  P = 0.02 
QUC009 (ST131-B2)     
VCC (CFU/mL log10)   
(mean ± SE) 
  6.73 ± 0.04 6.88 ± 0.05  7.90 ± 0.42 8.73 ± 0.06 
Range 6.62-6.90 6.73-7.08 7.30-8.29 8.62-8.81 
Proportion of total 
population range  
(mean ± SE) 
 
0.39-0.46  
(0.42 ± 0.01) 
 
0.54-0.61  
(0.58 ± 0.01) 
 
0.03-0.26  
(0.14 ± 0.04) 
 
0.74-0.97  
(0.86 ± 0.04) 
Ratio 1:1.38  1:6.14  
Degree of relative growth   1:4.5  
  P = 0.00  P = 0.00 
QUC0013 (ST131-B2)     
VCC (CFU/mL log10)   
(mean ± SE) 
 
6.64 ± 0.18 
 
6.90 ± 0.09 
 
8.04 ± 0.11 
 
8.42 ± 0.13 
Range 5.95-7.06 6.64-7.19 7.65-8.32 8.02-8.80 
Proportion of total 
population range  
(mean ± SE) 
 
0.17-0.55  
(0.36 ± 0.05) 
 
0.45-0.83  
(0.64 ± 0.05) 
 
0.20-0.57  
(0.31 ± 0.06) 
 
0.43-0.80  
(0.69 ± 0.06) 
Ratio 1:1.78  1:2.23  
Degree of relative growth   1:1.3  
  P = 0.06  P = 0.02 
QUC007 (ST1193-B2)     
VCC (CFU/mL log10)   
(mean ± SE) 
 
6.70 ± 0.23 
 
6.92 ± 0.23 
 
7.86 ± 0.29 
 
8.39 ± 0.06 
Range 6.11-7.54 6.36-7.75 7.00-8.72 8.23-8.66 
Proportion of total     
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population range  
(mean ± SE) 
0.20-0.62  
(0.38 ± 0.06) 
0.38-0.80  
(0.62 ± 0.06) 
0.06-0.70  
(0.30 ± 0.12) 
0.30-0.94  
(0.70 ± 0.12) 
Ratio 1:1.63  1:2.33  
Degree of relative growth   1:1.4  
  P = 0.13  P = 0.12 
QUC011 (ST1193-B2)     
VCC (CFU/mL log10)   
(mean ± SE) 
 
7.05 ± 0.17 
 
7.22 ± 0.05 
 
7.79 ± 0.07 
 
8.71 ± 0.07 
Range 6.65-7.45 7.11-7.36 7.60-7.93 8.57-8.88 
Proportion of total 
population range  
(mean ± SE) 
0.26-0.62  
(0.41 ± 0.08) 
0.38-0.74  
(0.59 ± 0.08) 
0.07-0.17  
(0.11 ± 0.02) 
0.83-0.93  
(0.89 ± 0.02) 
Ratio 1:1.44  1:8.09  
Degree of relative growth   1:5.6  
  P = 0.30  P = 0.00 
QUC018 (ST393-D)     
VCC (CFU/mL log10)   
(mean ± SE) 
  
6.68 ± 0.13 
 
6.69 ± 0.12 
 
8.46 ± 0.07 
 
8.38 ± 0.17 
Range 6.22-7.15 6.23-7.15 8.23-8.70 7.88-8.93 
Proportion of total 
population range  
(mean ± SE) 
 
0.43-0.55   
(0.50 ± 0.03) 
 
0.45-0.57  
(0.50 ± 0.03) 
 
0.29-0.72  
(0.54 ± 0.13) 
 
0.28-0.71  
(0.46 ± 0.13) 
Ratio 1:1  1:0.85  
Degree of relative growth   1:0.85  
  P = 0.85  P = 0.58 
QUC036 (ST354-F)     
VCC (CFU/mL log10)   
(mean ± SE) 
  
7.08 ± 0.07 
 
7.19 ± 0.03 
 
8.10 ± 0.08 
 
8.24 ± 0.06 
Range 6.88-7.20 7.11-7.26 7.95-8.33 8.06-8.30 
Proportion of total 
population range  
(mean ± SE) 
0.31-0.53  
(0.44 ± 0.05) 
0.47-0.59  
(0.56 ± 0.05) 
0.32-0.52  
(0.43 ± 0.04) 
0.48-0.68  
(0.57 ± 0.04) 
Ratio 1:1.27  1:1.32  
Degree of relative growth   1:1.05  
  P = 0.35  P = 0.20 
QUC016 (F)     
VCC (CFU/mL log10)  
(mean ± SE) 
 
6.89 ± 0.07 
 
6.85 ± 0.03 
 
8.26 ± 0.08 
 
8.17 ± 0.06 
Range 6.77-7.19 6.65-7.19 8.13-8.36 7.88-8.44 
Proportion of total 
population range  
(mean ± SE) 
 
0.39-0.60  
(0.52 ± 0.03) 
 
0.40-0.61  
(0.48 ± 0.03) 
 
0.40-0.72  
(0.54 ± 0.06) 
 
0.28-0.60  
(0.46 ± 0.06) 
Ratio 1:0.92  1:0.85  
Degree of relative growth   1:0.92  
  P = 0.50  P = 0.42 
QUC046 (F)     
VCC (CFU/mL log10)  
(mean ± SE) 
 
7.09 ± 0.07 
 
6.66 ± 0.08 
 
8.11 ± 0.11 
 
8.43 ± 0.10 
Range 6.89-7.30 6.41-6.95 7.81-8.49 8.08-8.69 
Proportion of total 
population range  
(mean ± SE) 
 
0.69-0.77  
(0.73 ± 0.01) 
 
0.23-0.31  
(0.27 ± 0.01) 
 
0.12-0.66  
(0.35 ± 0.10) 
 
0.34-0.88  
(0.65 ± 0.10) 
Ratio 1:0.37  1:1.86  
Degree of relative growth   1:5.02  
  P = 0.00  P = 0.16 
 
(VCC) viable cell count; (CFU) colony-forming units  
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Table 4.4 Competition experiments with E. coli 83972 and multidrug-resistant E. coli isolated 
from canine urine in pooled canine urine, and pooled urine with the addition of iron chelator 
DIP (50 µM), including emerging clonal groups (ST131-B2, ST1193-B2, and ST393-D) (paired 
two-tailed t-tests on log2 transformed VCC [P < 0.05]) 
 
 E. coli 83972         
0 hr 
Competing MDR 
isolate 0 hr 
E. coli 83972       
17 hr 
Competing MDR 
isolate 17 hr 
QUC013-ST131     
VCC (CFU/mL 
log10) (mean ± SE) 
 
6.62 ± 0.07 
 
6.95 ± 0.08 
 
8.26 ± 0.05 
 
8.44 ± 0.08 
Range 6.48-6.74 6.73-7.06 8.15-8.37 8.23-8.63 
Proportion of total 
population range 
(mean ±SE) 
 
0.26-0.39  
(0.32 ± 0.03) 
 
0.61-0.74  
(0.68 ± 0.03) 
 
0.30-0.58  
(0.40 ± 0.06) 
 
0.42-0.70  
(0.60 ± 0.06) 
Ratio 1:2.13  1:1.5  
Degree of relative 
growth 
  1:0.70  
  P = 0.01  P = 0.21 
QUC013-ST131 
+DIP 
    
VCC (CFU/mL 
log10) (mean ± SE) 
 
6.70 ± 0.10 
 
6.95 ± 0.16 
 
6.58 ± 0.08 
 
6.91 ± 0.12 
Range 6.41-6.85 6.67-7.36 6.47-6.81 6.74-7.26 
Proportion of total 
population range 
(mean ± SE) 
 
0.18-0.58  
(0.37 ± 0.08) 
 
0.42-0.82  
(0.63 ± 0.08) 
 
0.27-0.39  
(0.32 ± 0.02) 
 
0.61-0.73  
(0.68 ± 0.02) 
Ratio 1:1.70  1:2.13  
Degree of relative 
growth 
  1:1.26  
 
  P = 0.23  P = 0.01 
QUC007-ST1193     
VCC (CFU/mL 
log10) (mean ± SE) 
 
6.90 ± 0.17 
 
7.03 ± 0.22 
 
7.82 ± 0.72 
 
0.11 ± 0.21 
Range 6.48-7.27 6.85-7.32 7.00-8.32 8.06-8.57 
Proportion of total 
population range 
(mean ± SE) 
 
0.30-0.47  
(0.39 ± 0.04) 
 
0.53-0.70  
(0.61 ± 0.04) 
 
0.00-0.38  
(0.20 ± 0.10) 
 
0.62-1.00  
(0.80 ± 0.10) 
Ratio 1:1.56  1:4  
Degree of relative 
growth 
  1:2.57  
  P = 0.00  P = 0.30 
QUC007-ST1193 
+DIP 
    
VCC (CFU/mL 
log10) (mean ± SE) 
 
6.86 ± 0.10 
 
6.95 ± 0.08 
 
6.49 ± 0.16 
 
7.34 ± 0.04 
Range 6.71-7.16 6.76-7.13 6.00-6.70 7.22-7.41 
Proportion of total 
population range 
(mean ± SE) 
 
0.33-0.52  
(0.45 ± 0.04) 
 
0.48-0.67  
(0.55 ± 0.04) 
 
0.04-0.20  
(0.15 ± 0.04) 
 
0.80-0.96  
(0.85 ± 0.04) 
Ratio 1:1.22  1:5.67  
Degree of relative 
growth 
  1:4.70  
 
  P = 0.28  P = 0.02 
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QUC018-ST393     
VCC (CFU/mL 
log10) (mean ± SE) 
 
7.12 
 
7.15 
 
8.48 
 
8.74 
Range 7.00-7.27 6.98-7.30 8.29-8.64 8.65-8.80 
Proportion of total 
population range 
(mean ± SE) 
 
0.39-0.62  
(0.48 ± 0.05) 
 
0.38-0.61  
(0.52 ± 0.05) 
 
0.28-0.41  
(0.36 ± 0.03) 
 
0.59-0.72 
(0.64 ± 0.03) 
Ratio 1:1.08  1:1.78  
Degree of relative 
growth 
  1:1.64  
 
  P = 0.76  P = 0.02 
QUC018-ST393 
+DIP 
    
VCC (CFU/mL 
log10) (mean ± SE 
 
7.17 ± 0.06 
 
7.16 ± 0.08 
 
6.71 ± 0.04 
 
6.68 ± 0.31 
Range 7.06-7.34 6.88-7.41 6.60-6.81 6.02-7.34 
Proportion of total 
population range 
(mean ± SE) 
 
0.35-0.64  
(0.50 ± 0.06) 
 
0.36-0.65  
(0.5 ± 0.06) 
 
0.19-0.80  
(0.52 ± 0.15) 
 
0.20-0.81  
(0.48 ± 0.15) 
Ratio 1:1  1:0.92  
Degree of relative 
growth 
  1:0.92  
 
  P = 0.95  P = 0.92 
(VCC) viable cell count; (CFU) colony-forming units
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4.4 Discussion 
The strain-dependent properties of E. coli 83972 that make it an effective preventative for 
recurrent UTI in patients with neurogenic bladder disorders are likely to be multiple, but key 
phenotypic attributes appear to be the ability to multiply rapidly in human urine and to successfully 
outcompete uropathogens (Roos et al., 2006b). It is logical to assume that similar properties could 
also make it an effective control measure in canine recurrent UTI cases. This needs to be confirmed 
using both in-vitro and in-vivo experiments, however, since canine and human urine profiles may 
differ considerably. In this study, E. coli 83972 did not outcompete canine MDR UPEC 
representing highly pathogenic clonal lineages in pooled canine urine but in turn was not 
outcompeted by 4/10 tested isolates. Additionally, further restriction of iron availability in canine 
urine did not uniformly enhance the competitive ability of E. coli 83972 against MDR UPEC strains 
in growth competition experiments. 
 
In a previous study performed in pooled human urine, E. coli 83972 successfully 
outcompeted a range of human uropathogens isolated from patients with severe UTI, representing 
71-97% of the overall bacterial population at 17 hr in competition experiments (Roos et al., 2006b). 
In our study performed in pooled canine urine, E. coli 83972 was less successful in competing in 
vitro against canine UPEC in pooled canine urine, comprising only 11-54% of the overall 
population after the same length incubation in competition experiments. One explanation for this 
difference could be strain-dependent factors, since the current study did not utilise the same 
competing human uropathogenic E. coli isolates as Roos et al. (2006b); it was deemed more 
appropriate to test representatives of recently emerged MDR clonal groups such as ST131-B2, 
ST1193-B2 and ST354-F, common to both dogs and humans. Dogs with recurrent UTI are prone to 
infection with MDR strains, in which case antimicrobial options are often severely limited, 
prohibitively expensive, and considered last resort options in antimicrobial stewardship programs 
(Seguin et al., 2003; Wagner et al., 2014). Isolates representing successful human-associated clonal 
lineages such as ST131-B2 were of particular interest, given their recent epidemic spread in humans 
and the potential for dogs and in-contact humans to share similar strains such as pulsotype 968 
(Platell et al., 2011a). ST131-B2 pulsotype strains are fluoroquinolone resistant, possess the fimH30 
allele (ST131 H30 subclonal group), and belong to the most globally dominant lineages of ST131, 
referred to as Clade C or H30-R (Weissman et al., 2012; Johnson et al., 2013; Price et al., 2013; 
Petty et al., 2014)  
 
Whilst E. coli 83972 did not prove competitively superior to canine MDR UPEC in these in 
vitro experiments in canine urine, it is encouraging that for 5/10 of the competing isolates 
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(including one representative of each of four globally emerging clonal groups; ST131-B2, ST1193-
B2, ST393-D and ST354-F), the degree of relative growth of E. coli 83972 was comparable and the 
ASB strain was not outcompeted following 17 hr incubation for 4/5 such isolates. Given that the 
population of E. coli 83972 in a successfully colonised dog (expected to exceed 105 CFU per mL of 
urine) (Darouiche et al., 2011; Thompson et al., 2012) is likely to vastly outnumber that of invading 
uropathogens (in contrast to the target starting population ratio of 1:1 in the current study), it is 
possible that E. coli 83972 will successfully outcompete such strains in vivo and prevent urinary 
tract colonisation. Additionally, dogs with recurrent UTI have a variety of predisposing and/or 
comorbid conditions (Seguin et al., 2003) and the potential impact of conditions such as urine 
retention, urinary incontinence,  and immune system dysfunction on competition of bacterial strains 
in vivo is yet to be elucidated. 
 
Of the five MDR UPEC strains that outcompeted E. coli 83972 (QUC002-ST131, QUC008-
ST131, QUC009-ST131, QUC013-ST131 and QUC011-ST1193-B2), two of the ST131-B2 strains 
(QUC008 and QUC009) belonged to the highly successful pulsotype 968 (Platell et al., 2011a). 
Pulsotype 968 accounted for approximately one quarter of unpublished PFGE profiles of 533 
ST131-B2 isolates, the majority of which were collected in the United States (Johnson et al., 
2009b). Results of the current study suggest a possible hypothesis for further exploration that the 
success of this pulsotype may be linked to its rapid growth in urine and ability to outcompete other 
organisms. The remaining successfully competing ST131-B2 (QUC002, QUC013) and ST1193-B2 
(QUC011) strains also belonged to human-associated pulsotype groups distinct from the ST1193-
B2 (QUC007) strain that did not outcompete E. coli 83972 i.e. genetic differences may well explain 
varying levels of competitive ability of these clonal lineages in canine urine. No major differences 
in virulence gene profiles between the isolates that outcompeted E. coli 83972 in all trials and the 
remaining 5 MDR UPEC isolates as previously determined were apparent (Table 4.2) however it is 
important to note that possession of a virulence gene does not necessarily equate with expression 
(Thomas and Wigneshweraraj, 2014). 
 
Another attribute proposed to explain the success of E. coli 83972 in outcompeting human 
uropathogens is superior iron acquisition ability in the iron-poor environment of urine (Watts et al., 
2012). The ASB strain has been found to up-regulate several genes associated with iron uptake, 
transport and homeostasis during growth in human urine, and produces multiple siderophores (low-
molecular-weight Fe3+-chelating compounds) (Roos et al., 2006b; Watts et al., 2012). It was 
hypothesised that the addition of the iron chelator DIP to canine urine would further restrict iron 
and give E. coli 83972 a competitive advantage over canine MDR UPEC strains. In competitions 
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against the ST393-D isolate (QUC018), E. coli 83972 had a higher degree of relative growth in the 
presence of DIP and was outcompeted in the absence but not in the presence of DIP, i.e. E. coli 
83972 competed more effectively against QUC018-ST393 when DIP was added to urine. This 
suggests that iron acquisition ability may indeed play a role in the competitive ability of E. coli 
83972 when competing against certain individual strains in canine urine. No such apparent 
advantage was noted for E. coli 83972 in competition with the remaining two isolates (QUC013-
ST131 and QUC007-ST1193) and it appears likely that the MDR strains were able to better adapt to 
iron-poor conditions. The three MDR isolates used in Experiment 2 all possessed 5/8 iron 
acquisition genes tested (Table 4.2). It has been suggested that the citrate content in urine may be 
sufficient for iron acquisition in such competition assays, at least in human urine (Watts et al., 
2012), and this may explain why a uniform enhancement of the competitive ability of E. coli 83972 
in canine urine in the presence of DIP was not observed in this study.  
 
4.5 Conclusions 
The observation that the human ASB E. coli strain 83972 had a degree of relative growth 
comparable to 50% of canine MDR E. coli isolates and was not outcompeted by 4/5 of these 
isolates in canine urine in vitro tentatively supports future clinical trials of E. coli 83972 in dogs 
with recurrent UTI. Strains that outcompeted E. coli 83972 were genetically distinct from those that 
did not, and included strains belonging to the most successful ST131-B2 pulsotype group, pulsotype 
968, which has been shown to colonise both dogs and humans, and another newly recognised MDR 
zooanthroponotic B2 clonal lineage, ST1193. Future studies should include comparison of the 
competitive performance of E. coli 83972 against canine and human strains in both canine and 
human urine. Such studies may provide an insight into why E. coli 83972 competes so well with 
human uropathogens in human urine but appears to be less competitive in canine urine. Further 
insight may also be gained into the mechanisms involved in the successful global spread of specific 
E. coli clonal groups such as ST131-B2 pulsotype 968. 
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5.1  Abstract 
Establishment of asymptomatic bacteriuria (ASB) with Escherichia coli 83972 is a novel 
prophylactic alternative to antibiotic therapy for the prevention of recurrent bacterial urinary tract 
infection in dogs. Approximately 108 viable E. coli 83972 cells were introduced into the bladder of 
six healthy female dogs via a sterile urinary catheter. The presence of pyuria, depression, stranguria, 
pollakiuria and pigmenturia was documented for six weeks and urinalysis and aerobic bacterial 
cultures were performed every 24-72 hr. Pyuria was present in all dogs on day 1 post-inoculation 
and 4/6 dogs (67%) had a positive urine culture on this day. Duration of colonisation ranged from 0-
10 days (mean 4.8 days). Four dogs were re-inoculated on day 20. Mean duration of colonisation 
following the second inoculation was 2.5 days. Ten inoculation events resulted in nine colonisations 
(duration 1-10 days, mean 4.33 days).  No dog suffered pyrexia or appeared systemically unwell but 
all dogs initially exhibited mild pollakiuria and a small number displayed gross haematuria and/or 
stranguria. By day 3 of each trial all clinical signs had resolved. Persistent bacteriuria was not 
achieved in any dog but two dogs were colonised for 10 days following a single inoculation. 
Establishment of ASB in dogs may be a promising management strategy for recurrent urinary tract 
infection in dogs. 
 
5.2  Introduction 
Uncomplicated bacterial urinary tract infection (UTI) is common in dogs (Ling, 1984). 
Recurrent UTI is less common (Norris et al., 2000; Seguin et al., 2003), but may occur in 
approximately 4.5% of dogs with uncomplicated UTI (Seguin et al., 2003). In most cases, a 
predisposing factor can be identified including abnormal micturition, anatomic defects of the 
urinary tract, abnormal urothelium, altered urine composition and impaired immunity (Seguin et al., 
2003).  
 
Escherichia coli is the most common pathogen associated with recurrent UTI in dogs, 
accounting for 41.2-47.4% of isolates in two recent studies (Norris et al., 2000; Seguin et al., 2003).  
The recent emergence of multidrug-resistant (MDR) strains of this organism in such dogs highlights 
the need to develop alternative approaches to management and prevention (Gibson et al., 2008). 
Prophylactic colonisation of the canine urinary tract with non-pathogenic organisms is one possible 
alternative approach, thus preventing the establishment of invading pathogens (Roos et al., 2006b).   
 
Escherichia coli 83972 was isolated from the urine of a young Swedish girl who was 
colonised for at least three years without displaying clinical signs of a UTI (Andersson et al., 1991). 
The strain is well adapted for growth in the human urinary tract and long-term asymptomatic 
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bacteriuria (ASB) has been established in humans by inoculation via a urinary catheter (Andersson 
et al., 1991; Wullt et al., 1998, 2000; Darouiche et al., 2001, 2005). Deliberate colonisation of 
human patients with E. coli 83972 fails to induce a host inflammatory response and this is 
associated with the attenuation of several virulence determinants including type 1, P and F1C 
fimbriae (Wullt et al., 2000; Klemm et al., 2006; Roos et al., 2006a).  In successfully inoculated 
patients, the recurrence rate of bladder infections is significantly reduced and the need for antibiotic 
therapy thereby minimised (Darouiche et al., 2001, 2005).  
 
As E. coli isolates from canine and human sources share close phylogenetic and pathotypic 
similarities (Low et al., 1988; Johnson et al., 2003a, 2009a), it is possible that the long-term 
colonisation of dogs by E. coli 83972 may also prevent chronic, symptomatic UTI. Therefore, the 
aim of the current study was to determine if persistent bacteriuria with E. coli 83972 could be 
achieved in healthy dogs following a single bladder inoculation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
5.3  Materials and Methods 
5.3.1  Animals 
Six mixed breed female dogs, weighing between 2.6-10.0 kg, with an estimated age between 
8 months and 3 years were obtained from a local refuge. All dogs were spayed following 
recruitment to the study. The dogs underwent the following health screen: physical examination, 
complete blood count, serum biochemistry profile, urinalysis including a urine protein:creatinine 
ratio and aerobic urine culture. A sample of faeces was cultured to screen for and exclude dogs with 
gastrointestinal colonisation with multidrug-resistant (MDR) E. coli. The experiment was carried 
out with the approval of The University of Queensland Animal Ethics Committee (AEC no: 
555/08). Dogs were chosen for temperament and appeal, as at the conclusion of the trial all efforts 
were to be made to rehome the dogs in the community. Euthanasia would only be carried out on 
animals deemed to be unsuitable as pets by the chief investigator on the basis of irreversible health 
or behavioural abnormalities. 
 
5.3.2  Bacterial strain and preparation of inoculum 
E. coli 83972 is an ASB clinical isolate from the B2 phylogenetic group (Andersson et al., 
1991). In order to facilitate rapid identification of E. coli 83972 by culture, we used λ-Red mediated 
homologous recombination to replace the lacZYA genes with a kanamycin resistance gene cassette. 
This enabled differentiation of E. coli 83972 from other E. coli strains by its resistance to 
kanamycin and its white colony phenotype on MacConkey agar (MCA). For preparation of the 
challenge inoculum, a 10 mL overnight culture of E. coli 83972 grown in nutrient broth was 
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harvested by centrifugation and resuspended in phosphate-buffered saline at a concentration of 
approximately 108 bacterial cells per mL (as estimated by measuring the absorbance at 600nm 
[A600] in a spectrophotometer (U-1800 UV-Vis, Hitachi, Berkshire, UK) with subsequent 
confirmation by viable counts on trypticase soy agar supplemented with 5% defibrinated sheep 
blood plates). 
 
5.3.3  Bladder inoculation 
Each dog was pre-medicated with acepromazine (0.03 mg/kg SQ) and buprenorphine (0.01 
mg/kg SQ) and general anaesthesia was induced by intravenous administration of Alfaxan (10 
mg/kg) on day 0 for the temporary placement of a 6 French polypropylene urinary catheter (Smiths 
Medical International Ltd, Kent, UK). The bladder was emptied via the catheter and 2 mL of 
inoculum, containing approximately 2 x108 CFU/mL of E. coli 83972, was instilled into the 
bladder, followed by a 5 mL flush of Ringer’s solution. The catheter was then removed and the dog 
was allowed to recover from anaesthesia.  
 
5.3.4  Experimental design 
The duration of the trial was 6 weeks. Dogs were monitored on a daily basis for systemic 
signs of disease including pyrexia, depression and anorexia. They were also monitored for signs of 
lower urinary tract disease such as pollakiuria, stranguria and haematuria. Urinalysis and culture 
(including susceptibility testing) was performed on urine specimens obtained on days 1, 2, 3, 4, 6, 
8, 10 and 14. All urine specimens collected in the first 14 days were obtained by antepubic 
cystocentesis, apart from those collected on days 1 and 3, which were voided samples. On day 20 
post-inoculation, the four dogs that returned three consecutive negative urine cultures from day 6 
onwards were re-inoculated using an identical dose and protocol. Dogs were monitored as described 
above and urine samples were collected for urinalysis, urine protein:creatinine ratio and aerobic 
culture with viable cell count on days 1, 3 and 7 post-inoculation. Long-term colonisation was 
defined as the maintenance of E. coli 83972 for > 30 days and three successive cultures yielding no 
bacterial growth were required before defining the dogs as culture negative and no longer colonised. 
 
5.3.5  Clinical pathology 
Urinalysis, urine protein:creatinine ratio and urine culture and susceptibility with viable cell 
count (VCC) were performed on each sample. Leucocytes were quantified using a disposable 
counting chamber (Kova Glasstic Slide 10, Hycor, California, USA). Counts were reported as cells 
per µL (< 10, 10-990 and > 1000 cells per µL). Pyuria and haematuria were considered to be 
present if the white cell and red cell counts were ≥ 10 cells/µL, respectively. Urine was centrifuged 
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and the supernatant used for quantification of specific gravity (VET 360 Refractometer, Leica 
Microsystems Inc., New York, USA) and dipstick analysis (Multistix 10SG Dipticks, Siemens, 
Illinois, USA). Urine protein and creatinine levels were measured and significant proteinuria was 
confirmed if urine protein:creatinine ratio was > 0.5. 
 
5.3.6  Bacteriology  
Total bacterial cell counts in urine specimens were determined semi-quantitatively using 
A600 measurements. Qualitative culture (presence or absence of growth) was conducted by 
inoculating 100 µL of urine from each dog onto sheep blood agar (SBA), MCA, and MCA 
containing 25 µg/mL of kanamycin (MCA/KAN) and incubating aerobically for 18-24 hr at 37oC. 
Viable bacterial cell counts were then determined on specimens where growth was recorded using 
dried Plate Count Agar plates (PCA) and MCA/KAN plates inoculated with 100 µL of each dilution 
of the sample.  
 
5.4  Results  
Six dogs were inoculated with E. coli 83972 by urinary catheterisation. On day 1 post-
inoculation, no dog was pyrexic or systemically unwell. Mild pollakiuria was noted in all dogs and 
gross haematuria in two dogs. By day 2, pollakiuria had resolved but stranguria was present in one 
dog and persisted for 24 hr. No further signs of systemic or lower urinary tract disease were noted 
for the duration of the trial. Four of six dogs (67%) had a positive urine culture for E. coli 83972 on 
day 1. One dog had a single positive culture on day 4. The remaining dog did not have a positive 
urine culture from any sample. The duration of colonisation with E. coli 83972 for the six dogs 
ranged from 0-10 (mean 4.8) days (Figure 5.1). 
 
Urinary leukocyte counts were increased in all dogs on day 1 post inoculation (median 1000 
WBC/µL, range 230-1000 WBC/µL). On day 2, urinary leukocyte count was mildly increased (10 
WBC/µL; reference interval <10 WBC/µL) in a single dog (Dog 1) and this dog was one of the four 
dogs found to be colonised at this time. On day 3, urinary leukocyte count was increased in 2 dogs, 
Dogs 2 (1000 WBC/µL) and 4 (10 WBC/µL), and these were the only two dogs found to be 
colonised on that day. A mild pyuria persisted in these dogs on day 4. Beyond day 4, only sporadic 
mild pyuria was documented. Of the 17 occasions on which there was a positive urine culture, eight 
of these were accompanied by pyuria. On seven occasions, a positive culture was noted in the 
absence of pyuria. 
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Microscopic haematuria was present in all dogs on day 1 and persisted for 1-4 days. 
Significant proteinuria was unusual and was documented in only one dog (Dog 2) on two occasions 
(days 1 and 3), coinciding with peaks in viable cell count. Dogs 1, 3, 5 and 6 were inoculated a 
second time with an identical dose and protocol (day 20). On day 21 no dog was pyrexic or 
systemically unwell although vulval licking was noted in one dog. On day 22 one of the four dogs 
was noted to be stranguric. Gross haematuria of 2 days duration was noted in another dog. All four 
dogs that received the second dose were culture positive on day 1 post-inoculation (day 21). On day 
23, three of the dogs were still colonised but when next examined (day 27), all dogs were culture-
negative. Duration of colonisation with E. coli 83972 in this second trial was 1-3 days (mean 2.5 
days). All 4 dogs had pyuria on day 21 but this was absent on days 23 and 27, despite bacteriuria 
being present in 3 of the dogs on day 23. Proteinuria was not documented in any dog following the 
second bladder inoculation with E. coli 83972. 
 
5.5  Discussion 
This study examined the duration of urinary tract colonisation following a single inoculation 
with E. coli 83972 into the bladder of healthy dogs via a urinary catheter. Additionally, we 
examined the safety of the strain following inoculation to confirm that bladder colonisation in dogs 
was accompanied by minimal clinical signs of urinary tract infection. Following the first inoculation 
at day 0, 5/6 dogs were transiently colonised, with two dogs maintaining the strain for at least 10 
days and an average duration of colonisation of 4.8 days. The inability to establish long-term (i.e. > 
30 days) colonisation may be due largely to the fact that the dogs had an ostensibly normal urinary 
tract anatomy and function. Humans with normal bladder function also prove very difficult to 
colonise (Wullt et al., 1998). In addition, protocols for colonisation in humans generally involve a 
multi-dose protocol with inoculation occurring two to three times daily for three days (Hull et al., 
2000; Darouiche et al., 2001, 2005). We used only a single dose in healthy dogs, primarily to 
confirm that E. coli 83972 was safe and associated with minimal clinical signs in a different host 
species. A practical multi-dose protocol suitable for veterinary application will now be developed as 
the strain has been shown to induce only minor evidence of inflammation following inoculation into 
the canine bladder.  
 
Interestingly, there were several occasions on which confirmed bacteriuria was not 
accompanied by pyuria. Similar observations were made by Hedges et al. (1991), who reported that 
there was neither a threshold above which polymorphonuclear leukocyte recruitment was stimulated 
nor any direct correlation between the bacterial and neutrophil numbers in urine in women 
colonised with E. coli 83972 (Hedges et al., 1991). In a study reported by Andersson et al. (1991), 
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however, E. coli 83972 bacteriuria in humans was associated with pyuria in all samples and urinary 
leucocytes persisted as long as bacteriuria remained in the patient. In the latter study, marked pyuria 
did not appear to be associated with increased clearance of organisms from the urinary tract. 
 
5.6  Conclusions 
Long-term colonisation with E. coli 83972 (> 30 days) was not achieved in any of six 
normal dogs using a single-dose inoculation protocol. Encouragingly, however, urinary colonisation 
was achieved in all dogs for up to 10 days and only one inoculation event failed to lead to 
colonisation. No dog suffered more than mild clinical signs of lower urinary tract disease in 
response to colonisation and dogs could be colonised a second time, again with minimal symptoms 
of urinary tract infection. Long-term asymptomatic colonisation may be achieved in dogs if a 
dosing protocol similar to that used in human medicine is adopted. Colonisation with E. coli 83972 
may therefore prove a rational and practical prophylactic alternative to repeated courses of 
antibiotic treatment in the management of recurrent canine urinary tract infection. 
 
Figure 5.1 Persistence of E. coli 83972 in six dogs following a single bladder inoculation 
(VCC) viable cell count; (CFU) colony-forming units  
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6.1 Abstract 
Establishment of asymptomatic bacteriuria is a novel alternative to antimicrobial therapy for 
management of recurrent bacterial urinary tract infection in humans and may also be useful for dogs 
if it can be shown that colonisation of the canine bladder can be achieved. A three-dose protocol for 
Escherichia coli strain 83972 inoculation was developed to attempt induction of persistent 
bacteriuria in healthy dogs. A previous study using a single inoculation colonised dogs for no 
longer than 10 days and multi-dose protocols have been used to establish persistent bacteriuria in 
human patients. Three doses of approximately 109 E. coli 83972 bacteria were introduced into the 
bladder of eight healthy female dogs over 24 hr via an indwelling sterile urinary catheter. Three 
additional dogs were sham-inoculated.  
 
Duration of colonisation ranged from 1 to 28 days (median 2 days) with no discernible 
reason for the prolonged colonisation in one dog. Multi-dose inoculation of healthy dogs was not 
obviously superior to our previous use of single-dose inoculation apart from one dog remaining 
colonised for 28 days following the three-dose inoculation protocol. 
 
6.2 Introduction 
Given the phylogenetic and pathotypic similarity of E. coli isolates from canine and human 
sources (Low et al., 1988; Johnson et al. et al., 2003a, 2009a), prophylactic treatment with the 
human asymptomatic bacteriuria E. coli strain 83972 may prove a useful strategy in dogs with 
recurrent or persistent UTI.  
 
We recently inoculated the bladder of six healthy female dogs with a single dose of E. coli 
83972 and reported that two dogs carried the organism in their bladder for 10 days with minor, 
transient signs of lower urinary tract disease (pollakiuria, stranguria and/or gross haematuria) 
(Thompson, 2011). Following this initial success, we wished to design a protocol more akin to the 
most common multi-dose protocols used in human patients to improve the chances of achieving 
long-term (greater than 30 days) colonisation whilst offering a practical approach suitable for both 
veterinarians and owners. 
 
6.3  Materials and Methods 
E. coli 83972 is an asymptomatic bacteriuria clinical isolate capable of long term 
colonisation of the human bladder (Klemm et al., 2007). In this study, a modified E. coli 83972 
strain containing a kanamycin resistance gene inserted at the lacZYA genes was employed to 
facilitate its rapid identification (Thompson et al., 2011). Experimental design, animal management, 
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anaesthesia, culture, and pathological analysis were as previously published (Thompson et al., 
2011), with the following modifications; the experiment was carried out with the approval of the 
University of Queensland Animal Ethics Committee (AEC no: SVS/141/11), an indwelling 8-12 
French Foley urinary catheter (Smiths Medical, Waukesha, Wisconsin, USA) was placed under 
anaesthesia on day 0; an EDTA-coagulated blood sample was collected on days 0, 1, 2, 3, 4 and 7 
then weekly for four weeks for a complete blood count; and urinalysis and culture and susceptibility 
testing to assist confirmation of bacterial identity was performed on voided urine specimens 
obtained on days 1, 2, 3, 4, 7, 9, 11 and 14 post-inoculation. A urine sample was collected by 
antepubic cystocentesis when required to confirm that an isolate suspected to be a contaminant 
could not be implicated in a bacterial cystitis. After day 14, urine was collected at least twice 
weekly until 39 days post-inoculation (discontinued following the collection of three consecutive 
culture-negative samples from the dog with the longest duration of colonisation). Urine samples 
from inoculated and control dogs were handled identically; this entailed culturing on MacConkey 
agar in the presence and absence of kanamycin and determination of viable cell counts. 
 
Eleven mixed breed female dogs, weighing between 10.3 and 23.0 kg, with an estimated age 
between 9 months and 5 years were obtained from a local refuge. A random number sequence was 
used to assign eight dogs (Dogs 1, 2, 4, 5, 6, 7, 9 and 11) to the inoculation group and three dogs 
(Dogs 3, 8 and 10) to a sham-inoculated control group. Only one individual (MFT) was aware of 
the allocations and all scoring of clinical signs and analysis of laboratory specimens was performed 
by others. In the inoculated dogs, the bladder was emptied via the catheter and 2 mL of inoculum, 
containing approximately 109 CFU/mL of E. coli 83972, approximately 10x the inoculum size used 
in our single inoculation trial in healthy dogs (Thompson et al., 2011), was instilled into the 
bladder, followed by a 5 mL flush of Ringer’s solution. The catheter balloon was inflated and the 
catheter secured and attached to a sterile collecting system and clamped to prevent efflux of 
inoculum. The dog was allowed to recover from anaesthesia and two hr after application the urinary 
catheter clamp was released and urine allowed to flow into the collection bag. Inoculation including 
transient (2 h) clamping was repeated at 8 and 24 h, after which the urinary catheter was removed. 
Control dogs underwent an identical procedure apart from sham inoculation with 2 mL of Ringer’s 
solution at 0, 8 and 24 h.   
 
Urine leukocyte counts were not normally distributed as determined by the Shapiro-Wilk 
test, thus median urine leukocyte counts in inoculated and control dogs at each time point were 
compared using the non-parametric Mann-Whitney U test. Differences were considered statistically 
significant at P < 0.05. All statistical analyses were performed using IBM SPSS Statistics for 
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Windows, Version 20.0. (Armonk, NY: IBM Corp). 
 
6.4  Results 
The most noteworthy finding in this study was that a single dog (Dog 1) was colonised with 
E. coli 83972 for 28 days, in comparison to transient colonisation (median 2 days) in the remainder 
of the inoculated dogs (Table 6.1). A second dog (Dog 6) had a positive viable cell count for E. coli 
83972 at 21 days but this followed eight negative cultures and was of low magnitude (480 
CFU/mL). 
 
Pyuria was present in Dog 1 until Day 39, 11 days following the last positive culture for E. 
coli 83972. The remaining inoculated dogs had a more rapid return of their urinary leucocyte values 
to normal or near normal levels. Dog 1 also had the most markedly elevated urine protein:urine 
creatinine (UP:UC) ratio at 24 and 48 hr. Every urine sample from which E. coli 83972 was 
cultured in any dog had elevated leucocytes. Control dogs also had pyuria following catheterisation 
and 2/3 had an increased UP:UC ratio at 24 hr but urinary leukocyte counts were significantly lower 
in comparison to inoculated dogs at 8 hr and 30 hr (P <0.05). 
 
Complete blood counts performed on the dogs during this study were unremarkable. 
Neutrophilia, where present, was largely mild and transient (Table 6.2). The data from Dog 1, the 
successfully colonised dog, which had a mild neutrophilia on days 2, 3 and 7, indicated a minimal 
systemic response.  
 
Dog 1 was one of five dogs (including one control dog) that displayed clinical signs of 
lower urinary tract disease including stranguria and pollakiuria. Despite the duration of 
colonisation, these clinical signs were observed for only the first four days following catheter 
removal in Dog 1. Two dogs (one colonised for 30 hr and 1 control) displayed signs until Day 8 
post-inoculation. No dog exhibited signs of lower urinary tract disease of a magnitude considered to 
warrant intervention. As was the case for the other dogs, Dog 1 had minimal changes in attitude 
(possibly slightly more quiet than normal for 2 days post-inoculation) and no change in appetite for 
the study duration.  The dog displayed no abnormalities in micturition behaviour prior to or beyond 
the first 5 days post-inoculation, had normal bladder emptying and residual urine volume, and a 
later abdominal ultrasound and urethrocystoscopy revealed no discernible anatomic abnormalities 
(data not shown). 
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6.5     Discussion 
In this study we colonised the urine of a healthy dog with E. coli 83972 for 28 days, using a 
multi-dose inoculation protocol. This is in contrast to our previous single-dose inoculation study, in 
which the maximum duration of colonisation was ten days (Thompson et al., 2011). Whilst it is 
encouraging that E. coli 83972 can persist for four weeks in canine urine in vivo we were unable to 
find an explanation for the prolonged colonisation in this dog compared to the remaining inoculated 
dogs and thus cannot predict its repeatability. It should be noted, however, that it is difficult to 
colonise humans with normal bladder function (Wullt et al., 1998), and we would predict a higher 
success rate in dogs with overt urinary tract abnormalities. 
 
  It is also difficult to make definitive statements regarding the superiority of the multi-dose 
protocol over the previously reported single-dose inoculation protocol. The maximum duration of 
colonisation was inferior in the earlier study (10 days vs. 28 days) but median duration of 
colonisation was similar (4 days in the previous study vs. 2 days in the current study), as was the 
incidence of transient clinical signs. Long-term colonisation in humans with recurrent UTI is 
infrequently achieved following a single inoculation (Darouiche et al., 2001), but we would need to 
trial the protocols in larger numbers of dogs to observe whether this is also the case in dogs. 
 
Pyuria was present in all urine samples that yielded a positive culture for E. coli 823972, 
which was consistent with studies undertaken in humans (Andersson et al., 1991). This result differs 
from our previous study, in which only approximately 50% of positive cultures were accompanied 
by pyuria. One difference in study design, however, is that the urine samples in the previous study 
were primarily collected by cystocentesis, and this may account for some reduction in urinary 
leukocyte count due to minimisation of contamination. The viable cell counts for the dogs in the 
second study were also higher in the majority of samples and thus may be considered to be more 
likely to promote a leucocyte response. One possibility is that increased leucocyte response may 
explain the rapid elimination of E. coli 83972 in most of dogs in this study but this is not supported 
by the data for Dog 1, which had the longest duration of colonisation in the face of documented 
urinary tract inflammation. Finally, the indwelling urinary catheter placement/presence clearly 
accounts for some inflammation, as evidenced by the urinalysis results for the control dogs. 
 
The combination of urinalysis and haematology data with the transient low-grade clinical 
signs of lower urinary tract disease supports the contention that the more marked inflammatory 
response in Dog 1 was short-lived, largely localised, and somewhat attributable the catheterisation 
and inoculation procedure rather than ongoing bacterial colonisation, which appeared to induce a 
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reduced inflammatory cell response. This is in accordance with our expectation that any 
inflammatory response would be confined to the urinary tract, given the attenuated virulence of this 
asymptomatic bacteriuria strain, and the findings in humans, who display a localised immune 
response to colonisation (Hedges et al., 1991).  
 
We found no evidence to explain why Dog 1 had such a prolonged duration of urinary tract 
colonisation in comparison to the other dogs tested in this study. Successful colonisation in this 
healthy dog, however, suggests there is an increased probability of success for experiments aimed at 
establishing long-term E. coli 83972 colonisation in dogs with neurogenic bladder disorders and 
anatomic urinary tract abnormalities. 
 
6.6 Conclusions 
A practical multi-dose protocol for inoculation of the canine urinary tract with E. coli 83972 
is achievable and side effects are limited to short-term low-grade signs of lower urinary tract 
disease in approximately 50% of dogs. Longer-term colonisation (28 days) was achieved in a single 
dog with no discernible urinary tract abnormalities. 
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Table 6.1 Clinical parameters for 11 dogs following a three-dose inoculation protocol for 
induction of bladder colonisation with a human asymptomatic bacteriuria strain. Dogs 1, 3, 4, 
5, 6, 7, 9 and 11 received three doses of 109 CFU/mL E. coli 83972 and Dogs 2, 8 and 10 were 
sham-inoculated. 
(CFU) colony-forming units; (PI) post-inoculation; (VCC) viable cell count; pyuria (> 10 
white blood cells/µL); (UP:UC ratio) urine protein:urine creatinine ratio (normal < 0.5); 
normal leucocyte count (6.00-17.00 X 109/L leucocytes); neutrophilia (> 11.5 X 109 /L 
neutrophils); haematuria(> 10 red blood cells/µL); other symptoms (dysuria, stranguria 
and/or gross haematuria), (NA) not applicable, (ND) no data due to insufficient sample 
volume or laboratory error 
  
 85 
 
Variable Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Dog 7 Dog 8 Dog 9 Dog 
10 
Dog 
11 
Last day PI 
with VCC 
28 1  
(30 h) 
 
1  
(30 h) 
2 1  
(30 h) 
21 2 2 2 1 
(30h) 
2 
Highest 
VCC 
(CFU/mL) 
 
5.5 X 
108 
1 X 
108 
1.5 X 
102 
1.5 X 
108 
3.7 X 
108 
2.9 X 
108 
4.8 X 
106 
2 X 
103 
2.7 X 
104 
1.7 X 
103 
4.5 X 
108 
Urine 
WBC/µL 
8h 
24 h 
30 h 
48 h 
Day 3 
Day 4 
Day 7 
Day 9 
Day 11 
Day 14 
Day 17 
Day 21 
Day 24 
Day 28 
Day 31 
Day 35 
Day 39 
 
 
 
ND 
>1000 
>1000 
400 
60 
30 
240 
600 
110 
90 
80 
50 
70 
70 
100 
30 
<10 
 
 
140 
50 
>1000 
>1000 
30 
850 
100 
120 
<10 
<10 
<10 
10 
10 
20 
10 
20 
10 
 
 
220 
70 
60 
430 
<10 
<10 
10 
40 
10 
10 
<10 
<10 
<10 
<10 
<10  
10 
<10 
 
 
>1000 
220 
400 
20 
<10 
30 
60 
10 
10 
10 
10 
<10 
<10 
<10 
10 
30 
10 
 
 
>1000 
150 
>1000 
ND 
10 
<10 
110 
40 
30 
50 
 10 
<10 
<10 
20 
<10 
20 
10 
 
 
>1000 
290 
>1000 
240 
240 
40 
10 
180 
10 
10 
50 
290 
20 
210 
120 
70 
250 
 
 
>1000 
220 
>1000 
>1000 
110 
250 
90 
480 
340 
10 
40 
10 
60 
30 
20 
50 
10 
 
 
 
30 
150 
150 
870 
10 
30 
40 
<10 
<10 
<10 
10 
<10 
10 
<10 
<10 
<10 
<10 
 
 
>1000 
115 
>1000 
>1000 
120 
40 
10 
30 
10 
<10 
20 
<10 
20 
<10 
50 
<10 
<10 
 
 
100 
280 
50 
10 
10 
10 
<10 
10 
<10 
<10 
<10 
<10 
<10 
<10 
<10 
<10 
<10 
 
 
 
1000 
370 
880 
60 
<10 
20 
30 
270 
10 
<10 
80 
20 
<10 
10 
<10 
240 
10 
Pyuria (±) 
8h 
24 h 
30 h 
48 h 
Day 3 
Day 4 
Day 7 
Day 9 
Day 11 
Day 14 
Day 17 
Day 21 
Day 24 
Day 28 
Day 31 
Day 35 
Day 39 
 
 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
+ 
- 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
 
+ 
+ 
+ 
ND 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
- 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
- 
+ 
- 
- 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
+ 
- 
+ 
- 
- 
 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
+ 
+ 
- 
+ 
- 
+ 
+ 
UP:UC ratio 
24 h 
48 h 
Day 3 
Day 4 
Day 7 
Day 9 
Day 11 
Day 14 
Day 17 
Day 21 
Day 24 
Day 28 
 
6.29 
0.9 
0.29 
0.13 
0.12 
0.14 
0.09 
ND 
0.07 
0.08 
0.1 
0.08 
 
3.4 
0.52 
0.71 
0.54 
0.28 
0.17 
0.21 
0.16 
0.15 
0.13 
0.12 
0.09 
 
0.61 
0.37 
0.1 
0.09 
0.09 
0.11 
0.18 
0.08 
0.12 
0.09 
0.07 
0.08 
 
0.23 
ND 
0.1 
0.15 
0.14 
0.14 
ND 
0.14 
0.11 
0.14 
0.08 
0.11 
 
0.79 
ND 
0.11 
0.1 
0.1 
0.08 
ND 
0.29 
0.09 
0.06 
0.08 
0.08 
 
0.39 
0.15 
0.1 
0.08 
0.09 
0.11 
0.1 
0.06 
0.1 
0.09 
0.07 
0.06 
 
0.38 
0.38 
0.26 
0.11 
0.17 
0.11 
0.1 
0.1 
0.09 
0.06 
0.09 
0.09 
 
1.57 
0.19 
0.12 
0.1 
0.08 
0.11 
0.08 
0.08 
0.11 
0.07 
0.08 
0.08 
 
1.02 
0.26 
0.09 
0.12 
0.09 
0.06 
0.07 
0.05 
0.07 
0.05 
0.06 
0.05 
 
0.16 
0.08 
0.11 
0.08 
0.1 
0.07 
0.1 
0.07 
0.05 
0.07 
0.05 
0.08 
 
2.07 
0.11 
0.12 
0.06 
0.14 
0.13 
0.11 
0.06 
0.13 
0.09 
0.09 
0.11 
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Day 31 
Day 35 
Day 39 
0.08 
0.07 
0.1 
0.19 
0.23 
0.18 
0.06 
0.13 
0.09 
0.12 
0.12 
0.12 
 
0.09 
0.08 
0.09 
 
0.08 
0.06 
0.08 
 
0.07 
0.08 
0.11 
 
0.08 
0.08 
0.09 
0.05 
0.07 
0.08 
 
0.08 
0.08 
0.07 
 
0.1 
0.17 
0.14 
Leucocyte 
counts 
(x109/L) 
Day 0 
Day 1 
Day 2 
Day 3 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
 
 
9.0 
10.1 
19.6 
22.9 
18.5 
14.5 
11.4 
10.5 
 
 
 
6.3 
16 
15.8 
13.4 
16.6 
17.2 
15.1 
13.9 
 
 
 
8.9 
8.5 
10.9 
9.8 
10.4 
6.0 
6.0 
6.8 
 
 
 
16.1 
19.8 
ND 
22 
18.4 
15.9 
12.3 
12.7 
 
 
 
6.3 
8.3 
12.1 
9.2 
6.1 
13.3 
9.3 
10.6 
 
 
 
10.3 
8.5 
11.1 
14.4 
12 
8.7 
360 
413 
 
 
 
13.7 
17.5 
27.6 
22.8 
16.8 
21.9 
16.2 
15.8 
 
 
 
9.8 
8.5 
11.3 
9.6 
7.7 
7.6 
7.9 
9.9 
 
 
 
7.4 
11.8 
15.3 
11.2 
11.7 
7.9 
11.6 
9.1 
 
 
 
12.9 
9.3 
11.6 
13.9 
13.5 
10.8 
11.1 
9.2 
 
 
 
11.7 
15.5 
21.8 
15 
13.6 
12.44 
9.8 
10.9 
Neutrophilia 
(±) 
Day 0 
Day 1 
Day 2 
Day 3 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
 
- 
- 
+ 
+ 
+ 
- 
- 
- 
 
 
- 
- 
+ 
- 
+ 
+ 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
ND 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
+ 
+ 
- 
+ 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
+ 
- 
- 
- 
- 
- 
Haematuria 
(±) 
8 h 
24 h 
30 h 
48 h 
Day 3 
Day 4 
Day 7 
Day 9 
Day 11 
Day 14 
Day 17 
Day 21 
Day 24 
Day 28 
Day 31 
Day 35 
Day 39 
 
 
 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
+ 
+ 
- 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
- 
- 
- 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
- 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
- 
+ 
 
 
+ 
+ 
+ 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
- 
- 
- 
+ 
 
 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
- 
+ 
- 
+ 
- 
+ 
+ 
- 
+ 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
+ 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
+ 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
- 
- 
+ 
- 
+ 
+ 
Other 
clinical signs 
(±) 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
 
 
 
NA 
+ 
+ 
+ 
+ 
- 
- 
 
 
NA 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
 
NA 
+ 
+ 
+ 
- 
- 
- 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
NA 
- 
- 
- 
- 
- 
- 
 
 
NA 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
NA 
+ 
+ 
- 
+ 
- 
- 
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Table 6.2 Peripheral neutrophil count in four dogs following a three-dose inoculation protocol 
for induction of bladder colonisation with a human asymptomatic bacteriuria strain. Dogs 1, 
7, and 11 received three doses of 109 CFU/mL E. coli 83972 and Dog 2 was sham-inoculated. 
Reference interval: 3.0-11.5 X 109 /L neutrophils 
Peripheral 
neutrophil 
count 
(x109/L) 
 
Dog 1 Dog 2 Dog 7 Dog 11 
Day 1 7.6 10 10.2 10.1 
Day 2 15.8 12 23.1 12.3 
Day 3 19.4 10.1 17 11.4 
Day 7 13.5 13.3 10.8 7.9 
Day 14 10.9 12.2 17.6 4.8 
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7 Conclusions and future perspectives  
 89 
7.1 Revisiting the aims of the thesis 
Recurrent urinary tract infection (UTI) occurs with some frequency in canine practice and to 
date has been most often diagnosed in dogs with a predisposing disorder such as diabetes mellitus, 
hyperadrenocorticism, a neurologic abnormality precluding effective bladder emptying, or 
exogenous immunosuppression (Seguin et al., 2003). Likely related to an increase in the recognition 
of these underlying or comorbid disorders, diagnosis of recurrent urinary tract infection (arguably 
better broken down into episodes of lower urinary tract infection or bacterial cystitis/urethrocystitis 
versus subclinical bacteriuria, given that such a large percentage of episodes occur in the absence of 
clinical signs of lower urinary tract disease) appears to be becoming more commonplace in 
veterinary small animal practice. In spite of this, there have been few advances made in treatment 
and prevention of this condition, and antimicrobial therapy remains the most frequently utilised 
treatment (Seguin et al., 2003). Prevention currently centres on identifying and ameliorating any 
predisposing factors but this is not always possible (Seguin et al., 2003). 
 
A complicating factor regarding responsible management of dogs with recurrent urinary 
tract infection is the isolation of multidrug-resistant (MDR) bacteria (Seguin et al., 2003; Ball et al., 
2008; Blanco et al., 2011; Hall et al., 2013; Wagner et al., 2014). Avoidance of repeated 
antimicrobial use, which may select for MDR bacterial strains, is desirable because of the potential 
risk posed to the individual and in-contact humans and animals. Further intensifying concern is the 
isolation of successful human-associated clonal lineages including ST131-B2 from the urine of dogs 
(Pomba et al., 2009; Platell et al., 2010), as such strains have been reported in association with 
extraintestinal disease in both humans and animals (Nicolas-Chanoine et al., 2008; Blanco et al., 
2009; Oteo et al., 2009; Ewers et al., 2010; Johnson et al., 2010; Lee et al., 2010; Blanco et al., 
2011; Platell et al., 2011a, c; Rogers et al., 2011; Nebbia et al., 2014; Madigan et al., 2015). 
 
One strategy for prevention of recurrent urinary tract infection in humans, particularly well 
investigated in patients with spinal cord disease, is long-term colonisation of the urine with a non-
pathogenic or asymptomatic bacteriuria strain (ASB) (Hull et al., 2000; Trautner and Darouiche, 
2002). It has been hypothesised that such strains outcompete invading uropathogens that would 
otherwise cause symptomatic bacterial cystitis. Asymptomatic bacteriuria Escherichia coli strain 
83972 is the best reported of these “therapeutic” strains and has been successfully utilised to 
decrease the incidence of febrile urinary tract in humans following urinary tract inoculation (Hull et 
al., 2000; Darouiche et al., 2001, 2005, 2011). 
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The first aim of this thesis was to identify dogs in southeast Queensland with recurrent UTI 
and describe, compare and contrast the signalment and apparent predisposing causes for recurrent 
UTI in this population with those previously reported in North America (Norris et al., 2000; Seguin 
et al., 2003). A point of emphasis was documentation of clinical signs of lower urinary tract disease 
(LUTD) displayed by the dogs, and neutrophil response in the urinary tract i.e. pyuria coincident 
with each positive urine culture. The intention was to provide an indication as to the proportion of 
incidents that would have antimicrobial therapy withheld under current veterinary guidelines 
(Weese et al., 2011), as it is in many humans with asymptomatic bacteriuria (Nicolle, 2006), and to 
inform future guidelines. 
 
The next aim was to describe the E. coli isolates from a subset of the aforementioned dogs 
(recovered from the isolate collection at The University of Queensland Veterinary Microbiology 
Laboratory) using current molecular techniques, to achieve a better understanding of their clonality, 
antimicrobial susceptibility, and virulence gene repertoire. This information was intended to add to 
the debate on treatment with antimicrobials, as recognition of the potential overlap of clonal 
lineages causing infection in humans versus dogs could prove pivotal. 
 
If E. coli 83972 is to successfully prevent bacterial cystitis in dogs as it does in humans, it 
will presumably need to outcompete invading uropathogens. In vitro studies in pooled human urine, 
utilising E. coli 83972 in competition with isolates from severe urinary tract infections in humans, 
reported vastly superior growth of the ASB strain following 17 hr incubation (Roos et al., 2006b). 
Replicating the study in pooled canine urine with canine uropathogens was planned in order to 
predict, at least to some extent, the chance of success of E. coli 83972 as a prophylactic strain in 
dogs, and formed another thesis objective. 
 
The ability to safely colonise the canine urinary tract with E. coli 83972 also forms a vital 
component of its potential success in prevention of recurrent UTI in dogs. In addition to achieving 
this goal, the design of a regimen that would be both practical and effective for use in small animal 
practice, with its attendant time and expense limitations, comprised the final goal of this thesis.  
 
7.2 Recurrent urinary tract infection in dogs 
7.2.1  Signalment and presenting clinical signs 
Chapter 2 examined the signalment and presenting signs of dogs with recurrent UTI in 
southeast Queensland. In this study, dogs tended to be female (70%), geriatric (51% of dogs aged 
10 years or older), and purebred (86%). The findings were similar to what has been reported 
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previously in larger groups of dogs internationally (Norris et al., 2000; Seguin et al., 2003), 
although the median age of dogs in these studies was younger at 7 years of age, probably due to 
very small numbers of young dogs with anatomic abnormalities in the current study,  i.e. the SE 
Queensland population of dogs with recurrent UTI appears to be a fair representation of the 
population at large and suitable for further investigation of pathogen characteristics and therapeutic 
trials.  
 
All dogs in the study presented without signs of LUTD on at least one occasion; 75% of 
initial and 81% of subsequent positive urine cultures in non-paralysed dogs were subclinical, similar 
to what has previously been reported (Seguin et al., 2003). The remaining episodes were associated 
with typical signs of bacterial cystitis including stranguria, pollakiuria and gross haematuria. The 
paralysed dogs included in the study did not display stranguria and pollakiuria but had gross 
haematuria on a small number of occasions. For this reason they were excluded from the 
investigation of the degree of pyuria seen in dogs with clinical in comparison to subclinical 
incidences of positive urine culture. The high ratio of subclinical to clinical episodes supports the 
recognition of individual episodes as either bacterial cystitis or subclinical bacteriuria rather than 
grouping all episodes under the umbrella term “recurrent urinary tract infection” when describing 
dogs in this study and similarly affected dogs. 
 
7.2.2  Predisposing conditions 
Whilst Chapter 2 did not investigate risk factors per se, given that the population examined 
was restricted to dogs with recurrent UTI, the majority of dogs in the study (76%) had been 
diagnosed with a condition previously recognised as predisposing to recurrent urinary tract infection 
(Chew et al., 2011). An investigation as to why dogs had their urine cultured in the absence of 
clinical signs was not possible due to this not being recorded for the majority of episodes but a 
plausible explanation could be that urine cultures were ordered by the veterinarian because 
individual dogs had known predisposing conditions. The most common conditions encountered in 
the dogs in this study were diabetes mellitus, hyperadrenocorticism, exogenous corticosteroid 
administration, urolithiasis, and urinary incontinence. As was the case for signalment and 
presenting signs, this is similar to what has been previously reported in a large population of dogs 
presenting to a North American Veterinary Teaching Hospital (Seguin et al., 2003). 
 
7.2.3  Urinary cytology 
It is currently recommended that subclinical infections in dogs are not treated with 
antimicrobials if there is no evidence of UTI based on urinary cytology (Weese et al., 2011). One of 
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the important findings in Chapter 2 was that although subclinical infections were common, 
concurrent absence of pyuria, which is generally considered to support a diagnosis of bacterial 
cystitis, was not. Indeed, if following current veterinary recommendations regarding treatment with 
antimicrobials in cases of subclinical bacteriuria, only approximately 20% of dogs in this study 
would have had antimicrobials withheld. For dogs with hindlimb paralysis, the proportion would 
arguably be similar, with 16% of positive cultures associated with negligible to mild pyuria. More 
studies are required to examine the risks and benefits of witholding antimicrobials in subclinical 
bacteriuria accompanied by pyuria in these cases. 
 
7.2.4  Urine culture results 
Chapter 2 confirmed that a range of different bacterial species can be cultured from dogs 
with repeated postive urine cultures, with mixed cultures accounting for 52/223 (23%) of all postive 
cultures in the study. Escherichia coli was the most frequently isolated species (accounting for 41% 
of all isolates and 46% of positive cultures). Less frequently documented isolates included 
Enterococcus spp. (14%), Proteus spp. (10%), Klebsiella spp. (9%) and Staphylococcus spp. (8%). 
All of the bacterial species isolated in this study could be found on a list of the eleven most 
frequently isolated species from a large survey of positive urine cultures in dogs, and the proportion 
of mixed infections was similar (Ling et al., 2001).  
 
All nine bacterial species were isolated on multiple occasions in pure culture from non-
paralysed dogs with no clinical signs of LUTD i.e. all were associated with subclinical bacteriuria.  
E. coli comprised the biggest proportion (41%) of all subclinical isolates (isolates from mixed 
cultures included) with the remaining bacterial species accounting for ≤ 10% of subclinical isolates 
in non-paralysed dogs. For paralysed dogs, E. coli was the most frequently isolated species, 
accounting for 45/80 (56%) of all isolates.  
 
7.2.5 Antimicrobial susceptibility testing 
Approximately a third of all isolates in the study comprising Chapter 2 were classified as 
multidrug-resistant (MDR) using a species-specific scheme (Magiorakos et al., 2012). Multidrug-
resistance was more frequently seen in isolates from paralysed dogs, with the three dogs accounting 
for 56% of all MDR isolates. Further to this, one paralysed dog accounted for 51/61 (84%) of the 
MDR isolates for that group of dogs. This dog had 38 documented positive cultures and a similar 
number of prescribed antimicrobial courses making this finding unsurprising, given the reported 
link between antimicrobial therapy and isolation of MDR organisms in dogs (Gibson et al., 2008). 
Approximatley 2/3 of MDR isolates in non-paralysed dogs were associated with a subclinical 
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presenation. A small number of MDR isolates were associated with gross haematuria in paralysed 
dogs. E. coli accounted for the majority of MDR isolates with other bacterial species each 
accounting for less than 15% of MDR isolates.  
 
Further examination of the susceptibility of E. coli isolates to individual antimicrobials 
revealed that the level of resistance to most of the antimicrobials tested (amoxicillin-clavulanic acid, 
ampicillin, cephalothin, enrofloxacin, tetracycline, ticarcillin-clavulanic acid, and trimethoprim 
sulfamethoxazole) was high, which was not surprising given the high percentage E. coli isolates 
categorised as MDR (54%). For all but two antimicrobials (ceftazidime and gentamicin), isolates 
from paralysed dogs had the highest percentage of non-susceptible isolates. In contrast, for all but 
the same two antimicrobials, subclinical isolates from non-paralysed dogs had the highest 
proportion of susceptible isolates.  
 
Microscopic examination of sediment from a small number of urine samples from which 
MDR pathogens had been isolated revealed that pyuria may be absent in such cases i.e. MDR may 
not provoke an apparent inflammatory urinary tract response. It is possible that lack of pyuria was 
associated with decreased virulence of these MDR isolates, which has been reported in studies in 
both humans and dogs, with fewer virulence factors documented in fluoroquinolone-resistant E. coli 
urinary isolates in comparison to fluoroquinolone-sensitive isolates (Horcajada et al., 2005; Johnson 
et al., 2009a).  
 
7.2.6  Molecular diagnostics performed on E. coli isolates 
Chapter 3 revealed that the E. coli isolates from dogs with recurrent UTI represented clonal 
lineages from all but one (Group C) of the main phylogenetic groups as assigned under the new 
quadruplex PCR scheme (Clermont et al., 2013), with B2 the most prominent phylogroup in non-
MDR isolates and F the most frequently reported for MDR isolates. B2 is the most prominent 
phylogroup identified for susceptible canine UTI isolates (Wagner et al., 2014), and in general the 
B2 phylogroup is associated with a higher level of virulence and lower level of resistance (Johnson 
et al., 2000; Moreno et al., 2006).  
 
All but one isolate tested positive for at least one virulence gene, with the most frequently 
present virulence genes found to be the adhesin fimH and the iron acquisition gene chuA. Almost all 
isolates produced functional type 1 fimbriae, which has been associated with increased 
uropathogenicity (Connell et al., 1996; Mulvey et al., 1998). MDR isolates from dogs with recurrent 
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UTI possessed fewer virulence genes than non-MDR isolates in general but the difference in this 
study was not significant.  
 
7.2.7  Clonality of E. coli isolates 
A number of different sequence types were identified on the basis of multilocus sequence 
typing (MLST), which further supported the RAPD dendrogram analysis suggesting genetic 
diversity of isolates i.e. infections did not result from expansion of a single E. coli clone within the 
population of dogs. A close genetic relationship between the isolates was not expected as the dogs 
came from various suburbs in southeast Queensland and had no known contact with each other. 
 
The most important study finding, however, was that for one individual dog ST354-F 
isolates were repeatedly cultured from the urine over a 3-year period. Antimicrobial susceptibility 
data and virulence gene profiles were suggestive of a single recurring strain, but further 
fingerprinting such as pulsed field gel electrophoresis (PFGE) or whole genome sequencing would 
be necessary to confirm this suspicion. The implications for public health are clear, with this dog 
acting as potential reservoir for dissemination of ST354, a clonal lineage previously shown to cause 
extraintestinal disease in dogs, humans, and birds (Kim et al., 2011; Mora et al., 2011; Harada et al., 
2012; Blyton et al., 2015; Guo et al., 2015; Vangchhia), though direct interspecies transmission of 
ST354-F between dogs and humans is yet to be reported. Whole genome sequencing of canine and 
human ST354-F isolates would determine the likelihood of frequent cross-host species transmission 
for this clonal lineage.  
 
7.3  Implications of findings 
7.3.1  Implications for diagnosis 
Veterinarians should be aware that dogs with recognised predisposing conditions, e.g. diabetes 
mellitus and hyperadrenocorticism may return positive results (repeatedly) if their urine is 
submitted for aerobic culture. They will most frequently show no clinical signs of LUTD i.e. 
bacterial urethrocystitis, and pyuria is often absent. The organisms cultured are most likely to be E. 
coli; with the strains often possessing an arsenal of virulence genes and multidrug-resistance, 
limiting treatment options. Isolates from paralysed dogs appear more likely to be non-susceptible to 
antimicrobials and isolates from subclinical non-paralysed dogs more likely to be susceptible. It is 
recommended that a urinalysis be submitted to assess the degree of urinary tract inflammation, as 
this will guide treatment decisions, allow better analysis of outcomes, and inform future guidelines, 
which may include a recommendation to avoid culture in animals with no signs of LUTD so as to 
minimise unnecessary antimicrobial administration. 
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7.3.2  Implications for public health 
Of obvious concern is the possibility that dogs may be colonised with clonal strains of 
importance to both humans and animals (e.g. ST354-F) over extended periods of time, with dogs 
potentially acting as a reservoir for organisms that are both virulent and MDR. Whilst further 
studies are required to better quantify this risk, owners, veterinarians and other veterinary hospital 
staff should employ appropriate precautions when handling these animals and their urine. As noted 
above, reducing unnecessary use of antimicrobials should reduce selection for such strains. 
 
7.3.3  Implications for treatment 
There is currently insufficient data available to facilitate evidence-based treatment decisions 
in dogs with recurrent UTI, in particular those that present without clinical signs of lower urinary 
tract disease. Current recommendations are that dogs with subclinical presentations should not be 
prescribed antimicrobial treatment, provided that they have no cytologic evidence of urinary tract 
inflammation (Weese et al., 2011). This combination was uncommon in the study comprising 
Chapter 2. Urinalyses are not always performed in subclinical or paralysed dogs with recurrent UTI, 
however, so it is possible that pathogens that trigger urinary tract inflammation may be under-
treated under current guidelines i.e. treatment may be based on presentation alone. It should also be 
noted that pyuria is common in humans with ASB and has not been shown to have prognostic 
significance, and thus has minimal impact on treatment decisions (Harding et al., 2002; Nicolle, 
2006), keeping in mind that human urine is not collected via cystocentesis. It is possible that dogs 
with repeated subclinical positive urinary cultures would also convalesce in the absence of 
antimicrobial therapy, regardless of the degree of pyuria, and that such management would reduce 
both the virulence of associated organisms and selection of MDR bacteria (Gibson et al., 2008; 
Salvador et al., 2011). Further studies assessing outcome of modified treatment guidelines are 
needed and should incorporate the results of ancillary diagnostic tests such as diagnostic imaging of 
the bladder and kidneys, which may provide further information as to the likely pathogenicity of 
urinary tract isolates. 
 
   As noted above, a further outcome of research culminating in modified treatment guidelines 
that recommend withholding antimicrobial treatment in dogs with subclinical infection regardless of 
the presence of pyuria would be a debate on whether such dogs should have urine cultures 
performed at all, given that knowledge of a positive culture would not influence treatment. Further 
information on carriage of clonal strains by such dogs would inform that potential debate.  
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7.3.4  Implications for prevention 
The knowledge that dogs with recurrent UTI may harbour MDR E. coli clonal groups 
capable of causing disease in humans and animals provides more impetus for the development of 
strategies that prevent colonisation/infection with such strains.  
 
7.4  Use of Escherichia coli strain 83972 for the prevention of recurrent UTI in 
dogs 
7.4.1  Ability of asymptomatic bacteriuria strain 83972 to compete with canine uropathogenic E. 
coli isolates 
Chapter 4 examined the ability of E. coli 83972 to compete with the pathogens that would 
arguably prove the most difficult to eradicate once established, namely MDR E. coli strains, 
including those from emerging clonal groups known to cause extraintestinal disease in humans and 
animals, e.g. ST131-B2. The competitive performance of E. coli 83972 in canine urine against 
canine uropathogens in our study appeared to be inferior to that reported in human urine against E. 
coli isolates from human cases of severe UTI. The reason for this is unknown but may involve the 
different profile of canine urine and/or superior competitive abilities of the MDR E. coli isolates 
used in the study. In spite of the lack of an overwhelming dominance of E. coli 83972 over any 
competing isolate in this study, it had a similar degree of relative growth and was not outcompeted 
by 50% of the isolates. In a situation of intentional colonisation of the canine bladder with E. coli 
83972, however, the starting ratio would greatly favour this strain over an invading uropathogen, 
which may still prove an effective preventative strategy in dogs. 
 
7.4.2  Development of a safe protocol for inoculation of dogs with E. coli 83972 
Chapters 4 and 5 examined the development of a safe and effective protocol for the urinary 
tract colonisation of dogs with E. coli 83972. In order for the strain to be a therapeutic option, it 
must be capable of long-term colonisation of the canine urinary tract without triggering clinical 
signs of lower urinary tract disease, which would be intolerable to dogs and owners. It was 
hypothesised that long term colonisation of healthy dogs would be unlikely, given that colonisation 
of humans with neurologically normal bladders is difficult (Wullt et al., 1998), but it was necessary 
to determine the organism did make such dogs unwell, a situation that would be less well tolerated 
in dogs with pre-existing medical problems. The studies showed that healthy dogs tolerated bladder 
inoculation with E. coli 83972 with minimal consequences, regardless of whether they received a 
single dose via a one-off catheterisation event or three doses over 24 hr via an indwelling urinary 
catheter. The majority of dogs were colonised only transiently (for up to three days) but two dogs in 
the single inoculation study were colonised for up to 10 days and one dog in the multi-dose protocol 
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study was colonised for 28 days. Based on these studies a clinical trial in dogs with recurrent UTI 
can be justified and it would appear prudent to compare the more achievable one-dose protocol with 
the more complicated (but still manageable) multi-dose protocol. 
 
7.5  Study limitations and future directions 
One of the limitations of the studies comprising Chapters 2 and 3 is that a single dog 
accounted for a considerable percentage of isolates and despite attempts to minimise potential bias, 
e.g. removal of isolates with more than 95% similarity on the RAPD dendrogram for each 
individual dog, there may still have been an influence on results such as antimicrobial susceptibility 
and distribution of phylogenetic groups. The benefit of including all isolates for the dog concerned, 
however, was that multiple ST354-F isolates were documented over time, thus contributing greatly 
to understanding of the potential role of strain clonality in dogs with recurrent UTI. Future genome 
sequencing of these isolates will add to our understanding as to the likelihood of a single successful 
strain colonising an individual dog over time as well as facilitate single-nucleotide polymorphism 
SNP analysis to assess possible adaptation of the strain to the host environment over time. 
 
An additional limitation was the lack of opportunity to simultaneously compare the 
competitive performance of E. coli 83972 in both canine and human urine. It was also difficult to 
assess which of these liquid media was experimentally superior, because different competing strains 
were used. Whilst the canine MDR strains utilised in the study comprising Chapter 4 were arguably 
a good choice in terms of predicting efficacy of E. coli 83972 in the most difficult of canine cases, it 
is possible that this ASB strain would compete more effectively with less resistant and/or virulent 
canine E. coli strains. A key plan is to compare the competitive performance of E. coli 83972 in 
both human and canine urine against uropathogens of human and canine origin. In addition to 
providing information on the optimal environmental conditions for successful E. coli 83972 
competition, it may also provide key evidence as to the conditions favouring growth of emerging 
clonal strains of importance to humans and animals, such as ST131-B2. 
 
Another future goal is investigation of canine-derived subclinical bacteriuria strains as 
potentially more appropriate “therapeutic” strains in comparison to the human-derived E. coli 
83972 if planned clinical trials in dogs with recurrent UTI prove unsuccessful. The canine E. coli 
strains identified in Chapter 3 appeared largely unsuitable for such use as there were few isolates 
that were susceptible to all antimicrobials tested, which would be desirable for a therapeutic strain. 
Perhaps predictably, all four such susceptible isolates belonged to phylogenetic group B2, as does 
E. coli 83972, although one was a haemolytic strain, which would render it unsuitable. The 
 98 
remaining three isolates came from two different dogs and could be further examined as potential 
therapeutics in the aforementioned planned competition experiments. Another possibility is that a 
subclinical bacteriuria strain derived from a dog with a “healthy” urinary tract could be worth 
pursuing and a recent study suggests that such isolates are readily available (Wan et al., 2014). 
Given that the well-characterised E. coli 83972 did not cause anything more than minor, transient 
clinical signs in healthy dogs, was capable of colonising the urinary tract for 28 days and was not 
outcompeted by 50% of canine MDR E. coli strains in canine urine, clinical trials should be 
explored before considering alternative strategies for identifying a canine-specific ABU strain. 
 
The finding in Chapter 3 of an individual dog colonised with an important emerging clonal 
group, ST354-F, over three years is considered most noteworthy. As previously mentioned, genome 
sequencing of ST354 isolates from this dog is planned as a separate study and will add considerably 
to our knowledge regarding host versus bacterial factors affecting pathogenesis and epidemiology. 
A larger study is also planned to examine possible transmission of such strains from dogs to owners 
and vice versa by concurrently culturing the urine and faeces of in-contact humans and household 
animals for dogs with recurrent UTI with examination of isolates for clonality.  
 
Finally, prospective, randomised clinical studies using Consolidated Standards of Reporting 
methodology to compare the long-term outcome of antimicrobial treatment versus withholding such 
therapy in paralysed dogs and canine subclinical UTI, in the presence and absence of pyuria, with 
both susceptible and MDR strains, will greatly inform evidence-based treatment guidelines of dogs 
with recurrent UTI. This is of great importance to individual dogs and their owners, veterinary 
clinicians, and also to global health. 
 
7.6  Conclusions 
In conclusion, the development of a non-antimicrobial strategy for the prevention of 
recurrent UTI in dogs is of importance to both canine and human health, and E. coli 83972 is a 
feasible candidate for use in the dog. In addition, further exploration of the ability of E. coli 83972 
to compete with emerging clonal UPEC strains such as ST131 and ST1193 in both pooled human 
and canine urine may provide insight into why these emergent, multidrug-resistant high virulence-
associated clonal lineages have become so successful in colonising and causing extraintestinal 
infection in individuals of either species. 
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